<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Central Nervous System - QuizMaster Pro</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}


    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Cerebellum / qBank / Pharmacology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">87</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>
        let questionsData = [
  {
    "id": 14557,
    "choices": [
      {
        "id": 58189,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertrophy of gums </span></span></span></p>"
      },
      {
        "id": 58190,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hirsutism </span></span></span></p>"
      },
      {
        "id": 58191,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertension </span></span></span></p>"
      },
      {
        "id": 58192,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypersensitivity</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 35-year-old male patient with a history of epilepsy presents to your clinic. He has been taking phenytoin for several years to control his seizures. Which of the following is not an adverse effect of phenytoin?</span></span></span></p>",
    "unique_key": "Q3497293",
    "question_audio": null,
    "question_video": null,
    "map_id": 36161,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Hypertension</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Phenytoin</strong> is an <strong>antiepileptic medication </strong>that is commonly <strong>used to treat seizures. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">It can <strong>cause several adverse effects</strong>, including:</span></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Hypertrophy of gums</strong>: <strong>Phenytoin</strong> can <strong>cause overgrowth of the gum tissue</strong>, leading to a condition known as <strong>gingival hyperplasia.</strong></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Hirsutism: Phenytoin</strong> can cause<strong> excessive hair growth</strong>, particularly in<strong> women.</strong></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Hypersensitivity: Phenytoin</strong> can cause an<strong> allergic reaction</strong> in some patients, leading to symptoms such as <strong>rash, fever, and swollen lymph nodes.</strong></span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">However, <strong>hypertension</strong> is <strong>not </strong>a common adverse effect of<strong> phenytoin.</strong> It can cause <strong>cardiovascular effects</strong> such as <strong>hypotension and arrhythmias</strong>, but<strong> not hypertension.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Adverse effects of phenytoin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">H</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> &ndash; Hirsutism</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypertrophy of gums</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">O</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> &ndash; Osteomalacia</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">T</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> &ndash; Teratogenicity</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">M</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> &ndash; Megaloblastic anemia</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> &ndash; Ataxia and nystagmus</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">L</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> &ndash; Lymphadenopathy</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">I</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> &ndash; Inhibits insulin release (Hyperglycemia)<br />\r\n<strong>K</strong> &ndash; Vit K deficiency.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A </span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&ndash; Arrhythmias </span></span></p>",
    "correct_choice_id": 58191,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "TreatmentBased"
    ]
  },
  {
    "id": 14455,
    "choices": [
      {
        "id": 57781,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vigabatrin decreases GABA uptake at the synaptic cleft. </span></span></span></p>"
      },
      {
        "id": 57782,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vigabatrin increases GABA uptake at the synaptic cleft. </span></span></span></p>"
      },
      {
        "id": 57783,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Vigabatrin is a GABA transaminase inhibitor.</span></span></span></p>"
      },
      {
        "id": 57784,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vigabatrin is a GABA transacetylase inhibitor.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 35-year-old patient is present to the clinic with a history of seizures. The patient is diagnosed with epilepsy and started on vigabatrin therapy. Which of the following statements is true about vigabatrin?</span></span></span></p>",
    "unique_key": "Q8601060",
    "question_audio": null,
    "question_video": null,
    "map_id": 36159,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. C) Vigabatrin is a GABA transaminase inhibitor.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Vigabatrin</strong> is an<strong> antiepileptic drug </strong>effective in the treatment of<strong> partial seizures and infantile spasms</strong>. It functions by <strong>inhibiting GABA</strong> <strong>transaminase, </strong>an enzyme responsible for the <strong>breakdown of GABA.</strong> By <strong>inhibiting this enzyme</strong>,<strong> vigabatrin increases the concentration</strong> of<strong> GABA in the brain,</strong> <strong>enhancing</strong> its<strong> inhibitory effect on neuronal activity</strong>, which is crucial for<strong> controlling seizures.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Decreases GABA uptake at the synaptic cleft:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect</strong>, vigabatrin <strong>does not</strong> decrease GABA uptake; it<strong> increases GABA</strong> availability by<strong> inhibiting its breakdown.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Increases GABA uptake at the synaptic cleft:&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>Incorrect</strong>,<strong> vigabatrin&#39;s</strong> mechanism <strong>does not</strong> involve<strong> altering GABA uptake</strong> <strong>mechanisms directly.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. GABA transacetylase inhibitor:</span></strong><span style=\"font-size:12.0pt\"><strong> Incorrect,</strong> as there is <strong>no enzyme</strong> known as<strong> GABA transacetylase </strong>involved in<strong> GABA</strong> <strong>metabolism.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Vigabatrin </strong>effectively treats <strong>seizures</strong> by <strong>inhibiting GABA transaminase, </strong>thereby <strong>increasing the inhibitory neurotransmitter GABA</strong> in the<strong> brain</strong>, crucial for<strong> reducing excessive neuronal firing </strong>associated <strong>with epilepsy.</strong> Additionally, it is the <strong>drug of choice </strong>for <strong>infantile</strong> <strong>spasms</strong> related to<strong> tuberous sclerosis</strong>, but<strong> potential side effects</strong> include<strong> irreversible visual field defects and behavioral changes.</strong></span></span></span></p>",
    "correct_choice_id": 57783,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14467,
    "choices": [
      {
        "id": 57829,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Barbiturate</span></span></span></p>"
      },
      {
        "id": 57830,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ethyl alcohol</span></span></span></p>"
      },
      {
        "id": 57831,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Protamine sulphate</span></span></span></p>"
      },
      {
        "id": 57832,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Flumazenil</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which of the following drugs can be used in benzodiazepine toxicity? </span></span></span></p>",
    "unique_key": "Q4060972",
    "question_audio": null,
    "question_video": null,
    "map_id": 36157,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Flumazenil</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Flumazenil&nbsp;</span></strong><span style=\"font-size:12.0pt\">is an<strong> antagonist of the benzodiazepine receptor </strong>and is used to<strong> reverse the effects of benzodiazepines</strong> in cases of <strong>overdose or toxicity. </strong>It can <strong>rapidly reverse the sedation and respiratory depression</strong> that may occur with <strong>benzodiazepine overdose.</strong> <strong>Flumazenil </strong>is administered<strong> intravenously </strong>and is <strong>used in emergency settings </strong>where <strong>benzodiazepine overdose is suspected.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Barbiturate</span></strong><span style=\"font-size:12.0pt\">: Barbiturates act on the <strong>central nervous system </strong>similarly to <strong>benzodiazepines </strong>but through <strong>different</strong> <strong>mechanisms. </strong>They <strong>would not reverse benzodiazepine toxicity</strong> and could potentially <strong>worsen central nervous system depression</strong> if <strong>used together.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Ethyl alcohol</span></strong><span style=\"font-size:12.0pt\">: Ethanol (ethyl alcohol) was used as an<strong> antidote for methanol poisoning</strong> (now the <strong>drug of choice</strong> is <strong>fomepizole)</strong>. It has<strong> no role</strong> in the treatment of<strong> benzodiazepine toxicity</strong> and could potentially<strong> lead to further central nervous system depression.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Protamine sulphate</span></strong><span style=\"font-size:12.0pt\">: Protamine sulphate is used to<strong> reverse the effects of heparin, an anticoagulant, </strong>and has <strong>no </strong>role in treating<strong> benzodiazepine toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The key <strong>educational takeaway</strong> is to <strong>recognize flumazenil </strong>as the <strong>specific antidote for benzodiazepine toxicity.</strong> Antidotes of <strong>different toxicities</strong> is <strong>very important</strong> to remember for<strong> entrance exams. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">IMPORTANT ANTIDOTES</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-134937.jpg\" style=\"height:1091px; width:1000px\" /></span></span></strong></p>",
    "correct_choice_id": 57832,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14477,
    "choices": [
      {
        "id": 57869,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Amantadine causes ankle edema.</span></span></span></p>"
      },
      {
        "id": 57870,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Levodopa is effective in reducing tremors.</span></span></span></p>"
      },
      {
        "id": 57871,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Amantadine is more effective than levodopa.</span></span></span></p>"
      },
      {
        "id": 57872,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Anti-muscarinic agents are effective in drug induced Parkinsonism.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Mr. PL Sharma, a 60-year-old man with a history of Parkinson&#39;s disease, presents to hospital with complaints of tremors and difficulty walking. He is currently taking levo-dopa. He asks about other treatment options with his doctor. Which of the following statements is False regarding drugs used in the treatment of Parkinsonism? </span></span></span></p>",
    "unique_key": "Q7392664",
    "question_audio": null,
    "question_video": null,
    "map_id": 36158,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Amantadine is more effective than levodopa.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Levo-dopa plus carbi-dopa</strong> combination is<strong> most effective drug </strong>in treatment of <strong>Parkinsonism</strong></span><span style=\"font-size:12.0pt\">, known for significantly <strong>reducing</strong> <strong>symptoms </strong>such as<strong> tremors, rigidity, and bradykinesia</strong>.<strong> Amantadine</strong>, while <strong>useful for </strong>some symptoms and known to cause side effects like<strong> ankle edema and livedo reticularis</strong>, <strong>does not</strong> <strong>surpass levodopa in effectiveness</strong>. <strong>Anti-muscarinic agents </strong>are indeed <strong>helpful</strong> in managing<strong> drug-induced Parkinsonism, </strong>which occurs <strong>due to dopamine blockade </strong>from<strong> other medications.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>True, amantadine</strong> can cause <strong>ankle edema</strong> among <strong>other side effects.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.</span></strong><span style=\"font-size:12.0pt\">&nbsp;<strong>True</strong>,<strong> levodopa</strong> is<strong> well-known</strong> for <strong>its efficacy </strong>in<strong> reducing Parkinsonian tremors.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D.&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>True</strong>, <strong>anti-muscarinic agents </strong>help relieve <strong>symptoms of Parkinsonism</strong>, especially when caused by the <strong>use of drugs</strong> like <strong>antipsychotics.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Levodopa</strong> remains the <strong>cornerstone of Parkinson&#39;s disease </strong>treatment <strong>due to its superior effectiveness</strong> in<strong> reducing</strong> the core <strong>symptoms </strong>of the<strong> disorder</strong>, whereas <strong>amantadine, though beneficial,</strong> is<strong> less effective</strong></span></span></p>",
    "correct_choice_id": 57871,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14497,
    "choices": [
      {
        "id": 57949,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Piracetam </span></span></span></p>"
      },
      {
        "id": 57950,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Edaravone </span></span></span></p>"
      },
      {
        "id": 57951,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Ceftriaxone </span></span></span></p>"
      },
      {
        "id": 57952,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Doxycycline</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 54-year-old male presents to the clinic with symptoms of muscle weakness, twitching, and difficulty speaking. He is diagnosed with Amyotrophic Lateral Sclerosis (ALS). The patient is started on a new medication that has been shown to slow the decline of physical function in individuals with ALS. Which of the following is recently approved for the treatment of ALS? </span></span></span></p>",
    "unique_key": "Q6268921",
    "question_audio": null,
    "question_video": null,
    "map_id": 36156,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Edaravone. </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Edaravone,</strong> a<strong> free radical scavenger, </strong>has been approved for use in the treatment of<strong> ALS</strong> and is known to <strong>slow the progression of</strong> <strong>physical decline</strong> in patients with this condition. It functions by<strong> mitigating oxidative stress</strong>, which is believed to be a factor in the <strong>neuronal damage </strong>associated with<strong> ALS. Edaravone</strong> is <strong>administered intravenously,</strong> typically in treatment cycles that involve <strong>daily</strong> <strong>infusions</strong> for <strong>specific periods</strong> followed by <strong>drug-free intervals.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Piracetam:</span></strong><span style=\"font-size:12.0pt\"> While used for <strong>cognitive enhancement </strong>in some neurological conditions, it is <strong>not </strong>approved for<strong> treating ALS</strong> and <strong>does not </strong>address the <strong>motor neuron degeneration </strong>typical of the disease.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Ceftriaxone:</span></strong><span style=\"font-size:12.0pt\"> This <strong>antibiotic</strong> has been explored in research settings for<strong> potential benefits in ALS</strong> due to its<strong> neuroprotective</strong> <strong>properties</strong> in <strong>animal models,</strong> but it is <strong>not</strong> approved for this use pending further clinical trials.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Doxycycline:</span></strong><span style=\"font-size:12.0pt\"> An<strong> antibiotic</strong> with <strong>no approval</strong> or <strong>substantial evidence </strong>supporting its <strong>use in treating ALS.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Edaravone</strong> represents a significant advancement in the <strong>management of ALS </strong>by specifically<strong> targeting oxidative stress</strong>, providing hope for potentially <strong>slowing the disease&#39;s progression</strong>. This drug&#39;s role in<strong> ALS treatment</strong> <strong>underscores</strong> the importance of <strong>antioxidant</strong> therapy in<strong> neurodegenerative diseases.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Important Drugs Used in Treatment of ALS</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-150505.jpg\" style=\"height:403px; width:1000px\" /></span></span></strong></p>",
    "correct_choice_id": 57950,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 14619,
    "choices": [
      {
        "id": 58437,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Stop imipramine and start valproate.</span></span></span></p>"
      },
      {
        "id": 58438,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Add Benzodiazepine to imipramine.</span></span></span></p>"
      },
      {
        "id": 58439,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Add antipsychotic to imipramine. </span></span></span></p>"
      },
      {
        "id": 58440,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Start selective serotonin reuptake inhibitor.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A patient was presented with symptoms of depression and was started with imipramine. Post-treatment, he develops symptoms of excessive energy, elated mood and lack of sleep, excessive cheerfulness, and talkativeness. What should be the modification in the treatment? </span></span></span></p>",
    "unique_key": "Q3854389",
    "question_audio": null,
    "question_video": null,
    "map_id": 36160,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Stop imipramine and start valproate.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>patient&#39;s presentation</strong> after <strong>initiating treatment</strong> with <strong>imipramine</strong>, a <strong>tricyclic</strong> <strong>antidepressant (TCA),</strong> suggests a <strong>switch to manic symptoms</strong>, characterized by <strong>excessive</strong> <strong>energy, elated mood, lack of sleep, excessive cheerfulness, and talkativeness</strong>. This change in clinical presentation may <strong>indicate bipolar disorder, </strong>where the patient experiences<strong> episodes</strong> <strong>of depression</strong> as well as<strong> mania or hypomania.</strong> In such cases, the <strong>use of antidepressants</strong> alone, especially <strong>TCAs like imipramine,</strong> can precipitate <strong>manic episodes </strong>or <strong>rapid cycling</strong> between <strong>mood states. </strong>The appropriate <strong>modification in treatment </strong>involves <strong>discontinuing</strong> the <strong>antidepressant</strong> that may contribute to the <strong>manic switch and initiating a mood stabilizer.</strong> <strong>Valproate</strong> is a<strong> mood stabilizer</strong> that is effective in <strong>managing and preventing manic episodes</strong>, making it a<strong> suitable choice for this patient.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Add benzodiazepines to imipramine:</span></strong><span style=\"font-size:12.0pt\"> While benzodiazepines can be useful for managing <strong>acute anxiety or agitation,</strong> they do<strong> not</strong> address the underlying <strong>mood dysregulation</strong> seen in <strong>bipolar disorder</strong>. Adding a<strong> benzodiazepine to imipramine</strong> <strong>would not</strong> <strong>prevent future manic episodes </strong>and could potentially <strong>complicate </strong>the <strong>clinical picture</strong> with <strong>dependency or withdrawal issues.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Add antipsychotic to imipramine:</span></strong><span style=\"font-size:12.0pt\"><strong> Adding an antipsychotic</strong> can be an <strong>appropriate</strong> <strong>intervention for managing acute mania or psychosis.</strong> However, <strong>without</strong> <strong>discontinuing the</strong> <strong>antidepressant</strong> that potentially <strong>triggered the manic episode</strong>, this approach <strong>might not</strong> fully address the<strong> risk of future manic switches</strong>. Furthermore, for <strong>long-term management, focusing</strong> on <strong>mood stabilization is essential.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Start Selective Serotonin Reuptake Inhibitor:</span></strong><span style=\"font-size:12.0pt\"> <strong>Starting a </strong></span><span style=\"font-size:12.0pt\"><strong>Selective Serotonin</strong> <strong>Reuptake Inhibitor (SSRI) </strong>in a patient showing symptoms of<strong> mania could exacerbate manic</strong> <strong>symptoms</strong>. <strong>SSRIs,</strong> like <strong>TCAs</strong>, can<strong> precipitate manic episodes </strong>in patients with <strong>bipolar disorder.</strong> Therefore, this option <strong>would no</strong>t be appropriate for <strong>modifying the treatment </strong>in response to the<strong> emergence of manic symptoms.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational objective is to understand the management of <strong>mood disorders</strong>, particularly <strong>bipolar disorder</strong>, and the <strong>importance of identifying and treating manic symptoms </strong>that may <strong>emerge during antidepressant therapy.</strong> This <strong>scenario</strong> emphasizes the need for <strong>careful</strong> <strong>evaluation and modification of treatment</strong> in patients presenting with <strong>mania</strong>, highlighting the <strong>transition from antidepressants to mood stabilizers,</strong> such as<strong> valproate, </strong>for <strong>effective</strong> management of <strong>bipolar disorder.</strong></span></span></span></p>",
    "correct_choice_id": 58437,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14603,
    "choices": [
      {
        "id": 58373,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Felbamate</span></span></p>"
      },
      {
        "id": 58374,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Methadone </span></span></p>"
      },
      {
        "id": 58375,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ketamine </span></span></p>"
      },
      {
        "id": 58376,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diltiazem </span></span></p>"
      }
    ],
    "text": "<p style=\"margin-left:0; margin-right:0; text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">All the following drugs are NMDA receptor blockers except.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>",
    "unique_key": "Q8776061",
    "question_audio": null,
    "question_video": null,
    "map_id": 36181,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Diltiazem </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>N-methyl-D-aspartate (NMDA) receptors</strong> are <strong>ionotropic glutamate receptors</strong> found in the <strong>central nervous system (CNS).</strong> These <strong>receptors</strong> are involved in <strong>synaptic plasticity</strong>, which is the process by which<strong> neurons adapt</strong> and <strong>change their strength in response</strong> to <strong>stimuli, </strong>including<strong> learning and memory. </strong>The activation of <strong>NMDA receptors </strong>requires<strong> both glutamate and glycine or D-serine,</strong> as well as the removal of a <strong>magnesium ion </strong>that<strong> blocks the channel at resting membrane potentials.</strong> The<strong> influx of calcium ions</strong> through the <strong>open channel</strong> leads to the<strong> activation of various intracellular signalling pathways</strong>, which can have<strong> both beneficial and detrimental effects on neuronal function.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>NMDA receptor blockers</strong> are drugs that<strong> inhibit the activity of NMDA receptors</strong>. They can be classified as either<strong> competitive or non-competitive antagonists, </strong>depending on the <strong>mechanism of action</strong>. <strong>Competitive antagonists </strong>bind to the<strong> same site as the agonist,</strong> whereas <strong>non-competitive antagonists bind </strong>to a <strong>separate site on the receptor.</strong> <strong>Clinically useful drugs</strong> are all <strong>non-competitive NMDA</strong> <strong>antagonists.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">IMPORTANT NDMA RECEPTOR ANTAGONISTS:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">F</span></strong><span style=\"font-size:12.0pt\">inal:&nbsp;&nbsp; <strong>F</strong>elbamate, <strong>P</strong>hencyclidine</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">N</span></strong><span style=\"font-size:12.0pt\">: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>N</strong>itrous oxide</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">M</span></strong><span style=\"font-size:12.0pt\">:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>M</strong>ethadone, <strong>M</strong>emantine, <strong>M</strong>agnesium</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">D</span></strong><span style=\"font-size:12.0pt\">:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>D</strong>extromethorphan</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">A</span></strong><span style=\"font-size:12.0pt\">:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>A</strong>camprosate, <strong>A</strong>mantadine</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">R</span></strong><span style=\"font-size:12.0pt\">eceptor:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>R</strong>iluzole</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">K</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">nockout:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>K</strong>etamine and Es<strong>k</strong>etamine</span></span></p>",
    "correct_choice_id": 58376,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14499,
    "choices": [
      {
        "id": 57957,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Flumazenil</span></span></span></p>"
      },
      {
        "id": 57958,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Disulfiram</span></span></span></p>"
      },
      {
        "id": 57959,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Acamprosate </span></span></span></p>"
      },
      {
        "id": 57960,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Naltrexone</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which of the following drugs is not used in detoxification of patients with chronic alcohol use? </span></span></span></p>",
    "unique_key": "Q6071852",
    "question_audio": null,
    "question_video": null,
    "map_id": 36177,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Flumazenil</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Flumazenil</strong> is an <strong>antagonist</strong> for<strong> benzodiazepine receptors </strong>and is primarily used to <strong>reverse the effects</strong> of <strong>benzodiazepines </strong>in cases of <strong>overdose</strong> or to<strong> hasten recovery after anesthesia</strong>. It <strong>does not</strong> have any role in the<strong> treatment or detoxification process </strong>for<strong> alcohol</strong> <strong>dependency</strong>. Its use is <strong>specific</strong> to the<strong> management of benzodiazepine-related emergencies.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Disulfiram:</span></strong><span style=\"font-size:12.0pt\"> Used as<strong> part of alcohol aversion therapy</strong>, <strong>disulfiram inhibits the enzyme acetaldehyde dehydrogenase,</strong> which leads to <strong>unpleasant effects</strong> when <strong>alcohol is consumed, </strong>thereby <strong>deterring</strong> the <strong>intake of alcohol.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Acamprosate:</span></strong><span style=\"font-size:12.0pt\"> Helps <strong>reduce</strong> the<strong> craving and relapse</strong> in <strong>alcohol dependence </strong>by<strong> modulating neurotransmission </strong>via <strong>glutamate and GABA pathways.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Naltrexone:</span></strong><span style=\"font-size:12.0pt\"> Used as an<strong> anti-craving agent,</strong> <strong>naltrexone blocks opioid receptors</strong> that are part of the <strong>reward system</strong> affected by<strong> alcohol consumption.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While<strong> disulfiram, acamprosate, and naltrexone </strong>are <strong>directly</strong> involved in the <strong>treatment strategies for alcohol dependence </strong>to prevent <strong>relapse and manage cravings</strong>, <strong>flumazenil&#39;s </strong>application is<strong> restricted to benzodiazepine reversal,</strong> underscoring the<strong> </strong>importance of understanding<strong> specific drug roles in addiction therapy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Drugs Used in Acute Ethanol Withdrawal </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Benzodiazepines</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> (chlordiazepoxide, diazepam, lorazepam): They facilitate<strong> GABA-mediated activation of GABA receptors. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Thiamine</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> (vitamin B1): <strong>Alcoholic patients</strong> are <strong>deficient in thiamine.</strong> Hence, it must be <strong>administered to patients </strong>suspected of having <strong>alcoholism</strong> (those<strong> exhibiting acute alcohol intoxication or alcohol withdrawal syndrome</strong>) to <strong>prevent Wernicke-Korsakoff syndrome. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Drugs Used in Chronic Alcoholism (Alcohol dependence)</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Naltrexone</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">:<strong> Competitive antagonist </strong>of<strong> opioid receptors</strong>. It <strong>reduces</strong> <strong>craving </strong>in alcoholics.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Acamprosate</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: <strong>NMDA receptor antagonist &amp; GABAA agonist </strong>effects. It also <strong>reduces craving.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Topiramate</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: This <strong>anticonvulsant drug </strong>is also<strong> effective in reducing craving</strong>. It potentiates the <strong>inhibitory effects of GABA</strong> but <strong>acts at</strong> a <strong>site different from BZD.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Disulfiram</span></span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: It is an<strong> inhibitor of aldehyde dehydrogenase</strong> and therefore <strong>causes accumulation of aldehyde </strong>if <strong>alcohol is ingested. </strong>This results in<strong> troublesome symptoms</strong>, like<strong> facial flushing, nausea, dizziness, headache.</strong> It is used as a <strong>deterrent agent (aversion therapy)</strong> to<strong> reduce the consumption of alcohol</strong> in motivated individuals. </span></span></p>",
    "correct_choice_id": 57957,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14620,
    "choices": [
      {
        "id": 58441,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Migraine</span></span></p>"
      },
      {
        "id": 58442,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lennox Gastaut syndrome</span></span></p>"
      },
      {
        "id": 58443,
        "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Attention Deficit Hyperactivity Disorder</span></span></p>"
      },
      {
        "id": 58444,
        "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dementia</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Topiramate is used in the treatment of?</span></span></span></p>",
    "unique_key": "Q7232425",
    "question_audio": null,
    "question_video": null,
    "map_id": 36189,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans. B) Lennox Gastaut syndrome.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong>Topiramate</strong> is a medication with<strong> multiple indications.</strong> Let&#39;s evaluate each of the options provided:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong>&nbsp;Lennox-Gastaut syndrome</strong>: This is a<strong> correct indication </strong>for <strong>topiramate.</strong> It is one of the <strong>medications</strong> that can be<strong> used to</strong> manage <strong>seizures associated with Lennox-Gastaut syndrome,</strong> which is a <strong>severe form of childhood-onset epilepsy</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A. Migraine</strong>:<strong> Topiramate</strong> is used as a<strong> prophylactic agent for migraine</strong>. It&#39;s <strong>not </strong>used to treat an <strong>acute attack of migraine </strong>but rather to <strong>decrease the frequency, severity, and duration of migraine headaches </strong>when<strong> taken regularly.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Attention Deficit Hyperactivity Disorder (ADHD</strong>): <strong>Topiramate</strong> is <strong>not </strong>a <strong>standard</strong> treatment for <strong>ADHD</strong>. The primary treatments for<strong> ADHD are stimulant medications</strong>, such as <strong>methylphenidate and amphetamines,</strong> as well as certain <strong>non-stimulant medications.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Dementia</strong>: <strong>Topiramate</strong> is <strong>not</strong> indicated for the treatment of <strong>dementia</strong>. <strong>Treatments</strong> for<strong> dementia</strong> typically include<strong> cholinesterase inhibitors and memantine</strong>, which are aimed at <strong>improving cognitive symptoms</strong> or <strong>slowing their progression.</strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">NON-ANTIEPILEPTIC USES OF TOPIRAMATE:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-182151.jpg\" style=\"height:590px; width:1000px\" /></span></span></u></strong></p>",
    "correct_choice_id": 58442,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 14604,
    "choices": [
      {
        "id": 58377,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Cefixime</span></span></span></p>"
      },
      {
        "id": 58378,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Cefoperazone</span></span></span></p>"
      },
      {
        "id": 58379,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Chlorpropamide</span></span></span></p>"
      },
      {
        "id": 58380,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Metronidazole</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patients should be cautioned not to consume alcohol when given a prescription for any of the following EXCEPT? </span></span></p>",
    "unique_key": "Q2814714",
    "question_audio": null,
    "question_video": null,
    "map_id": 36182,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Cefixime</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Disulfiram-like reaction</strong> is characterized by symptoms such as <strong>flushing, headache, nausea, vomiting, palpitations, and hypotension,</strong> which occur<strong> due to inhibition of aldehyde dehydrogenase</strong> and <strong>accumulation of acetaldehyde in the body.</strong> </span><span style=\"font-size:12.0pt\"><strong>Cefixime</strong> is a <strong>third-generation cephalosporin</strong> <strong>antibiotic</strong> that is<strong> used to treat</strong> a variety of <strong>bacterial infections.</strong> <strong>Unlike </strong>some other <strong>cephalosporins, </strong>such as <strong>cefoperazone, cefixime does not</strong> have a significant <strong>disulfiram-like interaction with alcohol. </strong>Therefore, p<strong>atients taking cefixime</strong> are <strong>not </strong>specifically <strong>cautioned against consuming alcohol </strong>due to a <strong>risk of adverse reactions</strong>, though <strong>moderation </strong>is generally <strong>advisable</strong> <strong>with any medication.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Cefoperazone:</span></strong><span style=\"font-size:12.0pt\"> Cefoperazone, a <strong>cephalosporin antibiotic,</strong> is known to cause a<strong> disulfiram-like reaction with alcohol, </strong>which can lead to symptoms like <strong>flushing, nausea, vomiting, and tachycardia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Chlorpropamide:</span></strong><span style=\"font-size:12.0pt\"> Chlorpropamide, a<strong> sulfonylurea </strong>used in the treatment of<strong> type 2 diabetes</strong>, can also cause a <strong>disulfiram-like</strong> reaction with <strong>alcohol, </strong>leading to <strong>unpleasant symptoms.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Metronidazole:</span></strong><span style=\"font-size:12.0pt\"> Metronidazole, an <strong>antibiotic</strong> used for various<strong> bacterial and protozoal infections</strong>, is well-known for causing <strong>severe disulfiram</strong>-like reactions with alcohol, including <strong>nausea, vomiting, headache, and flushing.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational objective is to<strong> know</strong> the drugs causing <strong>disulfiram like reaction with alcohol. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">DRUGS SHOWING DISULFIRAM LIKE REACTION WITH ALCOHOL:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-175109.jpg\" style=\"height:837px; width:1000px\" /></span></strong></span></span></p>",
    "correct_choice_id": 58377,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14473,
    "choices": [
      {
        "id": 57853,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Retigabine</span></span></span></p>"
      },
      {
        "id": 57854,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Lamotrigine</span></span></span></p>"
      },
      {
        "id": 57855,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Levetiracetam</span></span></span></p>"
      },
      {
        "id": 57856,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Topiramate</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Drug E in the image shown is likely to be?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/picture4.jpg\" style=\"height:185px; width:400px\" /></span></span></span></p>",
    "unique_key": "Q5498655",
    "question_audio": null,
    "question_video": null,
    "map_id": 36180,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Retigabine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Retigabine</strong>, also known as<strong> ezogabine,</strong> is an <strong>antiepileptic drug</strong> primarily used as an<strong> adjunctive treatment for focal seizures.</strong> It is unique among <strong>antiepileptic drugs</strong> because<strong> it functions as a neuronal potassium channel opener</strong>. This <strong>mechanism of action helps</strong> <strong>stabilize neuronal membranes</strong> and <strong>reduces excitability, </strong>which <strong>can prevent</strong> the <strong>occurrence of seizures.</strong> <strong>Retigabine</strong> is <strong>distinct </strong>in its <strong>class </strong>due to this<strong> unusual method </strong>of<strong> influencing neuronal activity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Lamotrigine:</span></strong><span style=\"font-size:12.0pt\"> Works by<strong> blocking voltage-gated sodium channels</strong> and <strong>diminishing glutamate</strong> release but <strong>does not </strong>act as a <strong>potassium channel opener.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Levetiracetam:</span></strong><span style=\"font-size:12.0pt\"> Has a unique mechanism involving the <strong>modulation of neurotransmitter release</strong> through <strong>binding to the</strong> <strong>synaptic vesicle protein SV2A.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Topiramate:</span></strong><span style=\"font-size:12.0pt\"> Acts through <strong>multiple mechanisms</strong>, including<strong> blocking voltage-dependent sodium channels</strong> and <strong>enhancing</strong> <strong>GABA activity, </strong>but<strong> not </strong>specifically through <strong>opening potassium channels.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Retigabine</strong> is notable for<strong> its mechanism as a neuronal potassium channel opener, </strong>a <strong>distinct mode of action </strong>that differentiates it from other antiepileptic drugs. <strong>Major adverse effects</strong> to be aware of with<strong> retigabine include retinitis and blue pigmentation of the skin.</strong></span></span></p>",
    "correct_choice_id": 57853,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "ImageBased"
    ]
  },
  {
    "id": 14599,
    "choices": [
      {
        "id": 58357,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">SNRI</span></span></span></p>"
      },
      {
        "id": 58358,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">NDRI</span></span></span></p>"
      },
      {
        "id": 58359,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Antihistaminic</span></span></span></p>"
      },
      {
        "id": 58360,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Anticholinergic</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Tramadol acts on &micro; receptor as an agonist. Additionally, it also acts as: </span></span></span></p>",
    "unique_key": "Q9336520",
    "question_audio": null,
    "question_video": null,
    "map_id": 36178,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) SNRI</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In addition to acting as <strong>an agonist at the &micro;-opioid receptor, tramadol </strong>also has <strong>activity</strong> as a<strong> serotonin-norepinephrine</strong> <strong>reuptake inhibitor (SNRI). </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This <strong>dual mechanism of action</strong> provides <strong>analgesic effects</strong> beyond those <strong>produced by opioids alone. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Tramadol </strong>is <strong>not</strong> an <strong>NDRI (norepinephrine-dopamine reuptake inhibitor), antihistaminic, or anticholinergic.</strong></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 58357,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14568,
    "choices": [
      {
        "id": 58233,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Levodopa</span></span></span></p>"
      },
      {
        "id": 58234,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Amantadine</span></span></span></p>"
      },
      {
        "id": 58235,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Trihexyphenidyl</span></span></span></p>"
      },
      {
        "id": 58236,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Selegiline</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A patient with Parkinsonism developed this condition after treatment. Which of the following agents could be the causative agent?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/picture5.jpg\" style=\"height:134px; width:300px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>",
    "unique_key": "Q5797993",
    "question_audio": null,
    "question_video": null,
    "map_id": 36179,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Amantadine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The <strong>image</strong> provided appears to show a patient with <strong>marked purplish discoloration and swelling in the lower extremities, </strong>which could be consistent with<strong> livedo reticularis,</strong> a condition known to be a<strong> potential side effect</strong> of some medications like <strong>amantadine.</strong> </span><strong><span style=\"font-size:12.0pt\">Amantadine</span></strong><span style=\"font-size:12.0pt\"> is an <strong>antiviral medication</strong> that is also used in the <strong>treatment of Parkinson&#39;s disease.</strong> One of the<strong> known side effects </strong>of amantadine is <strong>livedo reticularis,</strong> a<strong> mottled discoloration of the skin</strong> that is often <strong>purplish and reticular (net-like)</strong>. This <strong>side effect</strong> can be<strong> reversible</strong> upon<strong> discontinuation of the drug.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Levodopa</span></strong><span style=\"font-size:12.0pt\">: While levodopa is the<strong> most effective</strong> medication for the management of<strong> Parkinson&#39;s disease symptoms,</strong> it is <strong>not </strong>commonly associated with <strong>skin changes</strong> like those <strong>depicted in the image.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Trihexyphenidyl</span></strong><span style=\"font-size:12.0pt\">: An<strong> anticholinergic drug</strong> used to<strong> treat Parkinsonism, </strong>but it is <strong>not </strong>typically <strong>linked with the skin condition</strong> <strong>shown.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. &nbsp;Selegiline</span></strong><span style=\"font-size:12.0pt\">: An <strong>MAO-B inhibitor </strong>used to help control the <strong>symptoms of Parkinson&#39;s disease</strong>. It also <strong>does not</strong> commonly cause the <strong>skin changes seen in the image</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational goal is to recognize the <strong>side effects</strong> associated with <strong>medications </strong>used in the <strong>treatment of Parkinson&#39;s disease</strong>. <strong>Amantadine </strong>can <strong>cause livedo reticularis</strong>, which is characterized by a<strong> purplish, mottled skin discoloration.</strong></span></span></span></p>",
    "correct_choice_id": 58234,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 14450,
    "choices": [
      {
        "id": 57761,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Varenicline</span></span></span></p>"
      },
      {
        "id": 57762,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Bupropion</span></span></span></p>"
      },
      {
        "id": 57763,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Nicotine chewing gum.</span></span></span></p>"
      },
      {
        "id": 57764,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">All the above</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which of the following drug is used in cigarette smoking cessation?</span></span></span></p>",
    "unique_key": "Q6652929",
    "question_audio": null,
    "question_video": null,
    "map_id": 36186,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) All the above</span></strong>&nbsp;</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">All the options listed (<strong>A: Varenicline, B: Bupropion, C: Nicotine chewing gum</strong>) are <strong>utilized </strong>for <strong>smoking cessation,</strong> <strong>each</strong> operating through <strong>distinct mechanisms:</strong></span></span></span></p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Varenicline:</span></strong><span style=\"font-size:12.0pt\"> Acts as <strong>a partial agonist at nicotinic receptors</strong> in the brain. It reduces <strong>cravings and withdrawal symptoms</strong> and <strong>blocks </strong>the<strong> rewarding effects of smoking.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Bupropion:</span></strong><span style=\"font-size:12.0pt\"> This <strong>antidepressant aids smoking cessation,</strong> likely by<strong> modulating neurotransmitters like dopamine</strong> and <strong>norepinephrine</strong>, though its exact<strong> mechanism in smoking cessation</strong> <strong>isn&#39;t fully understood.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Nicotine chewing gum:</span></strong><span style=\"font-size:12.0pt\"> Provides <strong>nicotine replacement therapy </strong>by <strong>delivering controlled nicotine doses,</strong> which <strong>helps</strong> <strong>manage withdrawal symptoms</strong> and <strong>reduce smoking urges.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Varenicline:</span></strong><span style=\"font-size:12.0pt\"> <strong>Correct</strong> in<strong> aiding smoking cessation </strong>but <strong>not </strong>the only option.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Bupropion:</span></strong><span style=\"font-size:12.0pt\"> <strong>Correct</strong> but is<strong> one among</strong> several<strong> options.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Nicotine chewing gum:</span></strong><span style=\"font-size:12.0pt\"> Also <strong>correct</strong>, functions as <strong>part of nicotine replacement therapy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Several pharmacological options</strong> are available for <strong>smoking cessation</strong>, as discussed below </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-135415.jpg\" style=\"height:469px; width:1000px\" /></p>",
    "correct_choice_id": 57764,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 14560,
    "choices": [
      {
        "id": 58201,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Diazepam </span></span></span></p>"
      },
      {
        "id": 58202,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Lorazepam </span></span></span></p>"
      },
      {
        "id": 58203,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Phenytoin </span></span></span></p>"
      },
      {
        "id": 58204,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Sodium valproate</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 25-year-old female patient with a history of epilepsy presents to the emergency room with a prolonged seizure. According to her relatives, she has been experiencing convulsions for over 10 minutes. Which of the following is the drug of choice for the treatment of status epilepticus in this patient?</span></span></span></p>",
    "unique_key": "Q8379190",
    "question_audio": null,
    "question_video": null,
    "map_id": 36174,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Lorazepam</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Status epilepticus </strong>is a <strong>medical emergency </strong>that<strong> requires prompt </strong>treatment to<strong> prevent neurological damage </strong>and other<strong> complications.</strong> The<strong> first-line treatment </strong>for <strong>status epilepticus</strong> is usually a benzodiazepine such as<strong> lorazepam, </strong>which can help to <strong>rapidly terminate the seizure activity.</strong> Lorazepam has a<strong> longer duration of action </strong>compared to diazepam and is <strong>less likely</strong> to cause <strong>respiratory depression.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">If the<strong> seizure continues despite benzodiazepine treatment, </strong>the next step is typically to administer a second-line antiepileptic medication, such as phenytoin or Fosphenytoin.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-162643.jpg\" style=\"height:793px; width:1000px\" /></span></span></span></p>",
    "correct_choice_id": 58202,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14580,
    "choices": [
      {
        "id": 58281,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phenytoin</span></span></p>"
      },
      {
        "id": 58282,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Carbamazepine</span></span></span></p>"
      },
      {
        "id": 58283,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Valproate</span></span></span></p>"
      },
      {
        "id": 58284,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ethosuximide</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 30-year-old woman with a history of epilepsy has been on antiepileptic medication for several years. She presents to the clinic with concerns about excessive hair growth on her face and body, which has been progressively increasing in density over the past year. Her medical history is otherwise unremarkable, and she is not on any other medications. Which of the following antiepileptic drugs, if it is part of her treatment regimen, is known to cause hirsutism and could be responsible for the excessive hair growth in this patient?</span></span></span></p>",
    "unique_key": "Q9650503",
    "question_audio": null,
    "question_video": null,
    "map_id": 36187,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Phenytoin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Phenytoin</span></strong><span style=\"font-size:12.0pt\"> is known to cause hirsutism as a side effect. Hirsutism refers to excessive, unwanted hair growth in women in areas where men typically grow hair, such as the face and back. Phenytoin can stimulate hair growth due to its effects on the hair follicles, and this side effect can be distressing to patients.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Carbamazepine</span></strong><span style=\"font-size:12.0pt\">: While carbamazepine has various side effects, hirsutism is not commonly reported with its use.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Valproate</span></strong><span style=\"font-size:12.0pt\">: Valproate is associated with several side effects, including weight gain and hair loss or changes in hair texture, but not typically with hirsutism.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Ethosuximide</span></strong><span style=\"font-size:12.0pt\">: Ethosuximide is used primarily for absence seizures and is not commonly associated with hirsutism as a side effect.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational goal is to identify the side effects associated with antiepileptic drugs, particularly phenytoin, which can cause hirsutism. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Important drugs associated with hirsutism are:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">P:&nbsp; P</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">henytoin</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">C:&nbsp; C</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">yclosporine</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">M:&nbsp; M</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">inoxidil</span></span></span></p>",
    "correct_choice_id": 58281,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14616,
    "choices": [
      {
        "id": 58425,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Pramipexole </span></span></span></p>"
      },
      {
        "id": 58426,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Gabapentin</span></span></span></p>"
      },
      {
        "id": 58427,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Iron supplementation </span></span></span></p>"
      },
      {
        "id": 58428,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Vit B12</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A young patient presents to OPD with complaints of crawling sensation under his skin on legs. This feeling is relieved as soon as he starts moving his legs. What is the appropriate treatment for him? </span></span></span></p>",
    "unique_key": "Q9614506",
    "question_audio": null,
    "question_video": null,
    "map_id": 36188,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Gabapentin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The<strong> patient&#39;s symptoms</strong> of<strong> crawling sensation</strong> under the<strong> skin in the legs </strong>that is <strong>relieved by movement</strong> are <strong>suggestive of restless legs syndrome (RLS).</strong> <strong>Gabapentin </strong>is<strong> DOC</strong> for <strong>restless leg syndrome </strong>according to latest guidelines.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Other Options:</span></span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option A. Pramipexole</strong> is a <strong>dopamine agonist</strong> that is<strong> effective</strong> in the <strong>treatment of restless</strong> <strong>legs syndrome</strong>. It works by <strong>increasing dopamine levels in the brain,</strong> which <strong>helps</strong> <strong>alleviate the unpleasant sensations</strong> and the<strong> urge to move the legs.</strong> It was considered <strong>DOC for restless leg syndrome previously</strong>, but <strong>gabapentin</strong> is preferred now due to<strong> its better safety profile.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option C. Iron supplementation</strong> could be <strong>beneficia</strong>l if the patient has <strong>iron deficiency</strong> <strong>anaemia</strong>.</span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option D. vitamin B12&nbsp; supplementation&nbsp;</strong>&nbsp;may be<strong> helpful </strong>if there is a<strong> vit-B12&nbsp;&nbsp;deficiency. </strong></span></span></p>",
    "correct_choice_id": 58426,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14464,
    "choices": [
      {
        "id": 57817,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Fentanyl</span></span></span></p>"
      },
      {
        "id": 57818,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Morphine</span></span></span></p>"
      },
      {
        "id": 57819,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Codeine</span></span></span></p>"
      },
      {
        "id": 57820,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Oxycodone</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Mr. Raj Kumar, a 60-year-old male, has been diagnosed with terminal pancreatic cancer and is experiencing severe pain that is not adequately controlled with oral medications. His physician wants to switch him to a transdermal opioid for more consistent pain control. Which of the following opioids would be the best choice for this patient&rsquo;s malignancy-associated pain?</span></span></span></p>",
    "unique_key": "Q8903345",
    "question_audio": null,
    "question_video": null,
    "map_id": 36175,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans.&nbsp;A) Fentanyl </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Fentanyl </strong>is a <strong>highly potent synthetic opioid </strong>ideal for the management of <strong>severe chronic pain</strong>, especially in <strong>cancer patients,</strong> due to its <strong>high lipophilicity </strong>which allows it to be <strong>effectively administered via a transdermal patch</strong>. This <strong>route</strong> provides <strong>consistent</strong> and <strong>sustained analgesia over 72 hours or more</strong>, crucial for patients<strong> requiring stable pain control.</strong> <strong>Fentanyl&rsquo;s effectiveness and ease</strong> of use via<strong> transdermal systems </strong>make it<strong> superior </strong>in this context <strong>compared to other opioids</strong> that are typically <strong>administered orally or by</strong> <strong>injection.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Morphine:</span></strong><span style=\"font-size:12.0pt\"> While effective for <strong>pain management, </strong>it is usually<strong> administered orally or intravenously </strong>and <strong>not commonly</strong> used <strong>transdermally.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Codeine:</span></strong><span style=\"font-size:12.0pt\"><strong> Less potent</strong> than fentanyl and generally used for <strong>milder pain.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Oxycodone:</span></strong><span style=\"font-size:12.0pt\"> Also<strong> effective for pain </strong>control but <strong>lacks the transdermal formulation</strong> that would provide the<strong> continuous</strong> <strong>delivery </strong>needed for this patient&rsquo;s condition.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Fentanyl transdermal patches</strong> are particularly <strong>suited for continuous</strong>, <strong>long-term pain management</strong> in patients with <strong>severe</strong> <strong>malignancy-associated pain, </strong>offering a <strong>practical and effective </strong>option for <strong>maintaining consistent analgesic levels.</strong></span></span></p>",
    "correct_choice_id": 57817,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 14607,
    "choices": [
      {
        "id": 58389,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Binding to a specific synaptic protein labelled &#39;SV2A&#39;.</span></span></span></p>"
      },
      {
        "id": 58390,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibitor of GABA transporter GAT-1 </span></span></span></p>"
      },
      {
        "id": 58391,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Inhibitor of GABA transaminase </span></span></span></p>"
      },
      {
        "id": 58392,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CRMP-2 inhibitor</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 35-year-old male presents with a history of recurrent seizures that have been unresponsive to first-line antiepileptic medications. His neurologist is considering adding levetiracetam as a part of his treatment plan. Which of the following best describes the mechanism of action of levetiracetam in controlling seizures?</span></span></span></p>",
    "unique_key": "Q2542630",
    "question_audio": null,
    "question_video": null,
    "map_id": 36185,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Binding to a specific synaptic protein labelled &#39;SV2A&#39;.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Levetiracetam </strong>is an <strong>antiepileptic drug</strong> that has a unique<strong> mechanism of action</strong> compared to other antiepileptic medications. The options provided describe<strong> different mechanisms</strong> related to <strong>seizure control:</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Binding to a specific synaptic protein labelled &#39;SV2A&#39;</strong>: <strong>Levetiracetam</strong> <strong>binds</strong> to a <strong>synaptic vesicle glycoprotein</strong> called <strong>SV2A.</strong> This <strong>interaction</strong> is believed to<strong> modulate neurotransmitter release,</strong> particularly<strong> reducing the excessive release </strong>of <strong>excitatory neurotransmitters </strong>like <strong>glutamate,</strong> thus<strong> reducing seizure activity.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Inhibitor of GABA transporter GAT-1</span></strong><span style=\"font-size:12.0pt\">: I<strong>nhibition of GAT-1</strong> would <strong>increase</strong> the availability of <strong>GABA,</strong> an <strong>inhibitory</strong> <strong>neurotransmitter</strong>, in the <strong>synaptic cleft.</strong> This mechanism is<strong> not </strong>the <strong>primary mode of action</strong> for<strong> levetiracetam, </strong>but it is the primary <strong>mechanism of action</strong> for <strong>other antiepileptic drugs</strong>, such as<strong> tiagabine.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Inhibitor of GABA transaminase:</span></strong><span style=\"font-size:12.0pt\"> <strong>Inhibition of GABA transaminase </strong>would<strong> prevent</strong> the breakdown of<strong> GABA,</strong> thereby <strong>increasing its concentration </strong>and enhancing its<strong> inhibitory effects.</strong> This mechanism is <strong>not</strong> the primary <strong>mode of action </strong>for <strong>levetiracetam but</strong> is the <strong>primary mechanism</strong> <strong>of action </strong>for drugs like <strong>vigabatrin.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CRMP-2 inhibitor:</span></strong><span style=\"font-size:12.0pt\"> <strong>Collapsin response mediator protein 2 (CRMP-2)</strong></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong> </strong>is a <strong>protein</strong> involved in <strong>neuronal development </strong>and <strong>axonal growth</strong>. <strong>Lacosamide,</strong> an<strong> antiepileptic drug,</strong> is indeed thought to <strong>interact with collapsin response mediator protein 2 </strong>(<strong>CRMP</strong>-2). This interaction is believed to <strong>stabilize hyperexcitable neuronal membranes</strong>, thus <strong>reducing seizure activity</strong>.<strong> Lacosamide</strong> also enhances the <strong>slow inactivation of voltage-gated sodium channels</strong>, contributing to its <strong>antiepileptic effects.</strong></span></span></span></p>",
    "correct_choice_id": 58389,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14466,
    "choices": [
      {
        "id": 57825,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Flumazenil should be administered intramuscularly for rapid onset of action. </span></span></span></p>"
      },
      {
        "id": 57826,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Flumazenil should be used as a first-line treatment for all cases of benzodiazepine overdose. </span></span></span></p>"
      },
      {
        "id": 57827,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Flumazenil may precipitate seizures in patients with a history of benzodiazepine dependence or withdrawal. </span></span></span></p>"
      },
      {
        "id": 57828,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Flumazenil is not effective in reversing the respiratory depression caused by benzodiazepine overdose.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Mr. Chetan, a 35-year-old male, is brought to the emergency department with a suspected drug overdose. He is unresponsive and has shallow breathing. His medical history indicates that he has a history of benzodiazepine abuse. Which of the following statements is true regarding the use of flumazenil in this patient? </span></span></span></p>",
    "unique_key": "Q6798747",
    "question_audio": null,
    "question_video": null,
    "map_id": 36176,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Flumazenil may precipitate seizures in patients with a history of benzodiazepine dependence or withdrawal.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Flumazenil</strong> is a <strong>benzodiazepine receptor antagonist</strong> used as an <strong>antidote</strong> in cases of <strong>benzodiazepine overdose.</strong> It can effectively <strong>reverse</strong> the c<strong>entral depressant effects of benzodiazepines,</strong> including <strong>sedation and respiratory depression</strong>, potentially<strong> restoring</strong> <strong>normal breathing and consciousness</strong>. However, its<strong> use carries the risk of precipitating seizures</strong>, particularly in individuals<strong> with long-term benzodiazepine use </strong>due to the <strong>sudden withdrawal effec</strong>t it <strong>can induce</strong>. This <strong>risk</strong> is significant in patients with a<strong> history of</strong> <strong>benzodiazepine dependence</strong> or those who have used these <strong>drugs to control seizure disorders.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Flumazenil should be administered intramuscularly for rapid onset of action:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect,</strong> as <strong>flumazenil </strong>should be administered<strong> intravenously for rapid </strong>and <strong>effective reversal of benzodiazepine effects.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Flumazenil should be used as a first-line treatment for all cases of benzodiazepine overdose:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect,</strong> because <strong>supportive care</strong> and<strong> ensuring airway management </strong>are priorities in<strong> benzodiazepine overdose situations </strong>before considering flumazenil, especially <strong>due to its risks </strong>in certain<strong> populations.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Flumazenil is not effective in reversing the respiratory depression caused by benzodiazepine overdose:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect</strong>, as <strong>flumazenil</strong> can <strong>effectively reverse respiratory depression </strong>caused by<strong> benzodiazepines</strong>, though it <strong>must be </strong>used <strong>cautiously.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Flumazenil</strong>, while <strong>effective </strong>as an<strong> antidote for benzodiazepine overdose,</strong> should be<strong> used with caution</strong>, <strong>especially in individuals</strong> with a <strong>history of long-term benzodiazepine use or dependence,</strong> as it may<strong> precipitate seizures</strong> due to<strong> withdrawal effects.</strong></span></span></p>",
    "correct_choice_id": 57827,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14507,
    "choices": [
      {
        "id": 57989,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue treatment. </span></span></span></p>"
      },
      {
        "id": 57990,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Continue treatment for 2 years.</span></span></span></p>"
      },
      {
        "id": 57991,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Continue lifelong treatment.</span></span></span></p>"
      },
      {
        "id": 57992,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue treatment and follow up with 6 monthly EEG.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">What is the appropriate management for a 16-year-old female who has been treated with antiepileptic medication for seizure episodes while asleep and has been seizure-free for 6 months with normal neuroimaging and EEG?</span></span></span></p>",
    "unique_key": "Q6393390",
    "question_audio": null,
    "question_video": null,
    "map_id": 36183,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Continue treatment for 2 years.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Continuing<strong> antiepileptic medication for 2 years </strong>after the<strong> last seizure</strong> is a <strong>common</strong> and <strong>recommended practice,</strong> especially in cases where the<strong> patient has achieved a good level of control,</strong> as evidenced by <strong>being seizure-free </strong>with <strong>normal EEG </strong>and <strong>imaging results.</strong> The <strong>rationale</strong> for continuing treatment is based on <strong>reducing the risk of recurrence</strong>, which remains <strong>significant during this period.</strong> <strong>After 2 years of seizure freedom,</strong> a <strong>trial</strong> of <strong>medication withdrawal </strong>may be considered, with <strong>careful monitoring</strong> for <strong>any signs of seizure recurrence</strong>. It is<strong> reasonable to attempt withdrawal </strong>of therapy <strong>after 2</strong> <strong>years in a patient</strong> who <strong>meets </strong>the following criteria: </span></span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Complete medical control of seizures</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Single seizure type, either focal or generalized. </span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Normal neurologic examination</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Normal EEG </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Discontinue treatment:</span></strong><span style=\"font-size:12.0pt\"> <strong>Premature discontinuation of antiepileptic drugs</strong> can lead to <strong>recurrence of seizures</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Continue lifelong treatment:</span></strong><span style=\"font-size:12.0pt\"> <strong>Not all cases</strong> require <strong>lifelong medication</strong>; the <strong>decision depends</strong> on<strong> individual risk factors </strong>and <strong>seizure control.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Discontinue treatment and follow up with 6 monthly EEG:</span></strong><span style=\"font-size:12.0pt\"> This <strong>might expose</strong> the patient to the <strong>risk of seizure recurrence</strong> <strong>without adequate monitoring. Regular monitoring with EEG </strong>is<strong> crucial </strong>if a decision to<strong> taper or discontinue the medication</strong> is made <strong>after the recommended period.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For a <strong>patient</strong> who <strong>has been seizure-free</strong> for a <strong>significant period,</strong> it is generally advisable to<strong> continue antiepileptic treatment for</strong> at <strong>least 2 years</strong> <strong>before </strong>considering a<strong> gradual withdrawal,</strong> <strong>contingent upon ongoing stability</strong> and <strong>normal neurological assessments.</strong></span></span></span></p>",
    "correct_choice_id": 57990,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14606,
    "choices": [
      {
        "id": 58385,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Epinephrine</span></span></span></p>"
      },
      {
        "id": 58386,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Dobutamine</span></span></span></p>"
      },
      {
        "id": 58387,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Morphine</span></span></span></p>"
      },
      {
        "id": 58388,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Indomethacin</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A boy aged 14 years was brought to the hospital emergency with crush injury of both lower legs. An eyewitness who brought the boy said that a bus had run over his legs about 20 min. ago. The legs were crushed but he had not bled much. He also said that initially the boy was shrieking in pain but had fainted on the way to the hospital. Preliminary examination reveals that the patient is in a semiconscious state, looks pale, the pulse is fast, low volume and collapsing. Both legs have sustained multiple fractures, the skin and soft tissues have lacerated from which blood is oozing, but there is no active bleeding. There is no apparent head injury. Which drug should be administered immediately, before even completing a thorough physical examination?</span></span></p>",
    "unique_key": "Q3884346",
    "question_audio": null,
    "question_video": null,
    "map_id": 36184,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Morphine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In this case, the<strong> boy </strong>has suffered a <strong>traumatic crush injury </strong>to<strong> both lower legs</strong> with <strong>multiple fractures and lacerations</strong>. He is in a <strong>semiconscious state,</strong> <strong>pale, with a fast and weak pulse,</strong> indicating that he may be in <strong>shock.</strong> </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Symptoms and signs </strong>indicate that the patient is <strong>going into neurogenic shock </strong>due to the<strong> excruciating pain of the crush injury</strong>. As such, the <strong>priority is to relieve acute pain.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Morphine</span></strong><span style=\"font-size:12.0pt\"> is an <strong>appropriate choice </strong>for managing the <strong>patient&#39;s pain </strong>and can also <strong>help to reduce anxiety.</strong> It has <strong>vasodilatory effects</strong> which can<strong> help to stabilize the patient&#39;s blood pressure</strong>. However, the use of<strong> morphine </strong>should be carefully <strong>monitored</strong> due to the <strong>risk of respiratory depression</strong>, especially in a <strong>patient with hemodynamic instability.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\"><strong>Other Options:</strong></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Epinephrine</span></strong><span style=\"font-size:12.0pt\"> is a<strong> vasoconstrictor</strong> and may help to <strong>temporarily stabilize</strong> the patient&#39;s <strong>blood pressure</strong>, but it can also <strong>increase heart rate</strong> and <strong>oxygen demand, </strong>potentially <strong>worsening the situation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Dobutamine</span></strong><span style=\"font-size:12.0pt\"> is a<strong> positive inotropic agent</strong> that can <strong>increase cardiac output</strong>, but it is <strong>not</strong> the <strong>first-line treatment </strong>in this situation.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Indomethacin&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is a <strong>nonsteroidal anti-inflammatory drug (NSAID) </strong>and is<strong> not</strong> the most appropriate<strong> choice for </strong>managing this patient&#39;s<strong> acute pain and potential shock.</strong></span></span></p>",
    "correct_choice_id": 58387,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14586,
    "choices": [
      {
        "id": 58305,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Parkinsonism</span></span></span></p>"
      },
      {
        "id": 58306,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Acute muscle dystonia</span></span></span></p>"
      },
      {
        "id": 58307,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Tardive dyskinesia</span></span></span></p>"
      },
      {
        "id": 58308,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Akathisia</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Propranolol is useful in the management of which of the following side effects of a typical neuroleptic?</span></span></span></p>",
    "unique_key": "Q5652478",
    "question_audio": null,
    "question_video": null,
    "map_id": 36207,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Akathisia</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Propranolol, </strong>a<strong> non-selective beta-blocker,</strong> is useful in the management of<strong> akathisia,</strong> which is a<strong> common side effect</strong> of <strong>typical neuroleptics (antipsychotic drugs).</strong> Akathisia is characterized by a <strong>subjective feeling of restlessness</strong> and an<strong> objective need to move</strong>, often<strong> resulting in</strong> <strong>pacing and inability to sit still</strong>. <strong>Propranolol </strong>helps <strong>alleviate </strong>these symptoms by <strong>blocking beta-adrenergic receptors</strong>, which can<strong> modulate </strong>some of the pathways involved in <strong>akathisia.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Parkinsonism:</span></strong><span style=\"font-size:12.0pt\"> Parkinsonism induced by<strong> neuroleptics </strong>is <strong>treated</strong> with <strong>anticholinergic medications</strong>, not beta-blockers like propranolol.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Acute muscle dystonia:</span></strong><span style=\"font-size:12.0pt\"> Acute dystonia resulting from <strong>neuroleptic use</strong> is usually <strong>treated </strong>with<strong> anticholinergic agents</strong> <strong>or benzodiazepines</strong>, not beta-blockers.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Tardive dyskinesia:</span></strong><span style=\"font-size:12.0pt\"> Tardive dyskinesia is a<strong> late-onset movement disorder </strong>caused by<strong> long-term use of neuroleptics</strong>. Treatment options may include <strong>reducing the dose</strong> of the <strong>neuroleptic,</strong> <strong>switching</strong> to a <strong>less potent agent,</strong> or using medications like <strong>valbenazine or</strong> <strong>deutetrabenazine, </strong>not typically beta-blockers.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational objective is to recognize that <strong>propranolol,</strong> a<strong> beta-blocker,</strong> is <strong>effective</strong> in <strong>managing akathisia,</strong> a <strong>side effect</strong> characterized by<strong> restlessness and an uncontrollable</strong> need to<strong> move</strong>, often associated with the<strong> use of typical neuroleptics. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment of extrapyramidal symptoms:</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-172358.jpg\" style=\"height:386px; width:1000px\" /></span></span></strong></p>",
    "correct_choice_id": 58308,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 14484,
    "choices": [
      {
        "id": 57897,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Polycystic ovarian syndrome </span></span></span></p>"
      },
      {
        "id": 57898,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Alopecia</span></span></span></p>"
      },
      {
        "id": 57899,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Weight loss </span></span></span></p>"
      },
      {
        "id": 57900,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Tremor</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which one of the following is a gender specific side effect of valproate? </span></span></span></p>",
    "unique_key": "Q2247699",
    "question_audio": null,
    "question_video": null,
    "map_id": 36193,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Polycystic ovarian syndrome</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Valproate</strong>, an <strong>antiepileptic drug</strong> used to<strong> treat seizures and mood disorders</strong>, has been associated with the <strong>development of polycystic</strong> <strong>ovarian syndrome (PCOS) in women</strong>. PCOS is characterized by the<strong> presence of ovarian cysts, irregular menstrual cycles,</strong> and <strong>elevated androgen levels,</strong> which can<strong> lead to</strong> symptoms such as<strong> hirsutism and acne.</strong> The <strong>link between</strong> <strong>valproate and PCOS </strong>is particularly noted in <strong>young women</strong> who use the<strong> drug over long periods, </strong>making it a significant<strong> gender-specific side effect.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Alopecia:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While <strong>hair loss</strong> is a known side effect of <strong>valproate</strong>, it is not gender-specific.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Weight loss:&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>Weight gain</strong>, rather than loss, is <strong>more </strong>commonly associated <strong>with valproate.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Tremor:&nbsp;</span></strong><span style=\"font-size:12.0pt\">This <strong>side effec</strong>t is not gender-specific and can affect <strong>anyone taking valproate.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The use of <strong>valproate in young women </strong>needs <strong>careful </strong>consideration <strong>due to the risk of inducing polycystic ovarian syndrome, </strong>a <strong>serious and gender-specific side effect</strong>, underscoring the need for <strong>monitoring </strong>and possibly<strong> seeking alternative treatments</strong> where <strong>feasible.</strong></span></span></p>",
    "correct_choice_id": 57897,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14608,
    "choices": [
      {
        "id": 58393,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Rivastigmine</span></span></span></p>"
      },
      {
        "id": 58394,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Donepezil</span></span></span></p>"
      },
      {
        "id": 58395,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Memantine</span></span></span></p>"
      },
      {
        "id": 58396,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Galantamine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which of the following agents is available as a patch for once-daily use and is likely to provide steady drug levels to treat Alzheimer&rsquo;s disease? </span></span></span></p>",
    "unique_key": "Q8627601",
    "question_audio": null,
    "question_video": null,
    "map_id": 36192,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Rivastigmine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Rivastigmine</strong> is a newer reversible<strong> anticholinesterase</strong> indicated for the <strong>treatment of dementia and Alzheimer&rsquo;s disease. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It has<strong> better CNS penetration</strong> than other drugs of this group. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It is the only agent available as a<strong> transdermal patch</strong> for the<strong> treatment of Alzheimer&rsquo;s disease. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It may also be <strong>used for dementia </strong>associated with <strong>Parkinson&rsquo;s disease. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It is applied<strong> every 24 hours </strong>to<strong> improve patient compliance.&nbsp;</strong></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 58393,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 14571,
    "choices": [
      {
        "id": 58245,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Give propranolol.</span></span></span></p>"
      },
      {
        "id": 58246,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Increase dose of haloperidol</span></span></span></p>"
      },
      {
        "id": 58247,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Reassurance</span></span></span></p>"
      },
      {
        "id": 58248,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Give benzhexol.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A patient of schizophrenia was prescribed haloperidol. Next day, he presented to the hospital with the features shown in the figure. What should be the treatment?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/picture6.jpg\" style=\"height:300px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q9547388",
    "question_audio": null,
    "question_video": null,
    "map_id": 36204,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"margin-right:-1px; text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Give benzhexol.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This figure shows <strong>torticollis</strong>. It is an <strong>acute muscular dystonia</strong>, an <strong>extrapyramidal side effect of typical antipsychotics. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This<strong> can </strong>appear <strong>within a few hours</strong> after the<strong> administration of antipsychotic drugs</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Extrapyramidal side effects</strong> are seen<strong> more </strong>commonly with the <strong>use of high potency </strong>drugs like <strong>haloperidol and fluphenazine. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Benzhexol </strong>is the<strong> drug of choice</strong> for<strong> acute muscular dystonia.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-164806.jpg\" style=\"height:465px; width:1000px\" /></span></span></span></p>",
    "correct_choice_id": 58248,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ImageBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 14452,
    "choices": [
      {
        "id": 57769,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Levodopa is an active metabolite of dopamine.</span></span></span></p>"
      },
      {
        "id": 57770,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">About 50% of administered levodopa is peripherally converted to carbidopa.</span></span></span></p>"
      },
      {
        "id": 57771,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">About 2 % of the administered levodopa crosses blood brain barrier.&nbsp;&nbsp;</span></span></span></p>"
      },
      {
        "id": 57772,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Levodopa is a first line drug in the treatment of hepatic coma.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">True about anti - Parkinson drug levodopa is?</span></span></span></p>",
    "unique_key": "Q3056515",
    "question_audio": null,
    "question_video": null,
    "map_id": 36205,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) About 2% of the administered levodopa crosses the blood brain border.&nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Levodopa</strong> is <strong>effectively used</strong> in the treatment of <strong>Parkinson&rsquo;s disease,</strong> primarily because it serves as a <strong>precursor to dopamine,</strong> a <strong>neurotransmitter</strong> that is <strong>deficient in patients with Parkinson&#39;s. Once administered, levodopa </strong>is<strong> converted</strong> into <strong>dopamine</strong> within the <strong>brain to alleviate symptoms </strong>such as <strong>tremors, rigidity, and bradykinesia</strong>. However, the challenge with<strong> levodopa</strong> treatment is its limited ability to<strong> cross the blood-brain barrier</strong>&mdash;only about <strong>1-3% of administered levodopa </strong>reaches the brain. To improve this <strong>delivery and increase the amount of levodopa</strong> reaching the<strong> brain,</strong> it is often <strong>administered with carbidopa,</strong> an <strong>inhibitor </strong>of the enzyme (aromatic <strong>L-amino acid decarboxylase</strong>) that <strong>converts levodopa to dopamine</strong> <strong>outside the brain.</strong> This<strong> inhibition prevents</strong> the <strong>peripheral metabolism of levodopa, </strong>thereby <strong>allowing more</strong> of it to <strong>cross into the brain </strong>where <strong>it can be effective.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Levodopa is an active metabolite of dopamine:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect,</strong> as <strong>levodopa is not a metabolite</strong> <strong>but a precursor </strong>that is <strong>converted to dopamine in the brain.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. About 50% of administered levodopa is peripherally converted to carbidopa:</span></strong><span style=\"font-size:12.0pt\"><strong> Incorrect,</strong> carbidopa is <strong>not</strong> a product of <strong>levodopa metabolism</strong> but is <strong>rather</strong> used to<strong> inhibit the peripheral conversion of levodopa to dopamine.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Levodopa is a first-line drug in the treatment of hepatic coma:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect, </strong>as levodopa <strong>is not</strong> used for <strong>hepatic coma</strong>, which is related to<strong> liver failure </strong>and<strong> not </strong>typically managed<strong> </strong>with<strong> dopamine precursors.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Only a <strong>small fraction (about 1-3%) </strong>of administered <strong>levodopa crosses the blood-brain barrier</strong> to become <strong>active in the brain,</strong> necessitating the<strong> co-administration of carbidopa</strong> to<strong> inhibit its peripheral metabolism</strong> and <strong>increase its central availability</strong> and <strong>effectiveness</strong> in<strong> treating Parkinson&#39;s disease.</strong></span></span></p>",
    "correct_choice_id": 57771,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14601,
    "choices": [
      {
        "id": 58365,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Tachycardia</span></span></span></p>"
      },
      {
        "id": 58366,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Respiratory depression</span></span></span></p>"
      },
      {
        "id": 58367,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Urinary retention</span></span></span></p>"
      },
      {
        "id": 58368,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Severe itching</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient is operated on for bile duct stricture. Post operatively he is receiving 3 ml epidural morphine for pain relief. One day he accidentally received 12 ml of morphine. What will not occur? </span></span></p>",
    "unique_key": "Q3760613",
    "question_audio": null,
    "question_video": null,
    "map_id": 36190,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Tachycardia</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Epidural administration of morphine</strong> can provide <strong>excellent pain relief, </strong>but it <strong>can</strong> also <strong>lead to adverse effects</strong> such as <strong>respiratory depression, urinary retention, and pruritus </strong>(<strong>severe itching</strong>). The <strong>risk </strong>of <strong>adverse effects is higher</strong> if the patient receives an <strong>overdose of morphine</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Tachycardia </strong>is <strong>not</strong> a<strong> common adverse effect of morphine</strong>, and it is<strong> not </strong>expected to occur in response to an <strong>overdose.</strong> Rather<strong> bradycardia </strong>can be seen<strong> due to depression of cardiovascular centre in brain.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Vomiting and retching</strong> are <strong>common adverse effects of morphine</strong> and can <strong>occur</strong> with an <strong>overdose. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Respiratory depression</strong> is the most significant <strong>adverse effect of morphine </strong>and can be <strong>life-threatening in severe cases. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Urinary retention </strong>is another common <strong>adverse effect</strong> of morphine that occurs due to the <strong>inhibition of bladder</strong> <strong>contractions. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Severe itching, or pruritus,</strong> is another common <strong>adverse effect of morphine</strong> that can be<strong> bothersome</strong> for the patient.</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 58365,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14505,
    "choices": [
      {
        "id": 57981,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Cardiac anomalies </span></span></span></p>"
      },
      {
        "id": 57982,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Neural defects </span></span></span></p>"
      },
      {
        "id": 57983,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Facial defects </span></span></span></p>"
      },
      {
        "id": 57984,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Urogenital malformations</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 30-year-old pregnant woman with a history of bipolar disorder has been taking lithium throughout her pregnancy. Her neonate should be screened for which of the following?</span></span></span></p>",
    "unique_key": "Q4598704",
    "question_audio": null,
    "question_video": null,
    "map_id": 36197,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Cardiac anomalies.</span></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Lithium</strong> use <strong>during pregnancy, </strong>especially during the <strong>first trimester,</strong> is associated with an <strong>increased risk of congenital cardiac</strong> <strong>anomalies in the neonate,</strong> most <strong>notably Ebstein&#39;s anomaly,</strong> which is a<strong> rare heart defect </strong>affecting the<strong> tricuspid valve and right side of the heart</strong>. Therefore, <strong>neonates born to mothers </strong>who have taken<strong> lithium</strong> during <strong>pregnancy </strong>should be<strong> closely monitored</strong> and <strong>screened for cardiac anomalies.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Neural defects</span></strong><span style=\"font-size:12.0pt\">: While<strong> important to screen</strong> for in <strong>general, neural tube defects</strong> are <strong>more closely </strong>associated with medications like<strong> valproate and carbamazepine </strong>rather than lithium.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Facial defects</span></strong><span style=\"font-size:12.0pt\">: Facial defects, such as<strong> cleft lip and palate,</strong> are<strong> not</strong> specifically associated with <strong>lithium </strong>use <strong>during pregnancy.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Urogenital malformations</span></strong><span style=\"font-size:12.0pt\">: While it&#39;s important to screen for <strong>urogenital malformations in neonates </strong>for a variety of reasons, <strong>lithium use in pregnancy</strong> is specifically noted for its association with <strong>cardiac anomalies</strong> rather than urogenital malformations.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational goal is to recognize the <strong>teratogenic risks </strong>associated with the <strong>use of lithium</strong> during <strong>pregnancy, </strong>particularly the <strong>increased risk of cardiac anomalies</strong> such as<strong> Ebstein&#39;s anomaly in the neonate.</strong></span></span></span></p>",
    "correct_choice_id": 57981,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 14582,
    "choices": [
      {
        "id": 58289,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It is highly protein bound.</span></span></span></p>"
      },
      {
        "id": 58290,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Its half-life increases with increase in dose.</span></span></span></p>"
      },
      {
        "id": 58291,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It is a microsomal enzyme inducer.</span></span></span></p>"
      },
      {
        "id": 58292,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It follows zero order kinetics at lower doses.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">False statement regarding phenytoin is?</span></span></span></p>",
    "unique_key": "Q5559169",
    "question_audio": null,
    "question_video": null,
    "map_id": 36206,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) It follows zero order kinetics at lower doses</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The<strong> false statement </strong>regarding phenytoin is that it<strong> follows zero order kinetics at lower doses. Phenytoin </strong>actually<strong> exhibits zero order</strong> <strong>kinetics at higher,</strong> often <strong>therapeutic, doses</strong>. This<strong> means</strong> that the drug is<strong> metabolized at a constant rate </strong>regardless of <strong>concentration,</strong> and the <strong>liver&#39;s capacity to metabolize the drug is saturated.</strong> At <strong>lower doses, phenytoin </strong>generally follows <strong>first order kinetics,</strong> where the<strong> rate of drug metabolism</strong> is <strong>proportional to its concentration.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. It is highly protein bound</span></strong><span style=\"font-size:12.0pt\">: This is<strong> true.</strong> <strong>Phenytoin</strong> is approximately<strong> 90% bound to plasma proteins, </strong>and because of this, it can be <strong>displaced by other drugs,</strong> leading to an<strong> increase in the concentration of free (active) phenytoin.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Its half-life increases with increase in dose</span></strong><span style=\"font-size:12.0pt\">: This is <strong>true</strong> and is related to <strong>phenytoin&#39;s zero order kinetics </strong>at <strong>therapeutic or higher doses</strong>. As the <strong>dose increases</strong>, the <strong>half-life becomes longer</strong> because the<strong> drug-metabolizing enzymes in the liver </strong>become <strong>saturated.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. It is a microsomal enzyme inducer</span></strong><span style=\"font-size:12.0pt\">: This is <strong>true</strong>. <strong>Phenytoin</strong> induces<strong> hepatic</strong> <strong>microsomal enzymes,</strong> which can lead to<strong> increased metabolism of other drugs</strong>, potentially <strong>requiring dose adjustments</strong> of<strong> concomitant medications.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational goal is to understand the<strong> pharmacokinetics of phenytoin</strong>, an<strong> antiepileptic</strong> <strong>drug.</strong> At <strong>lower doses,</strong> phenytoin follows<strong> first order kinetics</strong>, but as the<strong> dose increases </strong>and <strong>reaches therapeutic levels</strong>, it <strong>exhibits zero order kinetics</strong> where the <strong>drug is metabolized </strong>at a <strong>constant rate.</strong></span></span></p>",
    "correct_choice_id": 58292,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14489,
    "choices": [
      {
        "id": 57917,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Change atenolol and imipramine to ACE inhibitor and fluoxetine and add bisacodyl for constipation.</span></span></span></p>"
      },
      {
        "id": 57918,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Change imipramine and haloperidol to fluoxetine and risperidone and add bisacodyl for constipation.</span></span></span></p>"
      },
      {
        "id": 57919,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Only add bisacodyl for constipation and continue the rest of the medications.</span></span></span></p>"
      },
      {
        "id": 57920,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Discontinue all her medications and start her on steroids.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">An 86-year-old lady presented with severe constipation. She was a known hypertensive on medications for 10 years. In the clinic, her BP was 157/98 mm Hg on supine position with a heart rate of 48 beats per minute. On taking her BP in the sitting position, it was found to be 90/60 mm Hg. She had a recent history of depression. She is taking atenolol, thiazide, imipramine, haloperidol, and docusate. What will be the next best step in the management?</span></span></span></p>",
    "unique_key": "Q2633914",
    "question_audio": null,
    "question_video": null,
    "map_id": 36195,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Change atenolol and imipramine to ACE inhibitor and fluoxetine and add bisacodyl for constipation.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">This patient&#39;s presentation of <strong>bradycardia, postural hypotension, and severe constipation </strong>suggests <strong>adverse effects </strong>from her current medications. <strong>Atenolol, a beta-blocker,</strong> can <strong>cause bradycardia and exacerbate postural hypotension,</strong> while <strong>imipramine</strong>, a <strong>tricyclic</strong> <strong>antidepressant</strong>, is known to cause<strong> both constipation and postural hypotension.</strong>Therefore to address these cocerns we will like to <strong>change the culprit drugs atenolol and imipramine</strong> to relatively <strong>better drugs without </strong>these <strong>adverse effects.&nbsp;</strong></span></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Switching from atenolol</strong> to an <strong>ACE inhibitor</strong> may <strong>better control</strong> <strong>her hypertension</strong> <strong>without</strong> causing<strong> bradycardia. Replacing imipramine with fluoxetine,</strong> a <strong>selective serotonin reuptake inhibitor,</strong> could help manage her <strong>depression without contributing </strong>to <strong>constipation or postural</strong> <strong>hypotension</strong>. Though <strong>ACE inhibitors</strong> also can<strong> cause postural hypotension</strong> but the<strong> risk is quite negligible </strong>as compared to<strong> alpha</strong> <strong>blockers and TCAs</strong>. Adding<strong> bisacodyl</strong> will address<strong> her immediate</strong> need for<strong> relief from severe constipation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:16px\">&nbsp;other options:</span></strong></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Change imipramine and haloperidol to fluoxetine and risperidone and add bisacodyl for constipation.</span></strong><span style=\"font-size:12.0pt\">&nbsp;Changing imiparmine to fluoxetine will <strong>solve the problem of constipatoin </strong>but it<strong> does not </strong>address the <strong>hypertension or bradycardia effectively.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.</span></strong><span style=\"font-size:12.0pt\"> </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-size:16px\"><strong>Only add bisacodyl for constipation and continue the rest of the medications:</strong></span>&nbsp;It <strong>addresses</strong> the problem of <strong>costipation</strong> partly but <strong>d</strong></span><span style=\"font-size:12.0pt\"><strong>oes not resolve </strong>the <strong>other underlying issues </strong>causing <strong>her symptoms.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D<span style=\"font-size:16px\">:&nbsp;</span></span><span style=\"font-size:16px\"><span dir=\"ltr\" lang=\"EN-US\">Discontinue all her medications and start her on steroids:</span></span></strong><span style=\"font-size:12.0pt\">&nbsp;It Is<strong> inappropriate and potentially harmful.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Management of polypharmacy </strong>in elderly patients requires<strong> careful consideration </strong>of the <strong>side effects </strong>of <strong>each medication</strong>, especially when they contribute to conditions like<strong> constipation, postural hypotension, and bradycardia</strong>. <strong>Adjustments </strong>should<strong> aim to minimize</strong> <strong>these effects</strong> while<strong> effectively treating </strong>the<strong> underlying conditions</strong></span></span></span></p>",
    "correct_choice_id": 57917,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14510,
    "choices": [
      {
        "id": 58001,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">HLA-B 1507</span></span></span></p>"
      },
      {
        "id": 58002,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">HLA-B 1502</span></span></span></p>"
      },
      {
        "id": 58003,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">HLA-B 57</span></span></span></p>"
      },
      {
        "id": 58004,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">HLA-B</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The risk of carbamazepine induced Stevens Johnson syndrome is increased in the presence of which of the following gene? </span></span></span></p>",
    "unique_key": "Q7144228",
    "question_audio": null,
    "question_video": null,
    "map_id": 36199,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) HLA-B 1502</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Carbamazepine-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) </strong>are serious <strong>skin reactions</strong> that can be <strong>life-threatening.</strong> These conditions are significantly <strong>more likely </strong>to occur in individuals who have the<strong> HLA-B 1502 gene variant. </strong>This <strong>genetic marker</strong> is notably <strong>prevalent in populations</strong> of <strong>Asian descent</strong>, leading to <strong>heightened risk assessments </strong>and <strong>screening</strong> recommendations before the<strong> administration of carbamazepine</strong> in these populations. Testing for the <strong>presence of HLA-B 1502</strong> is recommended to <strong>prevent the initiation of carbamazepine in patients </strong>at <strong>increased risk of developing SJS/TEN,</strong> thereby <strong>enhancing</strong> <strong>patient safety.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Screening</strong> for the <strong>HLA-B 1502 gene</strong> variant in patients who are<strong> candidates for carbamazepine therapy,</strong> particularly those of<strong> Asian</strong> <strong>ancestry,</strong> is crucial in <strong>reducing the risk of potentially fatal skin reactions</strong> such as<strong> Stevens-Johnson syndrome</strong> and <strong>toxic epidermal</strong> <strong>necrolysis.</strong> This <strong>preemptive </strong>approach is a<strong> vital component of personalized medicine</strong>, aimed at ensuring the <strong>safety and efficacy </strong>of drug treatments.</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-155355.jpg\" style=\"height:684px; width:1000px\" /></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>",
    "correct_choice_id": 58002,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14460,
    "choices": [
      {
        "id": 57801,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Benzodiazepines act on the midbrain, ascending reticular formation, and limbic system. </span></span></span></p>"
      },
      {
        "id": 57802,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Benzodiazepines exert their effects through the GABA A receptors. </span></span></span></p>"
      },
      {
        "id": 57803,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Benzodiazepines increase the conductance of CI- channels. </span></span></span></p>"
      },
      {
        "id": 57804,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Benzodiazepines have GABA-mimetic action.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following statements is not true about the mechanism of action of benzodiazepines? </span></span></span></p>",
    "unique_key": "Q6652965",
    "question_audio": null,
    "question_video": null,
    "map_id": 36208,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Benzodiazepines have GABA-mimetic action.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Benzodiazepines </strong>are <strong>allosteric modulators of the GABA A receptor;</strong> they <strong>enhance </strong>the action of <strong>GABA</strong> but <strong>do not mimic its effects</strong> directly. By<strong> binding </strong>to their s<strong>pecific site on the GABA A receptor complex,</strong> benzodiazepines <strong>increase the frequency of chloride</strong> <strong>channel opening</strong> events when GABA is present, thereby <strong>enhancing the hyperpolarization </strong>and resulting in <strong>decreased neuronal</strong> <strong>excitability.</strong> They<strong> do not, </strong>however, <strong>activate these receptors independently</strong> like<strong> GABA (GABA-mimetic action), </strong>which is a <strong>distinction</strong> <strong>particularly important</strong> when<strong> comparing them to barbiturates </strong>that have <strong>both GABA facilitatory and mimetic actions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options A, B, C:</span></strong><span style=\"font-size:12.0pt\"> <strong>All these statements correctly </strong>describe the<strong> action of benzodiazepines</strong> as they highlight the <strong>enhancement of</strong> <strong>GABAergic transmission</strong> through <strong>allosteric modulation of GABA A receptors</strong>,<strong> influencing chloride ion flow </strong>and<strong> impacting</strong> areas of the <strong>brain </strong>involved in<strong> anxiety and arousal regulation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Benzodiazepines</strong> <strong>enhance </strong>but <strong>do not mimic </strong>the<strong> action of GABA,</strong> functioning as <strong>allosteric modulators </strong>rather than direct agonists of <strong>GABA A receptors,</strong> which is <strong>crucial for understanding </strong>their<strong> safety profile and therapeutic effects.</strong></span></span></p>",
    "correct_choice_id": 57804,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14479,
    "choices": [
      {
        "id": 57877,
        "text": "<p>&nbsp;<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Cocaine</span></span></span></p>"
      },
      {
        "id": 57878,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Amphetamine</span></span></span></p>"
      },
      {
        "id": 57879,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Cannabis</span></span></span></p>"
      },
      {
        "id": 57880,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dexamphetamine</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CNS stimulants are all except?</span></span></p>",
    "unique_key": "Q6399515",
    "question_audio": null,
    "question_video": null,
    "map_id": 36191,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Cannabis</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>CNS stimulants </strong>are characterized by their<strong> ability to increase alertness</strong>, <strong>energy, and attention.</strong> <strong>Cocaine, amphetamine,</strong> and <strong>dexamphetamine</strong> are classic examples of<strong> CNS stimulants </strong>used<strong> medically to treat </strong>conditions like<strong> ADHD and narcolepsy.</strong> <strong>Cannabis,</strong> however,<strong> primarily acts as a CNS depressant</strong> with some <strong>stimulant qualities</strong>, but it<strong> does not</strong> fit the typical profile of a<strong> CNS stimulant</strong> that <strong>enhances mental and physical functions</strong>. <strong>Instead, </strong>it is<strong> known for its sedative </strong>and <strong>psychoactive effects</strong>, which can lead to <strong>relaxation and altered sensory perceptions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options A, B, D:</span></strong><span style=\"font-size:12.0pt\"> <strong>Cocaine, amphetamine, and dexamphetamine</strong> all<strong> stimulate the central nervous system</strong> by<strong> increasing levels of</strong> <strong>dopamine and norepinephrine </strong>in the brain, thus <strong>enhancing activity, mood, and alertness.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Cannabis does not</strong> function <strong>primarily as a CNS stimulant </strong>and<strong> should not</strong> be classified alongside drugs like <strong>amphetamines and</strong> <strong>cocaine</strong>, which are<strong> direct stimulants of the central nervous system</strong></span></span></span></p>",
    "correct_choice_id": 57879,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased"
    ]
  },
  {
    "id": 14508,
    "choices": [
      {
        "id": 57993,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Thrombocytopenia</span></span></span></p>"
      },
      {
        "id": 57994,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hepatotoxicity</span></span></span></p>"
      },
      {
        "id": 57995,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hyperammonemia</span></span></span></p>"
      },
      {
        "id": 57996,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Pancreatitis</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">If carbamazepine is added to valproate, which of the following side- effects increases?&nbsp; </span></span></span></p>",
    "unique_key": "Q8245977",
    "question_audio": null,
    "question_video": null,
    "map_id": 36198,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Hepatotoxicity</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Valproate</strong> is known to be <strong>metabolized by the liver</strong> through the<strong> cytochrome P450 enzyme </strong>system. A<strong> minor but</strong> significant <strong>hepatotoxic metabolite</strong> is produced during this process. <strong>When carbamazepine</strong>, a <strong>known enzyme inducer</strong>, is added to <strong>valproate</strong> <strong>therapy,</strong> it can <strong>enhance the activity</strong> of these <strong>liver enzymes</strong>, leading to<strong> increased production of the hepatotoxic metabolite.</strong> This <strong>interaction</strong> <strong>raises </strong>the<strong> risk of liver damage</strong>, making <strong>hepatotoxicity </strong>a significant concern when these <strong>two medications</strong> are used <strong>concurrently.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Thrombocytopenia:</span></strong><span style=\"font-size:12.0pt\"> Although <strong>valproate</strong> can cause <strong>thrombocytopenia,</strong> there is <strong>no direct enhancement </strong>of this risk <strong>due to</strong> <strong>carbamazepine.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Hyperammonemia:</span></strong><span style=\"font-size:12.0pt\"> While <strong>valproate</strong> can cause<strong> hyperammonemia</strong>, <strong>carbamazepine does not</strong> typically <strong>exacerbate </strong>this condition.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Pancreatitis:</span></strong><span style=\"font-size:12.0pt\"><strong> Both drugs</strong> have been associated with <strong>pancreatitis,</strong> but the <strong>combination does not </strong>specifically <strong>increase this</strong> <strong>risk</strong> compared to <strong>each drug alone.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When<strong> combining carbamazepine with valproate,</strong> <strong>careful monitoring of liver function </strong>is essential due to the <strong>increased risk of</strong> <strong>hepatotoxicity</strong> from enhanced<strong> metabolism and production of a toxic metabolite.</strong></span></span></span></p>",
    "correct_choice_id": 57994,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14513,
    "choices": [
      {
        "id": 58013,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vivid dreaming </span></span></span></p>"
      },
      {
        "id": 58014,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anorgasmia </span></span></span></p>"
      },
      {
        "id": 58015,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bradycardia </span></span></span></p>"
      },
      {
        "id": 58016,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nausea</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A bank employee suffering from depression came to AIIMS OPD. He was started on Escitalopram. Which of the following adverse effects cannot be explained with Escitalopram?</span></span></span></p>",
    "unique_key": "Q3944713",
    "question_audio": null,
    "question_video": null,
    "map_id": 36200,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Bradycardia </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Escitalopram,</strong> a commonly used <strong>selective serotonin reuptake inhibitor (SSRI), </strong>has various known <strong>side effects</strong> that impact<strong> both the</strong> <strong>central nervous system </strong>and other <strong>bodily functions</strong>, but <strong>bradycardia</strong> is<strong> not </strong>typically one of them. Instead, <strong>SSRIs like Escitalopram </strong>are <strong>more </strong>likely to <strong>cause side effects</strong> such as:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Vivid dreaming:</span></strong><span style=\"font-size:12.0pt\"> This can be a result of<strong> increased serotonin levels </strong>affecting various<strong> neurotransmitter pathways,</strong> including those that<strong> influence sleep and dreaming.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Anorgasmia:</span></strong><span style=\"font-size:12.0pt\"><strong> Sexual dysfunction</strong> is a well-documented<strong> side effect of SSRIs</strong>, which can<strong> interfere </strong>with <strong>sexual arousal</strong> and <strong>orgasm,</strong> likely through their <strong>effects on serotonin receptors</strong> that<strong> impact sexual function.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Nausea:</span></strong><span style=\"font-size:12.0pt\"> This is a <strong>common initial side effect</strong> when<strong> starting SSRIs, </strong>resulting from the <strong>increased serotonin activity</strong> in the <strong>gastrointestinal tract.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Bradycardia, </strong>or a<strong> slower than normal heart rate,</strong> is <strong>not</strong> a typical reaction to <strong>Escitalopram</strong>. <strong>SSRIs</strong> can cause some<strong> cardiovascular</strong> <strong>effects</strong>, but they are<strong> more</strong> commonly associated with <strong>mild tachycardia</strong> rather than bradycardia.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">While <strong>Escitalopram </strong>is<strong> effective for treating depression </strong>and associated symptoms like <strong>anxiety,</strong> its <strong>adverse effects</strong> can <strong>impact sexual</strong> <strong>function, sleep, and gastrointestinal health</strong> but<strong> not </strong>typically<strong> heart rate</strong> in the form of<strong> bradycardia</strong></span></span></span></p>",
    "correct_choice_id": 58015,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 14554,
    "choices": [
      {
        "id": 58177,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Peripheral decarboxylase inhibitor&mdash;Benserazide</span></span></span></p>"
      },
      {
        "id": 58178,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Selective MAO- B inhibitor&mdash;Clorgyline</span></span></span></p>"
      },
      {
        "id": 58179,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">COMT inhibitor&mdash;Entacapone</span></span></span></p>"
      },
      {
        "id": 58180,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Dopamine facilitator&mdash;Amantadine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">All the following pairs of mechanism of action with the drug are correct except </span></span></span></p>",
    "unique_key": "Q8890139",
    "question_audio": null,
    "question_video": null,
    "map_id": 36202,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Selective MAO- B inhibitor&ndash; Clorgyline</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Clorgyline</strong> is a<strong> non-selective monoamine oxidase (MAO) inhibitor</strong> means it <strong>inhibits both MAO-A</strong> as well as <strong>MAO-B</strong> <strong>isoforms</strong>. <strong>MAO-A and MAO-B are enzymes</strong> involved in the <strong>breakdown of neurotransmitters</strong> such as <strong>dopamine,</strong> <strong>norepinephrine, and serotonin</strong>. <strong>MAO inhibitors</strong> can be <strong>used to treat depression and Parkinson&#39;s disease</strong>, as they can <strong>increase the levels </strong>of these <strong>neurotransmitters in the brain.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Benserazide</strong> is a <strong>peripheral decarboxylase inhibitor</strong> that is used in <strong>combination with levodopa </strong>to<strong> treat Parkinson&#39;s</strong> <strong>disease.</strong> It works by <strong>inhibiting the enzyme dopa decarboxylase,</strong> which <strong>converts levodopa</strong> <strong>into dopamine </strong>outside the <strong>brain</strong>. This allows<strong> more levodopa to cross the blood-brain barrier</strong> and<strong> increase dopamine levels </strong>in the brain.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Entacapone</strong> is a <strong>Catechol-O-methyltransferase (COMT) inhibitor</strong> that is<strong> used in combination with levodopa </strong>to treat <strong>Parkinson&#39;s disease</strong>. It works by<strong> inhibiting the enzyme COMT,</strong> which <strong>breaks down levodopa </strong>in the peripheral tissues. This allows <strong>more levodopa </strong>to cross the blood-brain barrier and<strong> increase dopamine levels in the brain.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Amantadine</strong> is an <strong>antiviral medication</strong> that is also <strong>used to treat Parkinson&#39;s disease</strong>. It works by <strong>increasing the release</strong> of <strong>dopamine in the brain </strong>and <strong>blocking the reuptake of dopamine</strong> into the<strong> presynaptic neuron.</strong></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 58178,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14612,
    "choices": [
      {
        "id": 58409,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Valproate</span></span></span></p>"
      },
      {
        "id": 58410,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Retigabine</span></span></span></p>"
      },
      {
        "id": 58411,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Topiramate</span></span></span></p>"
      },
      {
        "id": 58412,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Vigabatrin</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">All the following antiepileptic drugs may cause visual problems except. </span></span></span></p>",
    "unique_key": "Q1158051",
    "question_audio": null,
    "question_video": null,
    "map_id": 36194,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Valproate</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Valproate </strong>is an <strong>antiepileptic drug</strong> that works by<strong> increasing GABA levels, blocking</strong> <strong>voltage-gated sodium channels,</strong> and <strong>inhibiting</strong> <strong>T-type calcium channels</strong>. Visual problems are <strong>not</strong> a <strong>common side effect</strong> of<strong> valproate.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>other antiepileptic</strong> drugs mentioned may cause <strong>visual problems:</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-family:Calibri, sans-serif\"><span style=\"font-size:16px\"><strong>Other Options :</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Retigabine:</span></strong><span style=\"font-size:12.0pt\"> Retigabine is a <strong>potassium channel opener.</strong> It may cause <strong>visual</strong> <strong>disturbances</strong>, such as changes in <strong>colour vision and difficulty adjusting to darkness.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Topiramate:</span></strong><span style=\"font-size:12.0pt\"> Topiramate is an <strong>antiepileptic drug</strong> that works by <strong>blocking voltage-gated sodium channels,</strong> <strong>enhancing GABA activity,</strong> and<strong> inhibiting glutamate activity</strong>. It may cause<strong> visual problems</strong>, including <strong>acute angle-closure glaucoma, myopia, and diplopia (double vision).</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Vigabatrin:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vigabatrin is an <strong>antiepileptic drug</strong> that works by <strong>inhibiting GABA</strong> t<strong>ransaminase,</strong> <strong>increasing GABA levels in the brain</strong>. It may cause<strong> visual problems</strong>, such as <strong>peripheral visual field defects</strong> and <strong>retinal dysfunction.</strong></span></span></p>",
    "correct_choice_id": 58409,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14622,
    "choices": [
      {
        "id": 58449,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Nicotine gums have 10-15% more bioavailability than nicotine lozenges.</span></span></span></p>"
      },
      {
        "id": 58450,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Varenicline is ideal but has a risk of cardiovascular events.</span></span></span></p>"
      },
      {
        "id": 58451,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Efficiency of nicotine gums increases after coffee or tea intake.</span></span></span></p>"
      },
      {
        "id": 58452,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Nicotine replacement therapy is given only via oral route.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which of the following is true regarding smoking addiction? </span></span></span></p>",
    "unique_key": "Q6862017",
    "question_audio": null,
    "question_video": null,
    "map_id": 36196,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Varenicline is ideal but has a risk of cardiovascular events.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Varenicline</strong> is a medication<strong> used to aid</strong> in <strong>smoking cessation</strong>. It works by<strong> blocking the effects of nicotine </strong>in the brain, <strong>reducing cravings and withdrawal symptoms. </strong>Studies have shown that<strong> varenicline is more effective </strong>than<strong> nicotine replacement therapy </strong>or<strong> bupropion for smoking cessation</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">However, there is a<strong> risk of cardiovascular events </strong>associated with <strong>varenicline use</strong>, particularly in patients with<strong> pre-existing cardiovascular disease</strong>. Patients should be <strong>monitored closely for cardiovascular events </strong>while taking <strong>varenicline.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>other options </strong>are <strong>not </strong>true regarding<strong> smoking addiction.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong>Other Options:&nbsp;&nbsp;</strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Nicotine gums have 10-15% more bioavailability than nicotine lozenges</span></strong><span style=\"font-size:12.0pt\">: <strong>&nbsp;Nicotine</strong> <strong>lozenges have 10-15 %</strong> <strong>more </strong>bioavailability because some <strong>nicotine remains with gum</strong> even after t<strong>horough chewing</strong> whereas<strong> lozenges completely melt and release all nicotine present </strong>in<strong> it. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Efficiency of nicotine gums increases after coffee or tea intake</span></strong><span style=\"font-size:12.0pt\">: &nbsp;<strong>Caffeine</strong> can <strong>decrease</strong> the effectiveness of <strong>nicotine replacement therapy. </strong>Therefore, a<strong> gap of 15 minutes</strong> must be <strong>observed </strong>between<strong> use of NRT and drinking tea or coffee.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Nicotine replacement therapy is given only via oral route: </span></strong><span style=\"font-size:12.0pt\">&nbsp;<strong>Nicotine replacement</strong> therapy can be given <strong>via various routes,</strong> including <strong>oral</strong> (<strong>gum, lozenge, inhaler)</strong>,<strong> transdermal</strong> <strong>patch, and nasal spray.</strong></span></span></span></p>",
    "correct_choice_id": 58450,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14461,
    "choices": [
      {
        "id": 57805,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Ropinirole </span></span></span></p>"
      },
      {
        "id": 57806,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Levodopa </span></span></span></p>"
      },
      {
        "id": 57807,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Bromocriptine </span></span></span></p>"
      },
      {
        "id": 57808,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Entacapone</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old patient with a history of Parkinson&#39;s disease presents to the clinic complaining of peripheral numbness and tingling in his fingers and toes. He is currently taking medication for his Parkinson&#39;s disease, and upon further questioning, he mentions that he has noticed an increase in these symptoms since starting a new medication a few weeks ago. Which of the following anti-parkinsonian drugs is most likely to be causing the peripheral vasospasm observed in this patient?</span></span></span></p>",
    "unique_key": "Q2175909",
    "question_audio": null,
    "question_video": null,
    "map_id": 36209,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Bromocriptine.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Bromocriptine, a dopamine agonist</strong> used in the treatment o<strong>f Parkinson&#39;s disease,</strong> is known to cause <strong>peripheral vasospasm </strong>as a side effect. This can<strong> manifest as numbness, tingling, and pain in extremities </strong>due to its <strong>vasoconstrictive properties</strong>. Such<strong> side effects </strong>are p<strong>articularly </strong>concerning in<strong> patients with existing circulatory issues.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Ropinirole:</span></strong><span style=\"font-size:12.0pt\"> While also a<strong> dopamine agonist</strong>, it<strong> does not </strong>commonly cause <strong>peripheral vasospasm.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Levodopa:</span></strong><span style=\"font-size:12.0pt\"> The<strong> most commonly used </strong>medication in<strong> Parkinson&#39;s treatment</strong>, known for<strong> many side effects,</strong> but<strong> peripheral</strong> <strong>vasospasm is not </strong>typically <strong>one of them.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Entacapone:</span></strong><span style=\"font-size:12.0pt\"> A <strong>COMT inhibitor</strong> used to <strong>extend the effects of Levodopa</strong>;<strong> not </strong>associated with causing<strong> peripheral vasospasm.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Bromocriptine</strong> can cause<strong> peripheral vasospasm</strong> leading to symptoms like <strong>numbness and tingling in extremities, </strong>an important consideration when <strong>monitoring side effects in Parkinson&rsquo;s disease patients</strong>.</span></span></p>",
    "correct_choice_id": 57807,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14567,
    "choices": [
      {
        "id": 58229,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Opioid receptor agonist </span></span></span></p>"
      },
      {
        "id": 58230,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Opioid receptor partial agonist </span></span></span></p>"
      },
      {
        "id": 58231,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Opioid receptor antagonist </span></span></span></p>"
      },
      {
        "id": 58232,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Opioid receptor inverse agonist</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old male patient with a history of opioid addiction presents to your clinic for treatment. He has a long history of opioid use and has recently stopped using opioids. Which of the following is the mechanism of action of methadone, the medication that is commonly used to treat opioid addiction?</span></span></p>",
    "unique_key": "Q9005272",
    "question_audio": null,
    "question_video": null,
    "map_id": 36203,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Opioid receptor agonist.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Methadone</strong> is a<strong> synthetic opioid</strong> that is primarily <strong>used to treat opioid addiction</strong> by <strong>reducing withdrawal symptoms</strong> and <strong>cravings</strong>. It works by<strong> binding to the same opioid receptors </strong>in the<strong> brain</strong> that are targeted by<strong> natural opioids</strong>, such as <strong>endorphins</strong>, to produce <strong>pain relief, euphoria, and other effects.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Opioid receptor partial agonists,</strong> such as <strong>buprenorphine</strong>, have a<strong> weaker effect</strong> on the <strong>opioid receptors </strong>than <strong>full agonists</strong> like <strong>methadone.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Opioid receptor antagonists</strong>, such as<strong> naloxone and naltrexone</strong>, <strong>block </strong>the <strong>effects of opioids</strong> and are used to <strong>treat opioid</strong> <strong>overdose </strong>and <strong>prevent relapse </strong>in individuals who have <strong>stopped using opioids.</strong></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 58229,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14515,
    "choices": [
      {
        "id": 58021,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">1, 3 and 4 are correct. </span></span></span></p>"
      },
      {
        "id": 58022,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Only 2 are correct. </span></span></span></p>"
      },
      {
        "id": 58023,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">1 and 2 are correct. </span></span></span></p>"
      },
      {
        "id": 58024,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">All is correct.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Chlorpromazine acts on which of the following receptors?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">D2 and 5HT2 receptors </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">GABA and Beta-adrenergic receptors </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Muscarinic M1 and alpha-adrenergic receptors </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">H1 receptors </span></span></li>\r\n</ol>",
    "unique_key": "Q4174159",
    "question_audio": null,
    "question_video": null,
    "map_id": 36201,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) 1, 3 and 4 are correct.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Chlorpromazine,</strong> a<strong> first-generation antipsychotic</strong>, has a<strong> broad receptor profile </strong>that contributes to <strong>both its therapeutic effects</strong> and <strong>side effects:</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">D2 and 5HT2 receptors:</span></strong><span style=\"font-size:12.0pt\"> It <strong>acts</strong> as an<strong> antagonist at dopamine D2</strong> and <strong>serotonin 5HT2 receptors</strong>, which helps <strong>modulate</strong> <strong>mood and psychotic symptoms.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Muscarinic M1 and alpha-adrenergic receptors:</span></strong><span style=\"font-size:12.0pt\"> It also <strong>antagonizes these receptors</strong>, contributing to<strong> side effects</strong> such as <strong>dry mouth, sedation, and hypotension.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">H1 receptors:</span></strong><span style=\"font-size:12.0pt\"> <strong>Histamine receptor antagonism</strong> leads to <strong>sedative effects</strong>, which is typical of many<strong> first-generation</strong> <strong>antipsychotics.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">GABA and Beta-adrenergic receptors:</span></strong><span style=\"font-size:12.0pt\"> <strong>Chlorpromazine</strong> <strong>does not</strong> significantly interact with these<strong> receptor types,</strong> making statement <strong>2</strong> <strong>incorrect.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Chlorpromazine&#39;s</strong> action on <strong>multiple neurotransmitter receptors</strong> explains<strong> both its efficacy</strong> in treating <strong>psychotic symptoms </strong>and <strong>its</strong> <strong>wide range</strong> of <strong>potential side effects,</strong> <strong>underscoring</strong> the importance of<strong> careful patient monitoring</strong> when using this <strong>medication.</strong></span></span></span></p>",
    "correct_choice_id": 58021,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14605,
    "choices": [
      {
        "id": 58381,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propranolol</span></span></p>"
      },
      {
        "id": 58382,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Higher doses of haloperidol</span></span></span></p>"
      },
      {
        "id": 58383,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Valbenazine</span></span></span></p>"
      },
      {
        "id": 58384,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Dantrolene</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old male with schizophrenia was treated with haloperidol 5 mg once daily at bedtime, which was increased to 7.5 mg daily in the 2nd week and 10 mg daily in the 3rd week. His symptoms improved, but in the 5th week, his family reported that his restlessness had returned, and he kept pacing around in the room, though he was not aggressive. The patient also reported an uncontrollable urge to move around and difficulty in falling asleep. Which of the following drugs would be the best choice for this presentation?</span></span></p>",
    "unique_key": "Q3495651",
    "question_audio": null,
    "question_video": null,
    "map_id": 36169,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Ans. A) Propranolol</span></span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">The patient&#39;s symptoms suggest that he may be experiencing akathisia, a side effect of antipsychotic medications like haloperidol. Akathisia is characterized by restlessness, an uncontrollable urge to move, and difficulty in sitting still.</span></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Propranolol, a beta-blocker, is often used to treat akathisia and could be an appropriate choice to address the patient&#39;s symptoms.</span></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Other Options:</span></span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option B.</span></span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"> Higher doses of haloperidol may exacerbate the patient&#39;s restlessness and are not recommended in this case.</span></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option C. </span></span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Valbenazine is used to treat tardive dyskinesia, a different movement disorder associated with long-term antipsychotic use. It is not indicated for treating akathisia.</span></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Option D. </span></span></span></strong><span style=\"font-size:14.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">Dantrolene is a muscle relaxant used to treat muscle spasms and malignant hyperthermia. It is not used to treat akathisia.</span></span></span></span></span></p>",
    "correct_choice_id": 58381,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 14575,
    "choices": [
      {
        "id": 58261,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Acute dystonia</span></span></span></p>"
      },
      {
        "id": 58262,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Seizures</span></span></span></p>"
      },
      {
        "id": 58263,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Malingering</span></span></span></p>"
      },
      {
        "id": 58264,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Akathisia</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A young male patient who is a case of schizophrenia was started on haloperidol 5 mg. On the 3rd day, he came to the hospital accompanied by his father with rolling up both eyes. A complete neurological examination revealed no spasticity or any other abnormalities. Visual acuity was found to be normal. Most likely diagnosis is: </span></span></span></p>",
    "unique_key": "Q2210321",
    "question_audio": null,
    "question_video": null,
    "map_id": 36170,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Acute dystonia</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The most likely diagnosis in this scenario is acute dystonia, which is a type of extrapyramidal symptom (EPS) that can occur as a side effect of antipsychotic medications such as haloperidol.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute dystonia typically presents as involuntary muscle contractions, often involving the muscles of the neck, tongue, or eyes. In this case, the patient&#39;s rolling up of both eyes suggests involvement of the muscles controlling eye movements. Acute dystonia usually occurs within the first few days of treatment with an antipsychotic medication and can be a medical emergency if left untreated.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Seizures:</span></strong><span style=\"font-size:12.0pt\"> are unlikely to present with rolling up of both eyes without any other accompanying symptoms such as convulsions or loss of consciousness.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Malingering:</span></strong><span style=\"font-size:12.0pt\"> &nbsp;or feigning symptoms for secondary gain, is also unlikely in this case as there is no obvious reason for the patient to fake these symptoms.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Akathisia: </span></strong><span style=\"font-size:12.0pt\">&nbsp;another type of EPS, presents as restlessness, agitation, and inability to sit still, and is unlikely to cause the rolling up of both eyes.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anticholinergic drugs like benzhexol is drug of choice for treatment of acute muscular dystonia. Alternative drugs are first generation histamine H1 blockers like promethazine. </span></span></li>\r\n</ul>",
    "correct_choice_id": 58261,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14503,
    "choices": [
      {
        "id": 57973,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Administer sodium bicarbonate</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">.</span></span></span></p>"
      },
      {
        "id": 57974,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Consider hemodialysis</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">.</span></span></span></p>"
      },
      {
        "id": 57975,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Administer fomepizole</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">.</span></span></span></p>"
      },
      {
        "id": 57976,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Administer </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">flumazenil.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 25-year-old female presents to the emergency department with altered mental status and hypotension. Her electrocardiogram (ECG) shows wide QRS complexes and right axis deviation. She has a history of depression and is taking an antidepressant medication. What is the next best step in the management of this patient?</span></span></span></p>",
    "unique_key": "Q8201134",
    "question_audio": null,
    "question_video": null,
    "map_id": 36165,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Ans</span></strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">. <strong>A) Administer Sodium bicarbonate. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The clinical presentation suggests <strong>a tricyclic antidepressant (TCA) overdose,</strong> which is known to cause<strong> cardiotoxic effects </strong>such as <strong>wide QRS complexes</strong> due to <strong>sodium channel blockade.</strong> <strong>Administering sodium bicarbonate </strong>is an <strong>effective treatment</strong> as it <strong>helps</strong> to <strong>alkalinize the blood, counteracting the sodium channel-blocking</strong> effects of<strong> TCAs on the heart</strong>. This treatment helps to <strong>normalize</strong> <strong>QRS duration</strong> and <strong>mitigate</strong> the <strong>risk of arrhythmias, </strong>providing an<strong> immediate therapeutic benefit</strong> in <strong>acute TCA toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Consider hemodialysis:</span></strong><span style=\"font-size:12.0pt\"> While useful in <strong>certain poisonings,</strong> it is <strong>not</strong> the<strong> first-line treatment for TCA overdose </strong>and is generally <strong>reserved for severe cases.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Administer fomepizole:</span></strong><span style=\"font-size:12.0pt\"> This is used for<strong> methanol or ethylene glycol poisoning, not for TCA overdose.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Administer flumazenil:</span></strong><span style=\"font-size:12.0pt\"> This is an<strong> antidote for benzodiazepine overdose</strong> and is<strong> not </strong>useful in cases of<strong> TCA overdose.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Sodium bicarbonate</strong> is crucial for managing <strong>TCA overdose</strong> due to its <strong>ability to quickly mitigate</strong> the <strong>cardiotoxic effects </strong>associated with this<strong> type of poisoning</strong>, emphasizing the<strong> importance of rapid and appropriate intervention</strong> in such<strong> emergencies.</strong></span></span></p>",
    "correct_choice_id": 57973,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 14579,
    "choices": [
      {
        "id": 58277,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Valproate</span></span></span></p>"
      },
      {
        "id": 58278,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Pregabalin</span></span></span></p>"
      },
      {
        "id": 58279,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Levetiracetam</span></span></span></p>"
      },
      {
        "id": 58280,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Carbamazepine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A 35-year-old male presented to a hospital with focal seizures. His renal function was normal. Which of the following is the drug of choice for this patient? </span></span></span></p>",
    "unique_key": "Q4598242",
    "question_audio": null,
    "question_video": null,
    "map_id": 36171,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Carbamazepine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Carbamazepine (<strong>DOC</strong>) and oxcarbazepine (related drug), phenytoin, lamotrigine and levetiracetam are currently the <strong>first line drugs</strong> approved for the initial treatment of focal seizures, including those that secondarily generalize. Overall, they have very similar efficacy, but differences in pharmacokinetics and toxicity are the main determinants for use in each patient.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">An advantage of carbamazepine is that its metabolism follows first-order pharmacokinetics, and the relationship between drug dose, serum levels, and toxicity is linear.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Oxcarbazepine has the advantage of lesser enzyme induction (and thus drug interactions) than carbamazepine. However, it has more association with dilutional hyponatremia than carbamazepine. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Lamotrigine tends to be well-tolerated in terms of side effects. However, patients need to be particularly vigilant about the possibility of a skin rash during the initiation of therapy. This can be extremely severe and lead to Stevens-Johnson syndrome if unrecognized and if the medication is not discontinued immediately.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Valproic acid is an effective alternative for some patients with partial seizures, especially when the seizures secondarily generalize.</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 58280,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14600,
    "choices": [
      {
        "id": 58361,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Valproate</span></span></span></p>"
      },
      {
        "id": 58362,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ethosuximide</span></span></span></p>"
      },
      {
        "id": 58363,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">ACTH</span></span></span></p>"
      },
      {
        "id": 58364,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Vigabatrin</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 4-month-old infant is brought to the pediatric neurology clinic by concerned parents due to episodes characterized by sudden bending forward of the body with stiffening of the arms and legs. The episodes last for a few seconds and occur in clusters. After thorough evaluation, the child is diagnosed with infantile spasms. Considering the need for effective treatment to prevent potential developmental delays associated with this condition, which of the following is the drug of choice for managing infantile spasms in this child?</span></span></span></p>",
    "unique_key": "Q7264249",
    "question_audio": null,
    "question_video": null,
    "map_id": 36166,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) ACTH</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>ACTH (Adrenocorticotropic hormone) </strong>is considered one of the <strong>drugs of choice</strong> for the treatment of<strong> infantile spasms,</strong> a severe form of<strong> epilepsy in infants. ACTH </strong>has been shown to be<strong> effective in reducing and often stopping the spasms,</strong> thereby <strong>improving </strong>the <strong>developmental </strong>outcome for<strong> many children</strong>. Its<strong> use</strong> is<strong> based on</strong> its <strong>ability to modulate</strong> the <strong>adrenal axis and reduce the frequency</strong> of <strong>spasms, </strong>although the<strong> exact mechanism in infantile spasms </strong>is<strong> not</strong> fully understood.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Valproate:</span></strong><span style=\"font-size:12.0pt\"> While <strong>valproate</strong> is a<strong> broad-spectrum antiepileptic drug</strong> used for various <strong>seizure types, </strong>it is<strong> not</strong> the<strong> first-line</strong> treatment for <strong>infantile spasms.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Ethosuximide:</span></strong><span style=\"font-size:12.0pt\"> Ethosuximide is<strong> used </strong>primarily for <strong>absence seizures</strong> and is <strong>not </strong>effective for <strong>infantile spasms.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Vigabatrin:</span></strong><span style=\"font-size:12.0pt\"> <strong>Vigabatrin</strong> is an <strong>alternative first-line treatment for infantile spasms,</strong> especially in cases associated <strong>with</strong> <strong>tuberous sclerosis. </strong>However,<strong> ACTH i</strong>s generally considered the <strong>drug of choice</strong>, particularly in <strong>spasms </strong>of <strong>unknown cause</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational objective is to recognize <strong>ACTH</strong> as a<strong> first-line treatment </strong>option<strong> for infantile spasms. </strong></span></span></span></p>",
    "correct_choice_id": 58363,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 14504,
    "choices": [
      {
        "id": 57977,
        "text": "<p><span style=\"font-size:12.0pt;\">A</span></p>"
      },
      {
        "id": 57978,
        "text": "<p><span style=\"font-size:12.0pt;\">B</span></p>"
      },
      {
        "id": 57979,
        "text": "<p><span style=\"font-size:12.0pt;\">C</span></p>"
      },
      {
        "id": 57980,
        "text": "<p><span style=\"font-size:12.0pt;\">D</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">About anti-epileptic drugs, which of the following is an incorrect match?</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/image_92vX1cG.png\" width=\"965\" height=\"221\"></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\">&nbsp;</p>",
    "unique_key": "Q8485395",
    "question_audio": null,
    "question_video": null,
    "map_id": 36167,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Absence seizures - Phenytoin&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C:&nbsp;</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Phenytoin and carbamazepine worsen absence and myoclonic seizure. Drug of choice for absence seizure is ethosuximide.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option A. GTCS (Generalized Tonic-Clonic Seizures) - Lamotrigine</strong>:<strong> Lamotrigine </strong>is considered one of the <strong>first-line treatments </strong>for g<strong>eneralized tonic-clonic seizure</strong>s, making this a<strong> correct match.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Focal- Carbamazepine: </strong>Carbamazepine is one of the fist line drugs for focal seizures making this a correct match.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong>Option D. Myoclonic seizures - Valproate</strong>: <strong>Valproate</strong> is a <strong>first-line treatment for myoclonic seizures,</strong> which are characterized by <strong>sudden, brief muscle jerks.</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><strong><u>Educational Objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">The objective is to understand the <strong>first-line antiepileptic drug choices </strong>for <strong>different types of seizures: </strong>phenytoin and carbamazepine are not used in absence seizure however they even worsen absence and myoclonic seizure.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-153024.jpg\" alt=\"\" width=\"1000\" height=\"1448\"></span></p>",
    "correct_choice_id": 57979,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 14594,
    "choices": [
      {
        "id": 58337,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Anxiolytic + Muscle relaxant</span></span></span></p>"
      },
      {
        "id": 58338,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Anxiolytic alone</span></span></span></p>"
      },
      {
        "id": 58339,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Used as sedative hypnotic</span></span></span></p>"
      },
      {
        "id": 58340,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Used as Muscle relaxant</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which of the following is true regarding properties of Buspirone?</span></span></span></p>",
    "unique_key": "Q1583683",
    "question_audio": null,
    "question_video": null,
    "map_id": 36162,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Anxiolytic alone</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Buspirone</strong> is primarily known for its<strong> anxiolytic </strong>properties<strong> without</strong> the <strong>muscle relaxant,</strong> <strong>sedative, or anticonvulsant effects</strong> typical of <strong>benzodiazepines</strong>. It <strong>acts</strong> as a <strong>partial agonist at serotonin 5-HT1A receptors</strong> and possibly affects <strong>dopamine receptors, </strong>which contributes to its<strong> anxiolytic effect</strong>. Its<strong> mechanism of action </strong>is<strong> distinct from </strong>that of <strong>benzodiazepines, </strong>and it<strong> does not</strong> exhibit the <strong>same</strong> <strong>dependency potential</strong> or cause <strong>significant sedation</strong>, making it a preferred option for<strong> long-term management of anxiety </strong>in certain patients.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Anxiolytic + Muscle relaxant:</span></strong><span style=\"font-size:12.0pt\"> This is<strong> incorrect </strong>because <strong>buspirone does not </strong>have <strong>muscle relaxant properties.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Used as sedative hypnotic:</span></strong><span style=\"font-size:12.0pt\"> This is<strong> incorrect </strong>as <strong>buspirone does not</strong> have <strong>sedative properties</strong> typical of <strong>sedative-hypnotics</strong> like<strong> benzodiazepines</strong> and is<strong> not </strong>used to<strong> induce sleep.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Used as Muscle relaxant:</span></strong><span style=\"font-size:12.0pt\"> This is <strong>incorrect</strong> because<strong> buspirone</strong> is<strong> not </strong>used as a<strong> muscle relaxant;</strong> its primary use is for <strong>anxiety without</strong> the<strong> sedative and muscle relaxant</strong> effects associated with <strong>other anxiolytics.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The educational objective is to recognize <strong>buspirone as an anxiolytic </strong>medication that is used for its <strong>anti-anxiety effects without</strong> causing significant<strong> sedation, muscle relaxation, or the dependency issues </strong>associated with benzodiazepines.</span></span></p>",
    "correct_choice_id": 58338,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14563,
    "choices": [
      {
        "id": 58213,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acamprosate </span></span></span></p>"
      },
      {
        "id": 58214,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Bupropion </span></span></span></p>"
      },
      {
        "id": 58215,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methadone </span></span></span></p>"
      },
      {
        "id": 58216,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Naloxone</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following medications is commonly used to promote abstinence in patients with alcohol use disorder?</span></span></span></p>",
    "unique_key": "Q5473296",
    "question_audio": null,
    "question_video": null,
    "map_id": 36163,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Acamprosate.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>&nbsp;</strong></span></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Acamprosate</strong> is a <strong>medication</strong> that is used to <strong>promote abstinence</strong> in patients with <strong>alcohol use disorder.</strong> It <strong>works</strong> by <strong>modulating the levels of neurotransmitters</strong> in the<strong> brain</strong> that are involved in<strong> alcohol dependence and craving.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:16px\">Other Options:&nbsp;</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option B. Bupropion</strong> is a medication that is used to<strong> treat depression and smoking cessation,</strong> but it has <strong>not</strong> been shown to be effective for <strong>alcohol use disorder.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option C. Methadone</strong> is an <strong>opioid agonist</strong> medication that is primarily <strong>used to treat opioid addiction </strong>by <strong>reducing</strong> <strong>withdrawal symptoms and cravings.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option D. Naloxone</strong> is an <strong>opioid antagonist</strong> that is used to<strong> treat acute opioid poisoning. </strong></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 58213,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 14475,
    "choices": [
      {
        "id": 57861,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Phenothiazines reduces its anti-Parkinsonian efficacy.</span></span></span></p>"
      },
      {
        "id": 57862,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It is a pro-drug.</span></span></span></p>"
      },
      {
        "id": 57863,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Pyridoxine reduces the effect of levodopa in Parkinsonism.</span></span></span></p>"
      },
      {
        "id": 57864,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Domperidone blocks levodopa induced emesis as well as its therapeutic potential.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">All the following statements regarding levodopa are correct except. </span></span></span></p>",
    "unique_key": "Q5874122",
    "question_audio": null,
    "question_video": null,
    "map_id": 36168,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Domperidone blocks levodopa induced emesis and its therapeutic potential.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Domperidone</strong> is <strong>effectively</strong> used to manage the <strong>side effects of nausea and vomiting</strong> associated with<strong> levodopa treatment </strong>in <strong>Parkinson&#39;s disease,</strong> <strong>without</strong> affecting the <strong>drug&rsquo;s therapeutic benefits.</strong> This is<strong> because domperidone,</strong> a <strong>peripheral dopamine</strong> <strong>antagonist, does not cross the blood-brain barrier</strong> and hence<strong> does not</strong> affect the<strong> central dopaminergic activity </strong>crucial for <strong>levodopa&#39;s effectiveness.</strong> It <strong>acts outside the brain </strong>in areas accessible to<strong> blood circulation</strong>, such as the <strong>chemoreceptor trigger zone</strong> <strong>(CTZ)</strong>, which can<strong> access </strong>the<strong> circulatory system.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">Phenothiazines</span></strong><span style=\"font-size:12.0pt\">: can indeed <strong>reduce levodopa&#39;s effectiveness</strong> by <strong>blocking dopamine receptors.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. </span></strong><strong><span style=\"font-size:12.0pt\">&nbsp;Levodopa</span></strong><span style=\"font-size:12.0pt\"> is a<strong> pro-drug, </strong>converted to <strong>dopamine in the brain</strong> to exert<strong> its effects.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Pyridoxine (Vitamin B6)</strong> <strong>increases</strong> the<strong> peripheral metabolism of levodopa</strong>, <strong>reducing its availability </strong>to <strong>cross into the brain</strong> and therefore <strong>diminishing its effectiveness.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Domperidone</strong> is used to <strong>reduce levodopa-induced nausea without impairing its anti-Parkinsonian actions</strong>, demonstrating its value in managing <strong>side effects </strong>while <strong>preserving</strong> the<strong> main therapeutic intent of Parkinson&rsquo;s disease treatment.</strong></span></span></p>",
    "correct_choice_id": 57864,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 14555,
    "choices": [
      {
        "id": 58181,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">SNRI</span></span></span></p>"
      },
      {
        "id": 58182,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">SSRI</span></span></span></p>"
      },
      {
        "id": 58183,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">NA+ 5HT reuptake inhibitor</span></span></span></p>"
      },
      {
        "id": 58184,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Predominantly NA reuptake inhibitor</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old male patient presents to your clinic with symptoms of depression. Which of the following is the mechanism of action of nortriptyline, a medication that can be used to treat his depression?</span></span></span></p>",
    "unique_key": "Q5382132",
    "question_audio": null,
    "question_video": null,
    "map_id": 36173,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Predominantly NA reuptake inhibitor</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Most of the TCAs act by inhibiting the reuptake of both 5-HT and NA but nortriptyline</strong>&nbsp;is a<strong> tricyclic antidepressant (TCA)</strong> that works by <strong>blocking </strong>the <strong>reuptake of&nbsp;mainly&nbsp;norepinephrine</strong> (NA)&nbsp;in the<strong> brain.</strong> This leads to <strong>increased levels</strong> of this&nbsp;<strong>neurotransmitter</strong>&nbsp;in the <strong>synapse,</strong> which can<strong> help to alleviate symptoms of depression. Other selective NRIs include Reboxetine, atomoxetine etc.&nbsp;</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:18px\"><span style=\"font-family:Calibri,sans-serif\"><strong>EXPLANATION OF OTHER OPTIONS&nbsp;</strong></span></span></p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option A.</strong>&nbsp;<strong>SNRI:</strong>&nbsp;Refers to<strong> serotonin-norepinephrine reuptake inhibitors</strong>, which are a <strong>newer class of antidepressant</strong> <strong>medications</strong> that work by<strong> blocking the reuptake of both serotonin and norepinephrine. Examples include venlafaxine, duloxetine and milnacipran.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option B. SSRI:</strong>&nbsp;Refers to <strong>selective serotonin reuptake inhibitors</strong>, which are another class of <strong>newer antidepressant</strong> medications that work by <strong>blocking the reuptake of serotonin. These include fluoxetine, citalopram like drugs.&nbsp;</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option C.&nbsp;</strong><strong>NA+ 5HT reuptake inhibitor:</strong>&nbsp;It is <strong>not</strong> a specific class of <strong>antidepressant medication</strong> but may refer to medications that<strong> block the reuptake of both norepinephrine and serotonin</strong> like <strong>SNRI.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Educational Objective:</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nortriptyline is a TCA that acts predominatly as NA reuptake inhibitor unlike other TCAs which inhibit reuptake of both serotonin and nor-adrenaline.</span></span></span></p>",
    "correct_choice_id": 58184,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "TreatmentBased"
    ]
  },
  {
    "id": 14451,
    "choices": [
      {
        "id": 57765,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Benzhexol</span></span></span></p>"
      },
      {
        "id": 57766,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Promethazine</span></span></span></p>"
      },
      {
        "id": 57767,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Valbenazine</span></span></span></p>"
      },
      {
        "id": 57768,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">All the above</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which of the following can be used in the management of tardive dyskinesia?</span></span></span></p>",
    "unique_key": "Q5656214",
    "question_audio": null,
    "question_video": null,
    "map_id": 36172,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Valbenazine.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Valbenazine</strong> is specifically approved for the <strong>treatment of tardive dyskinesia (TD)</strong>, a condition characterized by <strong>involuntary, repetitive</strong> <strong>movements of the face and tongue</strong>, often developing <strong>after prolonged use of typical antipsychotic drugs</strong>. The<strong> efficacy of valbenazine</strong> in managing <strong>TD</strong> is due to its role as a<strong> vesicular monoamine transporter 2 (VMAT2) inhibitor,</strong> which <strong>modulates</strong> <strong>dopamine release</strong> and <strong>reduces </strong>the <strong>symptoms</strong> associated with this <strong>disorder</strong>. Its <strong>mechanism focuses</strong> on addressing the <strong>dopamine</strong> <strong>receptor supersensitivity</strong> that develops due to <strong>chronic dopamine D2 receptor blockade</strong> by <strong>antipsychotics.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Benzhexol:</span></strong><span style=\"font-size:12.0pt\"> Also known as<strong> trihexyphenidyl,</strong> is an<strong> anticholinergic drug, </strong>which is <strong>contraindicated</strong> in the management of <strong>TD</strong> as it can potentially<strong> worsen the symptoms.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Promethazine:</span></strong><span style=\"font-size:12.0pt\"> Has <strong>anticholinergic properties</strong> and is also<strong> contraindicated in TD</strong> for <strong>similar reasons to benzhexol</strong>, as it may <strong>exacerbate</strong> the </span></span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>involuntary movements.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. All the above:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect</strong> because<strong> both benzhexol and promethazine </strong>are <strong>not</strong> suitable for the management of <strong>TD and</strong> are <strong>contraindicated.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Valbenazine </span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is</span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> specifically used </span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">for the management of</span></span><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> tardive dyskinesia </span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">due to its <strong>VMAT2 inhibitory action,</strong> unlike <strong>anticholinergic</strong> drugs such as <strong>benzhexol and promethazine</strong>, which are<strong> contraindicated</strong> in this condition.</span></span></p>",
    "correct_choice_id": 57767,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14562,
    "choices": [
      {
        "id": 58209,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methadone </span></span></span></p>"
      },
      {
        "id": 58210,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Naltrexone </span></span></span></p>"
      },
      {
        "id": 58211,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Naloxone </span></span></span></p>"
      },
      {
        "id": 58212,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nalmefene</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old male patient with a history of alcohol use disorder presents to your clinic for treatment. He has a long history of heavy drinking and has recently stopped drinking. Which of the following medications is commonly used to prevent relapse in patients with alcohol use disorder?</span></span></p>",
    "unique_key": "Q1192313",
    "question_audio": null,
    "question_video": null,
    "map_id": 36164,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) Naltrexone.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Naltrexone</strong> is an<strong> opioid antagonist medication </strong>that is<strong> used to</strong> treat <strong>alcohol use disorder</strong> by <strong>reducing the craving </strong>for <strong>alcohol </strong>and preventing <strong>relapse in individuals </strong>who have <strong>stopped drinking.</strong> It works by <strong>blocking the effects of endorphins,</strong> which are <strong>naturally</strong> occurring<strong> chemicals in the brain</strong> that are released in<strong> response to alcohol consumption</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Methadone</strong> is an <strong>opioid agonist</strong> medication that is <strong>primarily used to treat opioid addiction </strong>by<strong> reducing withdrawal symptoms and cravings.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Naloxone and nalmefene </strong>are also <strong>opioid antagonist medications</strong>, but they are primarily used to <strong>reverse opioid overdose</strong> and are <strong>not</strong> typically <strong>used in the treatment of alcohol use disorder.</strong></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 58210,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14602,
    "choices": [
      {
        "id": 58369,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Chlordiazepoxide</span></span></span></p>"
      },
      {
        "id": 58370,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Diazepam</span></span></span></p>"
      },
      {
        "id": 58371,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Lorazepam</span></span></span></p>"
      },
      {
        "id": 58372,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Flunitrazepam</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old male with a history of chronic liver disease is admitted to the hospital for alcohol withdrawal management. Given his liver condition, the healthcare team needs to choose a medication that is safe and effective for managing his withdrawal symptoms while considering the potential impact on his liver function. Which of the following agents is most appropriate for managing alcohol withdrawal in this patient with liver disease?</span></span></p>",
    "unique_key": "Q1624936",
    "question_audio": null,
    "question_video": null,
    "map_id": 36235,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Lorazepam </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Benzodiazepines (BZDs) </strong>are the <strong>drugs of choice</strong> to treat <strong>alcohol withdrawal.</strong> <strong>Chlordiazepoxide</strong> is the <strong>first choice. Diazepam</strong> is the <strong>alternative.</strong><strong> </strong>But <strong>all BZDs </strong>given in the options (<strong>Chlordiazepoxide Diazepam and flunitrazepam</strong>) are <strong>metabolized extensively</strong> by <strong>enzyme CYP3A4 In liver and active metabolites </strong>are generated. Oxazepam, Lorazepam Temazepam are <strong>not metabolized</strong> but directly <strong>conjugated </strong>therefore they are<strong> relatively safer </strong>in <strong>elderly patients </strong>and in those with<strong> liver disease.</strong> <strong>&nbsp;</strong></span><span style=\"font-size:12.0pt\">Thus, <strong>Lorazepam (option C)</strong> is a <strong>benzodiazepine</strong> that is preferred for managing <strong>alcohol withdrawal symptoms</strong> in patients with <strong>liver disease</strong>. It <strong>undergoes</strong> <strong>glucuronidation </strong>rather than oxidation. This makes<strong> lorazepam a safer option</strong> for patients with<strong> compromised liver function</strong>, as it is <strong>less likely</strong> to <strong>accumulate to toxic levels.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Chlordiazepoxide:&nbsp;</span></strong><span style=\"font-size:12.0pt\">While chlordiazepoxide is<strong> commonly used </strong>for <strong>alcohol withdrawal,</strong> its<strong> metabolism</strong> is significantly affected by <strong>liver function,</strong> making it a<strong> less ideal choice</strong> for patients with <strong>liver disease</strong> due to the <strong>risk of accumulation and increased side effects</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Diazepam:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Diazepam is<strong> metabolized by the liver,</strong> and <strong>its active metabolites </strong>can <strong>accumulate in patients with liver disease,</strong> potentially leading to <strong>prolonged sedation and increased toxicity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Flunitrazepam:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Flunitrazepam is also <strong>metabolized by the liver,</strong> and like <strong>diazepam,</strong> it can <strong>accumulate in patients </strong>with <strong>liver</strong> <strong>impairment,</strong> making it a <strong>less favorable option.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational objective is to understand that <strong>lorazepam</strong> is the preferred<strong> benzodiazepine</strong> for managing <strong>alcohol withdrawal symptoms in patients with liver disease </strong>due to its <strong>metabolism through glucuronidation,</strong> which is <strong>less</strong> affected by <strong>liver function</strong> compared to the<strong> oxidative metabolism</strong> of<strong> other benzodiazepines. </strong></span></span></span></p>",
    "correct_choice_id": 58371,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14596,
    "choices": [
      {
        "id": 58345,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Lamotrigine </span></span></span></p>"
      },
      {
        "id": 58346,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Topiramate </span></span></span></p>"
      },
      {
        "id": 58347,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">ACTH </span></span></span></p>"
      },
      {
        "id": 58348,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Vigabatrin </span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 6-month-old infant presents with a history of infantile spasms and has recently been diagnosed with a visual field defect. The pediatric neurologist discusses treatment options with the parents, emphasizing the need for effective management of the spasms while also considering the potential side effects of medications. Which of the following drugs, despite being highly effective for treating infantile spasms, is not used in this patient due to the risk of exacerbating the visual defect?</span></span></p>",
    "unique_key": "Q1725512",
    "question_audio": null,
    "question_video": null,
    "map_id": 36233,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Vigabatrin </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Vigabatrin</strong> is a<strong> medication</strong> that is<strong> highly effective </strong>in the <strong>treatment of infantile spasms,</strong> particularly those associated with<strong> tuberous</strong> <strong>sclerosis.</strong> However, its use is associated with a<strong> risk of permanent visual field defects, </strong>making it <strong>contraindicated </strong>or used <strong>with caution</strong> in <strong>patients with pre-existing</strong> <strong>visual problems </strong>or when the<strong> risk of such adverse effects</strong> <strong>outweighs</strong> the<strong> benefits.</strong> In a child with <strong>infantile spasms</strong> and a <strong>visual defect</strong>,<strong> vigabatrin</strong> <strong>would not</strong> be the preferred <strong>choice </strong>due to this <strong>risk.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Lamotrigine:</span></strong><span style=\"font-size:12.0pt\"> Lamotrigine is an <strong>antiepileptic drug </strong>used for <strong>various seizure types</strong> but is <strong>not</strong> the <strong>first-line treatment</strong> for <strong>infantile spasms. </strong>It <strong>does not</strong> have a<strong> high risk </strong>of<strong> causing</strong> or <strong>exacerbating visual field defects.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Topiramate:</span></strong><span style=\"font-size:12.0pt\"> Topiramate is another <strong>antiepileptic</strong> that <strong>can be used </strong>in the management of<strong> infantile spasms</strong> but is also<strong> not</strong> primarily associated with<strong> visual field </strong>defects as a common adverse effect.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. ACTH (Adrenocorticotropic hormone):</span></strong><span style=\"font-size:12.0pt\"> ACTH is a<strong> standard treatment</strong> for <strong>infantile spasms </strong>and <strong>does not</strong> directly cause <strong>visual field defects</strong>, making it a suitable option for this condition.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational objective is to<strong> identify vigabatrin</strong> as an <strong>effective treatment</strong> for<strong> infantile spasms</strong> that is <strong>contraindicated in patients</strong> with <strong>pre-existing visual field defects</strong> due to the<strong> risk of exacerbating or causing permanent visual damage.</strong></span></span></span></p>",
    "correct_choice_id": 58348,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 14593,
    "choices": [
      {
        "id": 58333,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Psychosis</span></span></span></p>"
      },
      {
        "id": 58334,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Severe vomiting</span></span></span></p>"
      },
      {
        "id": 58335,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Arrhythmia</span></span></span></p>"
      },
      {
        "id": 58336,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Postural hypotension</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All the following adverse effects of Levodopa can be reduced by carbidopa except</span></span></p>",
    "unique_key": "Q7958063",
    "question_audio": null,
    "question_video": null,
    "map_id": 36231,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Psychosis</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Levodopa</strong> is a <strong>precursor of dopamine,</strong> a<strong> neurotransmitter</strong> that is depleted in <strong>Parkinson&#39;s disease.</strong> It is <strong>converted into dopamine</strong> in the <strong>brain,</strong> where it <strong>stimulates dopamine receptors</strong>, including<strong> D1 and D2 receptors. Levodopa</strong> is <strong>not</strong> a<strong> dopamine receptor agonist,</strong> but rather a <strong>precursor of dopamine</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Carbidopa</strong> is often <strong>co-administered</strong> with<strong> levodopa</strong> to prevent<strong> its peripheral breakdown</strong> and<strong> increase its availability </strong>in the<strong> brain. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Carbidopa</strong> is a <strong>peripheral dopa decarboxylase inhibitor</strong> that<strong> does not cross the blood-brain barrier.</strong> It helps to <strong>reduce</strong> the <strong>peripheral adverse effects of levodopa</strong>, such as <strong>nausea and vomiting,</strong> <strong>postural hypotension,</strong> and <strong>cardiac</strong> <strong>arrhythmias, </strong>by<strong> preventing its breakdown </strong>in the <strong>gastrointestinal tract. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">However, <strong>carbidopa</strong> <strong>does not </strong>directly affect <strong>levodopa&#39;s activity on dopamine receptors</strong> in the brain, which is thought to be responsible for the <strong>development of psychosis as an adverse effect</strong>. Therefore,<strong> carbidopa cannot</strong> <strong>reduce</strong> the risk of developing<strong> psychosis</strong> as an <strong>adverse effect of levodopa.</strong></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 58333,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14500,
    "choices": [
      {
        "id": 57961,
        "text": "<p><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Flumazenil</span></span></p>"
      },
      {
        "id": 57962,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Beta carboline</span></span></span></p>"
      },
      {
        "id": 57963,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Naltrexone</span></span></span></p>"
      },
      {
        "id": 57964,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Zopiclone</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which drug has inverse agonist activity at benzodiazepine receptors? </span></span></span></p>",
    "unique_key": "Q8955635",
    "question_audio": null,
    "question_video": null,
    "map_id": 36232,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Beta carboline</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Beta-carbolines</span></strong><span style=\"font-size:12.0pt\"> are compounds that have been identified to possess <strong>inverse agonist activity </strong>at the<strong> benzodiazepine site of the GABA-A receptor.</strong> Unlike <strong>benzodiazepines,</strong> which are<strong> agonists</strong> at this site and <strong>increase the inhibitory effect of GABA</strong> leading to <strong>sedation and anxiolysis, inverse agonists</strong> like<strong> beta-carbolines decrease the action of GABA</strong>. This can <strong>lead to effects opposite</strong> those of <strong>benzodiazepines</strong>, such as<strong> increased anxiety </strong>and <strong>seizures in susceptible individuals.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanatio:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Flumazenil</span></strong><span style=\"font-size:12.0pt\">: Flumazenil is a<strong> benzodiazepine receptor antagonist,</strong> <strong>not an inverse agonist</strong>. It is<strong> used to reverse</strong> the effects of <strong>benzodiazepines</strong> in cases of <strong>overdose.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Naltrexone</span></strong><span style=\"font-size:12.0pt\">: Naltrexone is an <strong>opioid receptor antagonist</strong> used primarily in the management of<strong> alcohol and opioid</strong> <strong>dependence</strong>, <strong>not</strong> related to<strong> benzodiazepine receptor</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Zopiclone</span></strong><span style=\"font-size:12.0pt\">: Zopiclone is a <strong>non-benzodiazepine hypnotic agent </strong>used for the treatment of <strong>insomnia.</strong> It <strong>acts </strong>as an <strong>agonist</strong> at the<strong> benzodiazepine site of the GABA-A receptor</strong>, similar to <strong>benzodiazepines,</strong> but it is <strong>not an inverse agonist.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational goal is to understand the concept of<strong> inverse agonism at the benzodiazepine receptors</strong>, <strong>exemplified by compounds</strong> such as <strong>beta-carbolines</strong>. This understanding <strong>highlights</strong> the <strong>diversity of drug actions at the GABA-A receptor complex</strong>, ranging from <strong>agonists (e.g., benzodiazepines)</strong> that enhance <strong>GABAergic activity to inverse agonists</strong> that <strong>reduce this activity,</strong> with significant <strong>implications</strong> for<strong> their effects</strong> on the<strong> central nervous system.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DRUGS ACTING AT GABA-BZD-CHLORIDE CHANNEL COMPLEX</span></span></strong></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-151400.jpg\" style=\"height:549px; width:1000px\" /></span></span></strong></p>",
    "correct_choice_id": 57962,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 14623,
    "choices": [
      {
        "id": 58453,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Sibutramine</span></span></span></p>"
      },
      {
        "id": 58454,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Fenfluramine</span></span></span></p>"
      },
      {
        "id": 58455,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Metformin</span></span></span></p>"
      },
      {
        "id": 58456,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liraglutide </span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which of the following drugs is used in the treatment of obesity? </span></span></span></p>",
    "unique_key": "Q2748236",
    "question_audio": null,
    "question_video": null,
    "map_id": 36242,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Liraglutide </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Liraglutide</strong> is a<strong> GLP-1 receptor agonist </strong>that is approved for the <strong>treatment of obesity.</strong> It works by<strong> mimicking the action of the GLP-1 hormone</strong>, which is involved in <strong>appetite regulation </strong>and <strong>calorie intake</strong>. Liraglutide <strong>promotes weight loss </strong>by <strong>increasing feelings of fullness</strong>, <strong>reducing</strong> <strong>hunger,</strong> and thereby<strong> lowering calorie intake. </strong>It is<strong> administered via injection</strong> and is used as <strong>part of a comprehensive weight management </strong>program that includes <strong>diet, exercise</strong>, and <strong>behavior modification.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-family:Calibri, sans-serif\"><span style=\"font-size:16px\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Sibutramine:</span></strong><span style=\"font-size:12.0pt\"> Sibutramine was<strong> previously used </strong>for the treatment of <strong>obesity.</strong> However, it was <strong>withdrawn from the market </strong>in many countries due to <strong>concerns</strong> over <strong>cardiovascular side effects,</strong> including<strong> increased risk of heart attack and stroke</strong>. Therefore, it is<strong> no</strong> longer<strong> recommended or available </strong>as a <strong>treatment option</strong> for <strong>obesity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Fenfluramine:</span></strong><span style=\"font-size:12.0pt\"> Fenfluramine, <strong>part of the fen-phen combination,</strong> was used in the <strong>past for weight loss</strong>. However, it was <strong>withdrawn from the market</strong> <strong>due to</strong> its association with <strong>serious</strong> <strong>heart valve problems and pulmonary hypertension</strong>. It is <strong>no longer </strong>available or recommended for the <strong>treatment of obesity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. &nbsp;Metformin:</span></strong><span style=\"font-size:12.0pt\"> Metformin is primarily <strong>used for</strong> the treatment of <strong>type 2 diabetes</strong>. While it is<strong> not</strong> approved specifically for the <strong>treatment of obesity, </strong>it may<strong> lead to modest</strong> <strong>weight loss </strong>in some<strong> individuals,</strong> especially those with<strong> insulin resistance</strong>. However,<strong> its primary</strong> indication is <strong>not obesity treatment</strong>, and it is used <strong>off-label for weight management</strong> in certain cases.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational objective of this question is to know different drugs like <strong>liraglutide </strong>which are <strong>used in treatment of obesity. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">US-FDA APPROVED ANTI-OBESITY DRUGS:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/1030.jpg\" style=\"height:824px; width:1000px\" /></p>",
    "correct_choice_id": 58456,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14458,
    "choices": [
      {
        "id": 57793,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GABA A-BZD - CI- channel stimulator </span></span></span></p>"
      },
      {
        "id": 57794,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">GABA B-BZD - CI- channel stimulator </span></span></span></p>"
      },
      {
        "id": 57795,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">BZD receptor stimulator </span></span></span></p>"
      },
      {
        "id": 57796,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">NMDA receptor stimulator</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old male patient with a history of anxiety and insomnia has been prescribed a benzodiazepine medication by his psychiatrist. Which of the following is the mechanism of action of benzodiazepine?</span></span></span></p>",
    "unique_key": "Q3635312",
    "question_audio": null,
    "question_video": null,
    "map_id": 36240,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) GABA A-BZD - CI- channel stimulator</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Benzodiazepines </strong>enhance the <strong>inhibitory neurotransmission mediated by GABA (gamma-aminobutyric acid) </strong>in the central nervous system. They<strong> bind</strong> to a <strong>specific site on the GABA A receptor complex</strong>, <strong>distinct from the GABA binding site</strong> but closely associated with it. This <strong>binding increases the frequency of chloride ion channel openings </strong>in response to <strong>GABA binding</strong>, leading to<strong> increased</strong> <strong>chloride ion influx. </strong>The <strong>influx of chloride</strong> ions results in<strong> hyperpolarization of neurons,</strong> making them<strong> less excitable </strong>and thereby producing a <strong>calming effect</strong>. This mechanism is critical in treating conditions like<strong> anxiety and insomnia</strong> by effectively <strong>reducing</strong> <strong>neuronal excitability and activity.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. GABA B-BZD - CI- channel stimulator:</span></strong><span style=\"font-size:12.0pt\"><strong> Incorrect </strong>because<strong> benzodiazepines</strong> <strong>do not act </strong>on <strong>GABA B receptors</strong>, which primarily involve <strong>different signaling mechanisms.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. BZD receptor stimulator:</span></strong><span style=\"font-size:12.0pt\"><strong> Misleading</strong> as <strong>benzodiazepines enhance GABA&#39;s effect</strong> rather than<strong> directly stimulating</strong> the <strong>receptor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. NMDA receptor stimulator:</span></strong><span style=\"font-size:12.0pt\"> <strong>Incorrect</strong> because <strong>benzodiazepines do not </strong>interact with <strong>NMDA receptors,</strong> which are involved in<strong> excitatory neurotransmission.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Benzodiazepines </strong>function by<strong> stimulating chloride ion channels</strong> associated with the<strong> GABA A receptor complex,</strong> enhancing the <strong>natural inhibitory effects of GABA</strong>, which is <strong>crucial for</strong> their efficacy in <strong>treating anxiety and insomnia.</strong></span></span></p>",
    "correct_choice_id": 57793,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 14621,
    "choices": [
      {
        "id": 58445,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Tourette syndrome</span></span></span></p>"
      },
      {
        "id": 58446,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Post-traumatic stress disorder</span></span></span></p>"
      },
      {
        "id": 58447,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Bipolar disorder</span></span></span></p>"
      },
      {
        "id": 58448,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Dementia </span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which of the following is not an off-label use of risperidone?&nbsp; </span></span></span></p>",
    "unique_key": "Q6727836",
    "question_audio": null,
    "question_video": null,
    "map_id": 36241,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Ans. C) &nbsp;Bipolar disorder</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Off-label </strong>use of a drug refers to the <strong>use of a medication for a purpose </strong>that <strong>has not</strong> been approved by <strong>regulatory agencies,</strong> such as the <strong>US Food and Drug Administration (FDA).</strong> <strong>Risperidone </strong>is approved for the <strong>treatment of Psychosis and Bipolar disorder</strong>. So, <strong>bipolar</strong> <strong>disorder</strong> is <strong>not an off-label use of risperidone.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Some Off-Label Uses of Risperidone are:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tourette&#39;s syndrome</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Obsessive-compulsive disorder (OCD)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Post-traumatic stress disorder (PTSD)</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Management of behavioural and psychological symptoms in dementia</span><strong> </strong></span></span></li>\r\n</ul>",
    "correct_choice_id": 58447,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14481,
    "choices": [
      {
        "id": 57885,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Dimethyl fumarate (DMF)</span></span></span></p>"
      },
      {
        "id": 57886,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Interferon-&beta;-1a</span></span></span></p>"
      },
      {
        "id": 57887,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Fingolimod</span></span></span></p>"
      },
      {
        "id": 57888,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Natalizumab</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A 38-year-old woman has relapsing/remitting multiple sclerosis. She has experienced two attacks of disease previously that have left her with residual lower extremity weakness. She was initially treated with glucocorticoids with some improvement in her symptoms. However, she is currently only able to walk with a rolling walker for about 100 m. A prior antibody test shows positive reactivity to the JC virus. You are planning to start disease-modifying therapy. Which of the following is LEAST appropriate for this individual?</span></span></span></p>",
    "unique_key": "Q5647149",
    "question_audio": null,
    "question_video": null,
    "map_id": 36238,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Natalizumab</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Natalizumab</strong> is an <strong>effective disease-modifying therapy </strong>for <strong>relapsing forms of multiple sclerosis</strong> but carries a <strong>significant risk </strong>for <strong>progressive multifocal leukoencephalopathy (PML)</strong>, especially in patients who are<strong> JC virus antibody positive</strong>. Given this patient&#39;s <strong>positive JC virus antibody status</strong>, the<strong> risk of developing PML</strong> with <strong>natalizumab treatment</strong> is considerably<strong> higher,</strong> making it the<strong> least</strong> appropriate <strong>option for her.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Dimethyl fumarate (DMF):</span></strong><span style=\"font-size:12.0pt\"> Suitable for <strong>relapsing-remitting MS</strong> with a different <strong>safety profile</strong> and <strong>lower risk of PML.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Interferon-&beta;-1a:</span></strong><span style=\"font-size:12.0pt\"> <strong>Commonly</strong> used in<strong> MS</strong>, works by <strong>modulating the immune system</strong> and also has a <strong>lower risk of PML.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Fingolimod:</span></strong><span style=\"font-size:12.0pt\"> Although it requires <strong>monitoring for other side effects</strong>, it has a <strong>lesser association with PML</strong> compared to natalizumab in <strong>JC virus positive patients.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In<strong> multiple sclerosis patients</strong> who are <strong>JC virus antibody positive</strong>, <strong>natalizumab</strong> presents an<strong> increased risk of PML</strong> and <strong>should be used</strong> with <strong>caution or avoided </strong>in favor of<strong> therapies with a safer profile </strong>under <strong>such conditions.</strong></span></span></p>",
    "correct_choice_id": 57888,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14509,
    "choices": [
      {
        "id": 57997,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 50-year-old male with a history of stable angina who presents with chest pain.</span></span></span></p>"
      },
      {
        "id": 57998,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 65-year-old female with metastatic breast cancer and severe pain.</span></span></span></p>"
      },
      {
        "id": 57999,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 30-year-old male with a history of biliary colic who presents with abdominal pain.</span></span></span></p>"
      },
      {
        "id": 58000,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 40-year-old female who underwent a minor surgical procedure and is experiencing postoperative pain.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following patients should not receive morphine?</span></span></span></p>",
    "unique_key": "Q8256132",
    "question_audio": null,
    "question_video": null,
    "map_id": 36237,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span style=\"font-size:12.0pt\">C) A 30-year-old male with a history of biliary colic who presents with abdominal pain.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Morphine</strong> can <strong>exacerbate biliary colic</strong> by causing <strong>spasm of the sphincter of Oddi,</strong> which controls the <strong>flow of bile into the intestine</strong>. This spasm can <strong>lead to an increase in biliary tract pressure </strong>and<strong> worsen pain</strong> in patients with <strong>biliary colic</strong>. Alternatives such as <strong>non</strong>-<strong>opioid analgesics</strong> or <strong>other opioids less</strong> likely to<strong> induce biliary spasm</strong>, like <strong>pethidine (meperidine),</strong> may be considered in such cases.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. </span></strong><span style=\"font-size:12.0pt\"><strong>&nbsp;Morphine</strong> is generally <strong>safe for patients</strong> with<strong> stable angina,</strong> provided it is used<strong> cautiously</strong> under<strong> medical supervision.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. </span></strong><span style=\"font-size:12.0pt\">&nbsp;Suitable for managing<strong> severe cancer pain.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. </span></strong><span style=\"font-size:12.0pt\">&nbsp;Appropriate for <strong>controlling moderate to severe postoperative pain.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Precautions and contraindications while using morphine.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol style=\"list-style-type:lower-alpha\">\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Morphine</strong> releases <strong>histamine</strong> which can cause <strong>bronchoconstriction. </strong>Therefore, <strong>avoided in patients</strong> of <strong>respiratory</strong> <strong>insufficiency.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Morphine</strong> causes <strong>spasm of sphincter of Oddi </strong>due to which <strong>intrabiliary pressure is increased</strong>, hence causing <strong>worsening of pain due to biliary colic.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Morphine</strong> causes <strong>spasm of both detrusor muscle and urinary sphincter,</strong> hence <strong>urinary urgency</strong> and<strong> difficulty in</strong> <strong>micturition </strong>can occur.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In<strong> case of head injury,</strong> morphine is<strong> contraindicated</strong> due to following reasons:</span></span></span>\r\n\t<ol style=\"list-style-type:lower-roman\">\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Increases intracranial tension </strong>by <strong>retaining CO<sub>2.</sub></strong></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Marked<strong> respiratory depression</strong> even <strong>at therapeutic doses</strong> in patients of<strong> head injury.</strong></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Morphine produces <strong>miosis, vomiting, and altered mental status</strong> which can interfere with assessment of patients.</span></span></span></li>\r\n\t</ol>\r\n\t</li>\r\n</ol>",
    "correct_choice_id": 57999,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14611,
    "choices": [
      {
        "id": 58405,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pimavanserin </span></span></span></p>"
      },
      {
        "id": 58406,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Riluzole </span></span></span></p>"
      },
      {
        "id": 58407,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Fingolimod </span></span></span></p>"
      },
      {
        "id": 58408,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tetrabenazine</span><strong> </strong></span></span><strong> </strong></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 72-year-old woman with a history of Parkinson&#39;s disease presents with new-onset hallucinations and delusions. Her neurologist is considering adding a medication to address these symptoms without worsening her motor symptoms. Which of the following medications would be most appropriate for this patient?</span></span></span></p>",
    "unique_key": "Q9950832",
    "question_audio": null,
    "question_video": null,
    "map_id": 36239,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Pimavanserin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Pimavanserin </strong>is a <strong>selective serotonin inverse agonist</strong> that specifically<strong> targets</strong> the <strong>5-HT2A receptor.</strong> It is approved for the <strong>treatment of Parkinson&#39;s disease</strong> <strong>psychosis, </strong>which can manifest as<strong> hallucinations and delusions</strong>. <strong>Pimavanserin</strong> <strong>does not</strong> affect <strong>dopamine levels</strong>, which makes it a<strong> suitable choice</strong> for patients with<strong> Parkinson&#39;s disease,</strong> as it is <strong>less likely</strong> to <strong>worsen motor </strong>symptoms compared to <strong>traditional antipsychotics.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Riluzole is</span></strong><span style=\"font-size:12.0pt\"> primarily used to treat <strong>amyotrophic lateral sclerosis (ALS).</strong> It is thought to work by <strong>reducing the release of the neurotransmitter glutamate,</strong> which may <strong>slow down</strong> the<strong> progression of ALS. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Fingolimod&nbsp;</span></strong><span style=\"font-size:12.0pt\">is used to treat<strong> multiple sclerosis (MS). </strong>It is a<strong> sphingosine-1-phosphate</strong> <strong>receptor modulator,</strong> which works by<strong> sequestering lymphocytes in the lymph nodes</strong>, <strong>reducing</strong> their ability to contribute to the <strong>autoimmune response in MS. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Tetrabenazine</span></strong><span style=\"font-size:12.0pt\"> is used to <strong>treat chorea</strong> associated with<strong> Huntington&#39;s disease</strong>. It works by<strong> inhibiting the vesicular monoamine transporter 2 (VMAT2),</strong> leading to a <strong>decrease</strong> in the <strong>release of dopamine in the brain.</strong> Although it may have some <strong>antipsychotic properties</strong>, <strong>tetrabenazine</strong> is <strong>not</strong> the most appropriate <strong>choice</strong> for treating<strong> hallucinations</strong> and <strong>delusions in Parkinson&#39;s disease</strong> patients, as it can exacerbate <strong>motor symptoms </strong>due to its <strong>dopamine-depleting effects.</strong></span></span></span></p>",
    "correct_choice_id": 58405,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14618,
    "choices": [
      {
        "id": 58433,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Serum electrolytes </span></span></span></p>"
      },
      {
        "id": 58434,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Serum lithium levels</span></span></span></p>"
      },
      {
        "id": 58435,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">ECG </span></span></span></p>"
      },
      {
        "id": 58436,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">MRI</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A female patient who has been on lithium therapy for bipolar disorder for 6 months presents with seizures, coarse tremors, confusion, and weakness of limbs after fasting for a few days due to religious reasons. To diagnose her condition, the following test should be performed:</span></span></p>",
    "unique_key": "Q3294249",
    "question_audio": null,
    "question_video": null,
    "map_id": 36236,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Serum lithium levels</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>patient&#39;s symptoms</strong> are suggestive of<strong> lithium toxicity,</strong> which can be <strong>confirmed by measuring serum lithium levels. Fasting and dehydration</strong> may have contributed to the <strong>development of lithium toxicity,</strong> as they can cause <strong>reduced renal clearance and increased reabsorption of lithium</strong>, leading to <strong>higher serum concentrations.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Other Options:</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option A. Serum electrolytes:&nbsp;</strong> It would also be important to evaluate the <strong>patient&#39;s serum electrolytes </strong>&nbsp;to assess for any<strong> imbalances</strong> that may have <strong>resulted from fasting or lithium toxicity.</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;<strong>Option C. ECG:</strong>&nbsp; An <strong>ECG&nbsp;&nbsp;</strong>may be necessary to<strong> check</strong> for any <strong>cardiac abnormalities, </strong>as <strong>lithium </strong>can<strong> sometimes affect the heart.</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Option D. MRI:</strong>&nbsp;An<strong> MRI (D)</strong> may be considered if there is concern for other <strong>underlying neurological issues</strong>, but it is <strong>not</strong> the<strong> first step</strong> in <strong>diagnosing lithium toxicity.</strong></span></span></p>",
    "correct_choice_id": 58434,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14502,
    "choices": [
      {
        "id": 57969,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">MAO B inhibitor </span></span></span></p>"
      },
      {
        "id": 57970,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Inhibitor of vesicular monoamine transporter </span></span></span></p>"
      },
      {
        "id": 57971,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Inhibitor of dopamine receptors </span></span></span></p>"
      },
      {
        "id": 57972,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Inhibitor of COMT</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A 45-year-old male with a history of Huntington&#39;s disease presents to the clinic with significant chorea. He is taking tetrabenazine to help control his symptoms. What is the mechanism of action of tetrabenazine? </span></span></span></p>",
    "unique_key": "Q9110465",
    "question_audio": null,
    "question_video": null,
    "map_id": 36234,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Inhibitor of vesicular monoamine transporter</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Tetrabenazine</strong> acts as an<strong> inhibitor of the vesicular monoamine transporter 2 (VMAT2),</strong> which is involved in the <strong>uptake of</strong> <strong>monoamines, including dopamine, into synaptic vesicles</strong>. By <strong>inhibiting this transporter</strong>,<strong> tetrabenazine reduces </strong>the amount of <strong>dopamine</strong> available for <strong>release into the synapse.</strong> This<strong> reduction in dopamine release</strong> is <strong>beneficial</strong> in managing symptoms like <strong>chorea</strong> <strong>in Huntington&#39;s disease,</strong> which are partly caused by<strong> excessive dopaminergic activity</strong> in certain<strong> brain regions.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. MAO B inhibitor:</span></strong><span style=\"font-size:12.0pt\"> These are typically<strong> used in Parkinson&#39;s disease</strong> to<strong> increase dopamine availability</strong> and <strong>are not </strong>relevant to the<strong> mechanism of tetrabenazine.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Inhibitor of dopamine receptors:</span></strong><span style=\"font-size:12.0pt\"> While<strong> blocking dopamine receptors</strong> can <strong>reduce chorea</strong>, <strong>tetrabenazine</strong> <strong>does not</strong> directly <strong>block these receptors but</strong> rather <strong>decreases dopamine availability.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Inhibitor of COMT:</span></strong><span style=\"font-size:12.0pt\"> This class of drugs is also <strong>used in Parkinson&rsquo;s disease </strong>and is <strong>not </strong>involved in the <strong>mechanism of action </strong>of <strong>tetrabenazine.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Tetrabenazine&rsquo;s</strong> ability to<strong> inhibit VMAT2 </strong>and<strong> reduce dopamine release </strong>makes it <strong>effective for treating chorea</strong> associated with <strong>Huntington&#39;s disease, highlighting</strong> its role in <strong>managing hyperkinetic movement disorders.</strong></span></span></p>",
    "correct_choice_id": 57970,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14617,
    "choices": [
      {
        "id": 58429,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Side effects of hydrochlorothiazide</span></span></span></p>"
      },
      {
        "id": 58430,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Decreased metabolism of hydrochlorothiazide by lithium.</span></span></span></p>"
      },
      {
        "id": 58431,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Increased renal tubular reabsorption of lithium.</span></span></span></p>"
      },
      {
        "id": 58432,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Thiazide acts as an add on drug to lithium.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with bipolar disorder was treated with lithium. Hydrochlorothiazide was prescribed for his hypertension. He developed nausea, vomiting, coarse tremors and brisk reflexes 2 weeks after taking drugs. What is the likely reason for this presentation? </span></span></p>",
    "unique_key": "Q1324794",
    "question_audio": null,
    "question_video": null,
    "map_id": 36219,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Increased renal tubular reabsorption of lithium.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>most likely cause </strong>of the patient&#39;s symptoms, including<strong> nausea, vomiting, coarse tremors,</strong> and <strong>brisk reflexes,</strong> is <strong>increased renal tubular reabsorption</strong> of <strong>lithium.</strong> When <strong>hydrochlorothiazide, a thiazide diuretic, </strong>is <strong>administered</strong> <strong>alongside lithium,</strong> it can<strong> lead to</strong> <strong>decreased renal clearance of lithium</strong> by <strong>increasing its reabsorption in the renal tubules</strong>. This pharmacological interaction results in <strong>elevated serum lithium levels</strong>, potentially <strong>culminating</strong> in <strong>lithium toxicity.</strong> The <strong>symptoms of lithium toxicity </strong>closely align with <strong>those experienced by</strong> the<strong> patient,</strong> making this<strong> option</strong> the <strong>most plausible explanation</strong> for the clinical presentation observed.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-family:Calibri, sans-serif\"><span style=\"font-size:16px\"><strong>Other Options:</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Side effects of hydrochlorothiazide:</span></strong><span style=\"font-size:12.0pt\"> While <strong>hydrochlorothiazide </strong>can cause side effects like <strong>electrolyte imbalances and dehydration</strong>, its <strong>common side effects do not</strong> typically include the combination of symptoms seen in<strong> lithium toxicity</strong> (<strong>nausea, vomiting, coarse</strong> <strong>tremors, and brisk reflexes</strong>). These<strong> symptoms </strong>are <strong>more specifically</strong> indicative of <strong>lithium</strong> <strong>toxicity</strong> <strong>rather than</strong> direct <strong>side effects of hydrochlorothiazide.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Decreased metabolism of hydrochlorothiazide by lithium:</span></strong><span style=\"font-size:12.0pt\"> Lithium <strong>does not</strong> significantly impact the<strong> metabolism of hydrochlorothiazide.</strong> The<strong> metabolism and clearance</strong> of <strong>hydrochlorothiazide </strong>are primarily<strong> renal</strong> and are <strong>not</strong> substantially <strong>altered by concurrent</strong> <strong>lithium use,</strong> making this option an <strong>unlikely cause </strong>of the<strong> patient&#39;s symptoms.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Thiazide acts as an add-on drug to lithium:</span></strong><span style=\"font-size:12.0pt\"> There is <strong>no</strong> evidence to suggest that thiazide diuretics <strong>act as add-on drugs to enhance the therapeutic effects of lithium</strong> in the treatment of <strong>bipolar disorder</strong>. The <strong>interaction between hydrochlorothiazide and lithium</strong> that is of clinical significance relates to the <strong>effect on lithium&#39;s renal handling</strong>, <strong>rather </strong>than a <strong>synergistic effect </strong>on <strong>mood stabilization.</strong></span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The key learning point from this scenario is understanding the<strong> pharmacological interaction</strong> <strong>between lithium and thiazide diuretics</strong>, such as <strong>hydrochlorothiazide</strong>, and how this <strong>interaction</strong> can lead to <strong>increased serum lithium levels </strong>and <strong>subsequent lithium toxicity. </strong></span></span></p>",
    "correct_choice_id": 58431,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14493,
    "choices": [
      {
        "id": 57933,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Venlafaxine</span></span></span></p>"
      },
      {
        "id": 57934,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Fluoxetine</span></span></span></p>"
      },
      {
        "id": 57935,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Valproate</span></span></span></p>"
      },
      {
        "id": 57936,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Olanzapine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Stoppage of which of the following drugs can result in anxiety and insomnia causing discontinuation syndrome? </span></span></span></p>",
    "unique_key": "Q1604156",
    "question_audio": null,
    "question_video": null,
    "map_id": 36221,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:14px\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\">Ans. A) Venlafaxine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:14px\"><strong>Discontinuation syndrome</strong> refers to a<strong> set of symptoms</strong> that can occur after <strong>abruptly stopping or significantly reducing</strong> the <strong>dose of certain medications</strong>, particularly those that affect <strong>neurotransmitter levels </strong>in the brain such as <strong>antidepressants. </strong>&nbsp;Common <strong>symptoms of discontinuation syndrome </strong>include<strong> anxiety, insomnia, dizziness, irritability,</strong> <strong>flu-like symptoms, and sensory disturbances </strong>(e.g., &quot;<strong>electric shock&quot;</strong> sensations). The <strong>severity and</strong> <strong>duration</strong> of symptoms can vary depending on th<strong>e drug&#39;s half-life, dosage, and the duration of treatment</strong>. <strong>Discontinuation syndrome</strong> is commonly noted with all <strong>antidepressants</strong> including <strong>SSRI, SNRI and MAO inhibitors.</strong> It is <strong>less</strong> frequently noted with <strong>fluxoetine</strong> because of<strong> its long half life</strong>. <strong>Gradual tapering</strong> of the medication <strong>under medical</strong> <strong>supervision is recommended</strong> to<strong> minimize the risk</strong> of <strong>discontinuation syndrome.</strong></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:14px\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Explanation:</u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A:&nbsp;Venlafaxine:</strong>&nbsp;It is an <strong>SNRI (serotonin-norepinephrine reuptake inhibitor),</strong> is known for its <strong>potent effects </strong>on <strong>both serotonin</strong> and <strong>norepinephrine reuptake</strong>. <strong>Discontinuation </strong>of<strong> venlafaxine</strong>, especially <strong>abruptly,</strong> can lead to a <strong>significant and distressing</strong> <strong>withdrawal</strong> syndrome characterized by<strong> anxiety, insomnia, and other physical and psychological symptoms. </strong>This is <strong>due to the rapid</strong> <strong>decline in neurotransmitter levels </strong>that had been maintained by the medication.</span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B. Fluoxetine:</strong> <strong>Less </strong>likely to cause <strong>severe discontinuation syndrome</strong> due to <strong>its long half-life, </strong>which provides a <strong>natural</strong> <strong>tapering effect.</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C. Valproate:</strong> An <strong>antiepileptic drug</strong> that<strong> does not</strong> typically cause <strong>discontinuation syndrome </strong>related to<strong> mood alterations</strong> like <strong>anxiety and insomnia.</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D. Olanzapine:</strong> While<strong> stopping antipsychotics</strong> like<strong> olanzapine </strong>can lead to <strong>withdrawal symptoms</strong>, they <strong>do not</strong> typically manifest as <strong>anxiety and insomnia</strong> linked to <strong>discontinuation syndrome.</strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\"><span style=\"font-family:Calibri,sans-serif\"><strong><u>Educational Objective:</u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Venlafaxine</strong> <strong>discontinuation</strong> needs to be <strong>managed</strong> <strong>carefully to avoid severe withdrawal symptoms</strong>, often requiring a <strong>gradual</strong> <strong>tapering of the dose</strong> under medical supervision to <strong>mitigate the risk</strong> of<strong> discontinuation syndrome.</strong></span></span></p>",
    "correct_choice_id": 57933,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14573,
    "choices": [
      {
        "id": 58253,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Carbamazepine</span></span></span></p>"
      },
      {
        "id": 58254,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Phenytoin</span></span></span></p>"
      },
      {
        "id": 58255,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Phenobarbitone</span></span></span></p>"
      },
      {
        "id": 58256,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Valproate</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which antiepileptic drug can cause this adverse effect?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/picture7.jpg\" style=\"height:227px; width:300px\" /></span></span></span></p>",
    "unique_key": "Q1093531",
    "question_audio": null,
    "question_video": null,
    "map_id": 36224,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Phenytoin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Figure shows gum hypertrophy caused by Phenytoin. </span><span style=\"font-size:12.0pt\">Phenytoin is an antiepileptic drug known to cause gingival hyperplasia as a side effect. This adverse effect is more commonly associated with phenytoin than with the other antiepileptic drugs listed. The exact mechanism is not fully understood, but it is thought to involve the stimulation of fibroblasts to produce more collagen and other extracellular matrix substances, leading to the overgrowth of gum tissue.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Carbamazepine</span></strong><span style=\"font-size:12.0pt\">: While carbamazepine can have several side effects, it is not typically associated with gingival hyperplasia.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Phenobarbitone</span></strong><span style=\"font-size:12.0pt\">: Phenobarbitone (phenobarbital), another antiepileptic drug, also does not commonly cause gingival hyperplasia.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Valproate</span></strong><span style=\"font-size:12.0pt\">: Valproate does not typically cause gingival hyperplasia as a side effect.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The educational goal is to recognize the side effects associated with antiepileptic drugs, particularly phenytoin, which is known to cause gingival hyperplasia. Healthcare providers should monitor patients on phenytoin for this condition and educate them about maintaining good oral hygiene to help prevent or minimize this adverse effect.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Drugs causing gum hypertrophy are:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Phenytoin</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Cyclosporine</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Calcium channel blockers like verapamil, diltiazem and nifedipine</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 58254,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 14588,
    "choices": [
      {
        "id": 58313,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">More potently blocks 5HT2 as compared to D2 receptors.</span></span></span></p>"
      },
      {
        "id": 58314,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Blood level below 350 ng/ml should be maintained to avoid agranulocytosis.</span></span></span></p>"
      },
      {
        "id": 58315,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Should not be used along with Carbamazepine.</span></span></span></p>"
      },
      {
        "id": 58316,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Should be discontinued if the WBC count is below 3,000/mm3 cells.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">All are true about Clozapine except</span></span></span></p>",
    "unique_key": "Q9127716",
    "question_audio": null,
    "question_video": null,
    "map_id": 36229,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Blood level below 350 ng/ml should be maintained to avoid agranulocytosis.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The<strong> false</strong> statement about <strong>clozapine is option B, </strong>which states that <strong>&quot;Blood level below 350</strong> <strong>ng/ml </strong>should be maintained to <strong>avoid agranulocytosis.</strong>&quot; This statement is<strong> not true </strong>because there is <strong>no specific blood level of clozapine</strong> that is associated with the<strong> risk of agranulocytosis</strong>, which is<strong> dose-independent adverse effect of clozapine</strong>.<strong> High plasma</strong> <strong>concentration of Clozapine</strong> increases the<strong> risk of seizures (dose-dependent)</strong>. However, the usual <strong>plasma concentration </strong>required in many people is <strong>300-600 ng/ml.</strong></span></span></span></p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Clozapine</strong> is an <strong>atypical antipsychotic</strong> drug that has <strong>high potency to block 5HT2</strong> <strong>receptors</strong> as <strong>compared to D2 receptors.</strong> However, it also<strong> blocks D4 receptors,</strong> <strong>muscarinic receptors, alpha receptors </strong>and <strong>H1 receptors. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It<strong> suppresses both positive</strong> as well as<strong> negative symptoms of schizophrenia</strong>. It is the<strong> first FDA</strong> approved drug for <strong>anti-suicide indication.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It is used only as a<strong> reserve drug</strong> due to the<strong> risk of precipitation of seizures </strong>(<strong>even</strong> in<strong> non-epileptics</strong>) and<strong> agranulocytosis.</strong> <strong>Convulsions</strong> are <strong>dose-dependent </strong>adverse effects seen only<strong> at higher doses </strong>whereas <strong>agranulocytosis is independent</strong> of <strong>dose.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Clozapine</strong> should be <strong>started at low doses (12.5 mg) </strong>and <strong>gradually dose </strong>should be <strong>increased.</strong> <strong>Baseline WBC counts</strong> should be <strong>measured, </strong>and then <strong>weekly counts</strong> should be done<strong> at least for the first 6 months</strong>. When <strong>WBC count </strong>becomes <strong>less</strong> <strong>than 3000/mm3</strong> or <strong>absolute neutrophil </strong>count becomes<strong> less than 1500/mm3,</strong> <strong>Clozapine</strong> should be<strong> discontinued.</strong> <strong>After discontinuation,</strong> <strong>weekly WBC counts</strong> should be measured for an<strong> additional 4 weeks.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It should<strong> not</strong> be used with<strong> Carbamazepine</strong> due to two reasons:</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Carbamazepine</strong> <strong>induces its metabolism </strong>and thus <strong>decreases plasma concentration.</strong></span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Carbamazepine </strong>has<strong> bone marrow suppressant action </strong>and can add to <strong>agranulocytosis </strong>caused by <strong>Clozapine</strong>.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>",
    "correct_choice_id": 58314,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14574,
    "choices": [
      {
        "id": 58257,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A</span></span></p>"
      },
      {
        "id": 58258,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">B </span></span></span></p>"
      },
      {
        "id": 58259,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C</span></span></p>"
      },
      {
        "id": 58260,
        "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">D</span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">This figure represents the mechanism of drugs used in the treatment of parkinsonism. Which of the following options correctly represents the drugs shown in the figure?</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/picture8.jpg\" style=\"height:373px; width:300px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/screenshot-2024-05-10-170850.jpg\" style=\"height:301px; width:1000px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>",
    "unique_key": "Q6316085",
    "question_audio": null,
    "question_video": null,
    "map_id": 36225,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Ans. C) A: Pramipexole, B: Entacapone, C: Selegiline, D: Carbi-dopa</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The mainstay of treatment for Parkinson&#39;s disease is the use of dopaminergic medications, which increase the levels of dopamine in the brain. These medications can be </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dopamine precursors: These medications are converted into dopamine in the brain and include levodopa (L-dopa) and its combination with carbidopa. Carbidopa prevents the breakdown of levodopa in the bloodstream (by inhibiting dopa decarboxylase enzyme), allowing more of it to reach the brain.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Dopamine agonists: These medications mimic the action of dopamine in the brain and include pramipexole and ropinirole.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">MAO-B inhibitors: These medications block the breakdown of dopamine in the brain and include selegiline and rasagiline. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Catechol-O-methyl transferase (COMT) inhibitors: These inhibit the metabolism of levo dopa and dopamine. These are used in0 combination with levodopa to prolong its effect. Examples of COMT inhibitors include entacapone and tolcapone.</span></span></span></li>\r\n</ol>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/10/picture9.jpg\" style=\"height:303px; width:350px\" /></span></span></span></p>",
    "correct_choice_id": 58259,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 14453,
    "choices": [
      {
        "id": 57773,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It is less damaging to intima on intravenous administration.</span></span></span></p>"
      },
      {
        "id": 57774,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It can be injected in a drip of glucose solution.</span></span></span></p>"
      },
      {
        "id": 57775,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It is a prodrug of phenytoin.</span></span></span></p>"
      },
      {
        "id": 57776,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">All the above</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Fosphenytoin is different from phenytoin as?</span></span></span></p>",
    "unique_key": "Q1739266",
    "question_audio": null,
    "question_video": null,
    "map_id": 36227,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) All the above&nbsp;</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Fosphenytoin</strong> offers <strong>several advantages over phenytoin</strong>, particularly in how it <strong>is administered:</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">It is a water-soluble prodrug of phenytoin</span></strong><span style=\"font-size:12.0pt\">, meaning it is <strong>converted into phenytoin once administered</strong>. This conversion allows it to be<strong> more versatile</strong> and <strong>manageable in clinical settings.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Less damaging to the vein intima</span></strong><span style=\"font-size:12.0pt\">: <strong>Fosphenytoin</strong> is <strong>less irritating to the veins </strong>compared to<strong> phenytoin,</strong> which is known for<strong> causing phlebitis</strong> and <strong>damage to the vein walls.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Can be mixed with glucose solutions</span></strong><span style=\"font-size:12.0pt\">: <strong>Unlike phenytoin</strong>, which <strong>precipitates in glucose solutions</strong>,<strong> fosphenytoin&rsquo;s water</strong> <strong>solubility</strong> allows it to be<strong> administered</strong> with various<strong> diluents</strong>, including <strong>glucose</strong>, <strong>enhancing its usability</strong> in different <strong>infusion setups.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">A, B, C</span></strong><span style=\"font-size:12.0pt\">: Each of these statements<strong> correctly</strong> describes how<strong> fosphenytoin differs from phenytoin</strong>, as detailed above.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Fosphenytoin</strong> provides <strong>critical advantages </strong>for<strong> intravenous use over phenytoin,</strong> particularly its<strong> solubility, less vein irritation</strong>, and <strong>flexibility in dilution </strong>options, making it<strong> preferable</strong> in <strong>emergency and hospital settings</strong> for <strong>rapid seizure control.</strong></span></span></p>",
    "correct_choice_id": 57776,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14552,
    "choices": [
      {
        "id": 58169,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Furosemide</span></span></span></p>"
      },
      {
        "id": 58170,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diclofenac</span></span></span></p>"
      },
      {
        "id": 58171,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Morphine</span></span></span></p>"
      },
      {
        "id": 58172,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mannitol</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old male is brought to the emergency department following a motor vehicle accident. He has sustained a significant head injury, characterized by a loss of consciousness and visible head trauma. The medical team is evaluating his condition and considering management options.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Considering the patient&#39;s head injury, which of the following drugs is contraindicated due to the potential for exacerbating his condition?</span></span></span></p>",
    "unique_key": "Q7538638",
    "question_audio": null,
    "question_video": null,
    "map_id": 36223,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Morphine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In the context of a significant<strong> head injury</strong> with a<strong> loss of consciousness and visible trauma,</strong> <strong>Morphine</strong> is <strong>contraindicated</strong> due to its <strong>potential to exacerbate the patient&#39;s condition</strong>.<strong> Morphine, an opioid analgesic</strong>, can lead to<strong> respiratory depression, </strong>resulting in <strong>increased carbon dioxide (CO2) levels</strong>. Elevated CO2 can cause<strong> cerebral vasodilation</strong>, leading to an<strong> increase in intracranial pressure</strong> (ICP), which is particularly<strong> dangerous in patients</strong> with <strong>head injuries</strong> as it can <strong>worsen brain injury </strong>and <strong>increase the risk of brain</strong> <strong>herniation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Furosemide</span></strong><span style=\"font-size:12.0pt\">: A<strong> diuretic</strong> used to<strong> reduce fluid overload</strong> but <strong>not</strong> typically <strong>contraindicated in head injury.</strong> It <strong>does not </strong>have the <strong>same impact on ICP as morphine.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. &nbsp;Diclofenac</span></strong><span style=\"font-size:12.0pt\">: A <strong>non-steroidal anti-inflammatory drug (NSAID) </strong>used for<strong> pain management.</strong> While NSAIDs can have their <strong>own set of considerations in trauma</strong> (e.g., concerns <strong>about bleeding</strong>), they <strong>do not</strong> directly<strong> increase ICP like morphine can.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. &nbsp;Mannitol</span></strong><span style=\"font-size:12.0pt\">: An <strong>osmotic diuretic </strong>specifically <strong>used in the management </strong>of <strong>elevated ICP </strong>in patients with<strong> head injuries</strong>. <strong>Mannitol helps</strong> to <strong>reduce ICP</strong> and is<strong> indicated, not contraindicated,</strong> in cases of significant<strong> head trauma</strong> where <strong>increased ICP </strong>is a concern.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The key educational takeaway is to <strong>recognize the contraindication </strong>of <strong>using morphine</strong> in <strong>patients with head injuries</strong> due to its potential to <strong>cause respiratory depression, leading to increased CO2, cerebral vasodilation</strong>, and a subsequent <strong>rise in ICP. </strong></span></span></span></p>",
    "correct_choice_id": 58171,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14462,
    "choices": [
      {
        "id": 57809,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It is a long acting &micro; -receptor agonist.</span></span></span></p>"
      },
      {
        "id": 57810,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It is rapidly absorbed from the gastrointestinal tract and is detected in plasma 30 minutes after oral administration.</span></span></span></p>"
      },
      {
        "id": 57811,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The primary use of methadone is relief of chronic pain.</span></span></span></p>"
      },
      {
        "id": 57812,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The onset of analgesia is 60 minutes after parenteral administration and 2-4 hours after oral administration.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">True statements regarding methadone are all, except?</span></span></span></p>",
    "unique_key": "Q5863551",
    "question_audio": null,
    "question_video": null,
    "map_id": 36230,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) The onset of analgesia is 60 minutes after parenteral administration and 2-4 hours after oral administration.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Methadone,</strong> a<strong> long-acting &micro;-opioid receptor agonist, </strong>is known for its <strong>extended binding to the &micro;-opioid receptors</strong>, which provides <strong>prolonged pain relief </strong>as well as effects like<strong> sedation and euphoria.</strong> It is <strong>rapidly absorbed </strong>from the <strong>gastrointestinal tract,</strong> detectable in <strong>plasma within 30 minutes</strong> after <strong>oral administration</strong>. Its<strong> peak plasma concentrations </strong>and the <strong>onset of analgesia </strong>can vary among individuals but generally occur much sooner than stated in option D. Typically, the <strong>onset of analgesia</strong> is about<strong> 10-20 minutes after</strong> <strong>parenteral administration</strong> and <strong>30-60 minutes after oral administration, </strong>making<strong> option D incorrect.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options A, B, C:</span></strong><span style=\"font-size:12.0pt\"> All are<strong> accurate statements</strong> about<strong> methadone</strong>, describing its<strong> pharmacokinetics and primary uses.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Methadone</strong> provides <strong>extended pain relief</strong> due to its <strong>long-acting nature </strong>as a<strong> &micro;-opioid receptor agonist.</strong> The<strong> onset </strong>of its <strong>analgesic</strong> <strong>effects</strong> is <strong>faster than </strong>indicated in<strong> option D</strong>, which is critical for understanding its<strong> effective use</strong> in <strong>pain management </strong>and <strong>opioid</strong> <strong>dependency treatments.</strong></span></span></span></p>",
    "correct_choice_id": 57812,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14468,
    "choices": [
      {
        "id": 57833,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Parkinson&rsquo;s disease</span></span></span></p>"
      },
      {
        "id": 57834,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Serotonin syndrome</span></span></span></p>"
      },
      {
        "id": 57835,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Neuroleptic malignant syndrome</span></span></span></p>"
      },
      {
        "id": 57836,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hyperpyrexia</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Mrs. Kanchan, a 50-year-old female, has been prescribed both clomipramine and escitalopram for the treatment of depression and anxiety. Which of the following should be monitored in her due to the combination of these medications?</span></span></span></p>",
    "unique_key": "Q1770942",
    "question_audio": null,
    "question_video": null,
    "map_id": 36210,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Serotonin Syndrome</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Serotonin syndrome </strong>is a<strong> critical condition</strong> to <strong>monitor</strong> in patients prescribed <strong>both clomipramine,</strong> a<strong> tricyclic antidepressant,</strong> and <strong>escitalopram, a selective serotonin reuptake inhibitor (SSRI)</strong>.<strong> Clomipramine inhibits </strong>the <strong>reuptake of serotonin</strong> and <strong>norepinephrine,</strong> while <strong>escitalopram</strong> primarily <strong>increases serotonin levels</strong> by<strong> inhibiting its reuptake </strong>at the<strong> synaptic cleft.</strong> The <strong>combined effect </strong>of these drugs significantly<strong> raises serotonin levels</strong>, which can lead to <strong>serotonin syndrome</strong>. This syndrome is characterized by<strong> symptoms such</strong> as <strong>agitation, confusion, rapid heart rate, dilated pupils, muscle rigidity, fever, </strong>and in severe cases, can be<strong> life-threatening.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Parkinson&rsquo;s disease:</span></strong><span style=\"font-size:12.0pt\"> <strong>Not</strong> directly related to the <strong>combined use of clomipramine and escitalopram.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Neuroleptic malignant syndrome:</span></strong><span style=\"font-size:12.0pt\"> Typically associated with the <strong>use of antipsychotic drugs,</strong> not antidepressants.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Hyperpyrexia:</span></strong><span style=\"font-size:12.0pt\"> While hyperpyrexia can occur as a<strong> part of serotonin syndrome</strong>, it is <strong>not</strong> a<strong> standalone</strong> concern with these <strong>medications</strong> outside of that context.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When <strong>combining clomipramine</strong> <strong>with</strong> an<strong> SSRI like escitalopram</strong>, there is an <strong>increased risk of serotonin syndrome</strong>, a <strong>serious medical</strong> condition resulting from<strong> too much serotonin in the body.</strong> It is crucial to<strong> monitor for signs and adjust treatment </strong>if <strong>symptoms</strong> <strong>develop.</strong></span></span></span></p>",
    "correct_choice_id": 57834,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14470,
    "choices": [
      {
        "id": 57841,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Akathisia </span></span></span></p>"
      },
      {
        "id": 57842,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tardive dyskinesia </span></span></span></p>"
      },
      {
        "id": 57843,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Rabbit syndrome </span></span></span></p>"
      },
      {
        "id": 57844,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Acute dystonia</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 45-year-old male patient complained of hearing voices and was started on haloperidol for the treatment of his symptoms. However, for the past few days, he has been very restless and constantly moving about. What is the most likely condition that the patient is experiencing?</span></span></span></p>",
    "unique_key": "Q1754365",
    "question_audio": null,
    "question_video": null,
    "map_id": 36211,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Akathisia </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Akathisia </strong>is a <strong>movement disorder</strong> commonly associated with the <strong>use of antipsychotic medications,</strong> such as <strong>haloperidol.</strong> It is characterized by an <strong>inner sense of restlessness</strong> and an <strong>uncontrollable </strong>need to be in <strong>constant motion.</strong> Patients often describe it as a <strong>compelling urge to move</strong>, and they are <strong>frequently seen shifting their position or walking about</strong>. This condition typically appears <strong>shortly </strong>after <strong>starting the medication</strong> or <strong>after a dose increase</strong>. <strong>Akathisia </strong>is<strong> distressing </strong>and <strong>can adversely affect</strong> compliance with <strong>medication.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Tardive dyskinesia:</span></strong><span style=\"font-size:12.0pt\"> This condition involves<strong> involuntary, repetitive movements of the face and limbs </strong>but typically develops <strong>after long-term use of antipsychotics</strong>, making it<strong> less likely </strong>in this <strong>acute setting.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Rabbit syndrome:</span></strong><span style=\"font-size:12.0pt\"> Characterized by<strong> rapid movements of the lips and mouth,</strong> <strong>rabbit syndrome</strong> is associated with <strong>prolonged antipsychotic use, not</strong> <strong>acute symptoms</strong> following<strong> recent medication initiation.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Acute dystonia:</span></strong><span style=\"font-size:12.0pt\"> While this<strong> involves sudden muscle contractions,</strong> it usually presents as <strong>twisted postures or abnormal</strong> <strong>movements of the face, neck, and eyes</strong>, rather than the restlessness and constant movement typical of akathisia.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Akathisia </strong>is a<strong> significant side effect </strong>of <strong>antipsychotic medications</strong> like<strong> haloperidol</strong>, presenting as an <strong>uncontrollable urge to move</strong> and <strong>restlessness</strong>, often occurring<strong> shortly after</strong> the<strong> initiation or increase of medication</strong>.<strong> Monitoring</strong> and managing this <strong>side effect</strong> are <strong>crucial for patient comfort</strong> and <strong>treatment adherence. Propranolol</strong> is<strong> frequently used </strong>to <strong>treat this condition effectively.</strong></span></span></span></p>",
    "correct_choice_id": 57841,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14506,
    "choices": [
      {
        "id": 57985,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Antipsychotic</span></span></span></p>"
      },
      {
        "id": 57986,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Anti-Depressants</span></span></span></p>"
      },
      {
        "id": 57987,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Selective serotonin reuptake inhibitors </span></span></span></p>"
      },
      {
        "id": 57988,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Stimulants</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A 12-year-old boy is referred to his physician because of &ldquo;blinking too much,&rdquo; which his mother thinks she first noted &gt;1 year ago. The boy states that he does not notice that it is occurring unless someone tells him about it. When he is nervous, it seems to worsen. He is embarrassed about it and wants to control it. What class of medications has been shown to worsen this condition? </span></span></span></p>",
    "unique_key": "Q2951384",
    "question_audio": null,
    "question_video": null,
    "map_id": 36222,
    "difficulty_level": "difficult",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Stimulants</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The symptoms described are characteristic of <strong>Tourette syndrome,</strong> a condition marked by<strong> repetitive involuntary movements</strong> and vocalizations known as<strong> tics</strong>. <strong>Stimulants</strong>, commonly prescribed for conditions like <strong>ADHD,</strong> can <strong>exacerbate tics</strong> in individuals<strong> diagnosed</strong> <strong>with Tourette syndrome</strong>. The<strong> use of stimulants </strong>in patients with<strong> Tourette&#39;s needs careful consideration</strong>, as they can <strong>increase the</strong> <strong>frequency or severity of tics.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Antipsychotic:</span></strong><span style=\"font-size:12.0pt\"> These medications are <strong>sometimes used</strong> to<strong> manage severe tics</strong>, not worsen them.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Anti-Depressants:</span></strong><span style=\"font-size:12.0pt\"> Typically,<strong> do not exacerbate tics </strong>and are <strong>used to treat co-morbid conditions</strong> like<strong> anxiety or depression</strong> in <strong>Tourette syndrome.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Selective serotonin reuptake inhibitors (SSRIs):</span></strong><span style=\"font-size:12.0pt\"> <strong>Used</strong> to address associated <strong>symptoms of anxiety and depression </strong>but <strong>do</strong> <strong>not</strong> typically<strong> worsen tics.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When <strong>treating </strong>patients with <strong>Tourette syndrome</strong> who require medication for<strong> coexisting conditions</strong> such as <strong>ADHD,</strong> <strong>careful</strong> <strong>consideration</strong> must be given to the<strong> choice of medication</strong>, as<strong> stimulants may worsen tic symptoms.</strong></span></span></span></p>",
    "correct_choice_id": 57988,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14610,
    "choices": [
      {
        "id": 58401,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Thiamine</span></span></span></p>"
      },
      {
        "id": 58402,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Diazepam</span></span></span></p>"
      },
      {
        "id": 58403,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT\" style=\"font-size:12.0pt\">Lorazepam</span></span></span></p>"
      },
      {
        "id": 58404,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Chlordiazepoxide</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment of choice for delirium tremens in alcohol withdrawal in a patient with severe alcoholic liver disease is? </span></span></p>",
    "unique_key": "Q6537114",
    "question_audio": null,
    "question_video": null,
    "map_id": 36214,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Lorazepam</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Delirium tremens </strong>is a<strong> severe form </strong>of<strong> alcohol withdrawal syndrome</strong> that can be<strong> life-threatening. Benzodiazepines</strong> are the<strong> first-line treatment</strong> for managing<strong> alcohol withdrawal symptoms</strong>, including <strong>delirium tremens</strong>. However, in patients with<strong> severe liver disease,</strong> it is crucial to choose a<strong> benzodiazepine</strong> that is<strong> metabolized more safely </strong>in this population.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Lorazepam </strong>is preferred<strong> over</strong> other benzodiazepines like <strong>diazepam and chlordiazepoxide </strong>because it has a <strong>shorter half-life</strong> and<strong> undergoes glucuronidation, </strong>a metabolic pathway that is <strong>less affected </strong>by <strong>liver dysfunction</strong>. This makes <strong>lorazepam safe</strong>r for <strong>patients with impaired liver function.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Thiamine (vitamin B1) </strong>is important to<strong> administer in patients </strong>with <strong>alcohol use disorder</strong> to <strong>prevent Wernicke-Korsakoff</strong> <strong>syndrome</strong>, but it is <strong>not </strong>the treatment of for <strong>delirium tremens.</strong></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 58403,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14613,
    "choices": [
      {
        "id": 58413,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Nausea and vomiting</span></span></span></p>"
      },
      {
        "id": 58414,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Tremors</span></span></span></p>"
      },
      {
        "id": 58415,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hypothyroidism</span></span></span></p>"
      },
      {
        "id": 58416,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Hypocalcemia</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The side effects of lithium in psychiatry practice includes all except? </span></span></p>",
    "unique_key": "Q7917218",
    "question_audio": null,
    "question_video": null,
    "map_id": 36215,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Hypocalcemia</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><br />\r\n<span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypocalcemia (low calcium levels in the blood) is not a side effect of lithium therapy. In rare cases, lithium may cause hyperparathyroidism and elevated parathyroid hormone levels, which can lead to hypercalcemia (elevated calcium levels in the blood).</span></span><br />\r\n</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:16px\"><strong>Other options:</strong></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Lithium</strong> is a<strong> mood stabilizer </strong>commonly used in the <strong>treatment of bipolar disorder.</strong> The <strong>common side effects </strong>of<strong> lithium</strong> include:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Nausea and vomiting</span></strong><span style=\"font-size:12.0pt\">: <strong>Gastrointestinal disturbances</strong>, such as <strong>nausea and vomiting,</strong> are common side effects of <strong>lithium</strong>, particularly during the<strong> initial stages of</strong> <strong>treatment.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Tremors</span></strong><span style=\"font-size:12.0pt\">: <strong>Fine tremors</strong> are a<strong> well-known side effect of lithium therapy</strong>. These tremors may be<strong> dose-dependent</strong> and can be <strong>reduced by lowering the dose </strong>or by <strong>adding a</strong> <strong>beta-blocker.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Hypothyroidism:</span></strong><span style=\"font-size:12.0pt\"> <strong>Lithium</strong> can interfere with <strong>thyroid function</strong>, leading to <strong>hypothyroidism </strong>in some patients.<strong> Regular monitoring </strong>of <strong>thyroid function </strong>is recommended during<strong> lithium treatment.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>",
    "correct_choice_id": 58416,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 14614,
    "choices": [
      {
        "id": 58417,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Dry mouth </span></span></span></p>"
      },
      {
        "id": 58418,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Sexual&nbsp;</span></span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">dysfunction</span></span></p>"
      },
      {
        "id": 58419,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Visual disturbance </span></span></span></p>"
      },
      {
        "id": 58420,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Constipation </span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A psychotropic drug inhibiting the reuptake of serotonin is likely to cause which of the following side effects?</span></span></p>",
    "unique_key": "Q6487234",
    "question_audio": null,
    "question_video": null,
    "map_id": 36216,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Sexual dysfunction </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>SSRIs</strong> are commonly used to<strong> treat depression and anxiety disorders.</strong> They work by <strong>increasing the levels of serotonin</strong> in the brain, which helps<strong> regulate mood.</strong> However, <strong>SSRIs</strong> can also <strong>cause several side effects</strong>, including<strong> sexual dysfunction.</strong> This can manifest as<strong> decreased libido,</strong> <strong>difficulty achieving orgasm, or erectile dysfunction.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The <strong>other side effects</strong> listed <strong>(dry mouth, visual disturbance, and constipation)</strong> can be associated with <strong>other types of psychotropic medications</strong> but are <strong>not</strong> as commonly linked to<strong> serotonin reuptake inhibitors.</strong></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 58418,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14615,
    "choices": [
      {
        "id": 58421,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Depression</span></span></span></p>"
      },
      {
        "id": 58422,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Insomnia</span></span></span></p>"
      },
      {
        "id": 58423,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Schizophrenia</span></span></span></p>"
      },
      {
        "id": 58424,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Epilepsy</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Mirtazapine is useful in the treatment of which of the following conditions? </span></span></span></p>",
    "unique_key": "Q4872240",
    "question_audio": null,
    "question_video": null,
    "map_id": 36218,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Depression</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">MIRTAZAPINE</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Mirtazapine</strong> is an <strong>atypical antidepressant drug.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It <strong>inhibits presynaptic &alpha;2 receptors</strong> and thus<strong> increases NA and 5-HT release </strong>due to<strong> inhibition of auto- and hetero- receptors</strong>, respectively. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">There is <strong>selective activation of 5-HT1 receptors</strong> due to <strong>antagonistic activity at 5-HT2 and 5-HT3 receptors</strong>. So, <strong>mirtazapine</strong> is also known as <strong>noradrenergic</strong> and <strong>specific serotonergic antidepressant (NSSA). </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It also has <strong>H1 blocking property, </strong>but <strong>not anticholinergic</strong> or <strong>antidopaminergic</strong> <strong>properties. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Side effects </strong>include <strong>sedation, weight gain, dizziness, lipid abnormalities. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Sexual dysfunction </strong>is <strong>not </strong>a problem with <strong>this drug.</strong></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 58421,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14457,
    "choices": [
      {
        "id": 57789,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Naloxone</span></span></span></p>"
      },
      {
        "id": 57790,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Naltrexone</span></span></span></p>"
      },
      {
        "id": 57791,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Buprenorphine</span></span></span></p>"
      },
      {
        "id": 57792,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Nalmefene</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which of the following acts as partial/weak &micro; agonist + k antagonist on opioid receptors?</span></span></span></p>",
    "unique_key": "Q6248414",
    "question_audio": null,
    "question_video": null,
    "map_id": 36228,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Buprenorphine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Buprenorphine</strong> is unique among <strong>opioids</strong> as it<strong> acts as a partial agonist at the &micro;-opioid receptor</strong> and a <strong>weak antagonist</strong> at the <strong>&kappa;</strong>-<strong>opioid receptor.</strong> Its <strong>partial agonist </strong>activity at the <strong>&micro; receptor</strong> allows it to produce<strong> analgesic effects</strong> <strong>similar to those of full agonists </strong>like<strong> morphine </strong>but with a <strong>ceiling effect </strong>that <strong>limits the maximum effect regardless of dose increase.</strong> This makes<strong> buprenorphine less</strong> likely to<strong> cause respiratory depression</strong>&mdash;a <strong>serious risk </strong>associated with<strong> full opioid agonists</strong>. Additionally, its <strong>weak antagonist activity</strong> <strong>at &kappa; receptors</strong> may contribute to <strong>its effectiveness</strong> in treating <strong>addiction without</strong> providing the <strong>full euphoric effects </strong>that are typically <strong>sough</strong>t by<strong> individuals using opioids.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Naloxone:</span></strong><span style=\"font-size:12.0pt\"> This is a <strong>pure opioid antagonist</strong>, primarily used to<strong> reverse opioid overdose.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Naltrexone:</span></strong><span style=\"font-size:12.0pt\"> Also an <strong>opioid antagonist,</strong> used in addiction treatment to <strong>block the effects of opioids and alcohol.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Nalmefene:</span></strong><span style=\"font-size:12.0pt\"> An <strong>opioid antagonist</strong> used to manage<strong> alcohol dependence</strong>,<strong> not</strong> providing <strong>partial agonist effects at opioid</strong> <strong>receptors.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Buprenorphine&rsquo;s partial agonist</strong> <strong>action at &micro;-opioid receptors </strong>combined with <strong>its weak &kappa; antagonism </strong>makes it an<strong> effective option</strong> for <strong>opioid addiction treatment, reducing potential abuse</strong> while managing <strong>withdrawal and dependence symptoms.</strong></span></span></span></p>",
    "correct_choice_id": 57791,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 14486,
    "choices": [
      {
        "id": 57905,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Levetiracetam </span></span></span></p>"
      },
      {
        "id": 57906,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Phenytoin</span></span></span></p>"
      },
      {
        "id": 57907,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Vigabatrin </span></span></span></p>"
      },
      {
        "id": 57908,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ethosuximide</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old male patient with a history of seizures presents to the clinic. He has been taking anticonvulsants for the last few years, and he reports experiencing visual disturbances, including a narrowing of his visual field. He is concerned about the possibility of permanent vision loss. Which of these anticonvulsants causes contraction of visual field? </span></span></p>",
    "unique_key": "Q1260861",
    "question_audio": null,
    "question_video": null,
    "map_id": 36217,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. C) Vigabatrin</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Vigabatrin </strong>is an<strong> anticonvulsant </strong>known for <strong>its mechanism </strong>of action as a <strong>GABA transaminase inhibitor,</strong> which <strong>increases the level of</strong> <strong>gamma-aminobutyric acid (GABA)</strong> in the<strong> brain</strong>, <strong>beneficial</strong> for <strong>controlling seizures.</strong> However, a significant <strong>side effect </strong>associated <strong>with</strong> <strong>vigabatrin </strong>is the <strong>contraction of the visual field,</strong> which can be <strong>severe and </strong>is often <strong>irreversible.</strong> This <strong>adverse effect </strong>necessitates <strong>regular and careful monitoring of visual function </strong>in patients <strong>using vigabatrin, </strong>particularly those who <strong>report visual disturbances</strong>, as these<strong> could indicate</strong> the <strong>onset of this irreversible side effect.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option A. Levetiracetam:</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Does not&nbsp;</strong>commonly cause<strong> visual field changes.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Phenytoin:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Known for <strong>different side effects</strong>, <strong>primarily </strong>affecting the<strong> CNS and skin</strong>, <strong>not</strong> specifically<strong> linked to visual field</strong> <strong>contraction.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Ethosuximide:&nbsp;</span></strong><span style=\"font-size:12.0pt\">Used<strong> primarily for absence seizures </strong>and<strong> does not</strong> typically cause <strong>visual field changes.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Vigabatrin</strong>, while <strong>effective for controlling </strong>certain <strong>types of seizures,</strong> carries a<strong> risk of </strong>causing <strong>permanent visual field contraction,</strong> <strong>underscoring</strong> the <strong>need for regular ophthalmologic monitoring</strong> in patients <strong>undergoing this treatment.</strong></span></span></span></p>",
    "correct_choice_id": 57907,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "TreatmentBased"
    ]
  },
  {
    "id": 14474,
    "choices": [
      {
        "id": 57857,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It is a specific antagonist of benzodiazepines.</span></span></span></p>"
      },
      {
        "id": 57858,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It may be used to treat barbiturate poisoning.</span></span></span></p>"
      },
      {
        "id": 57859,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It is given intravenously.</span></span></span></p>"
      },
      {
        "id": 57860,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It acts on the same site on GABA channel where benzodiazepines bind.</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Mr. Atiq, a 40-year-old man, presents to the emergency department with symptoms of benzodiazepine overdose. He has a history of anxiety and has been taking benzodiazepines for several months. The medical team decides to administer flumazenil to reverse the effects of benzodiazepines. </span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">All the following statements about flumazenil are true EXCEPT</span></span></span></p>",
    "unique_key": "Q5411038",
    "question_audio": null,
    "question_video": null,
    "map_id": 36212,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) It may be used to treat barbiturate poisoning.</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Flumazenil</strong> is a <strong>specific antagonist</strong> for<strong> benzodiazepines,</strong> meaning it <strong>reverses their effects</strong> by <strong>competitively binding</strong> to the <strong>benzodiazepine receptor site on the GABA-A receptor complex. </strong>It is <strong>administered intravenously,</strong> often in<strong> cases of overdose</strong> or to <strong>hasten </strong>recovery from <strong>benzodiazepine sedation in medical settings</strong>. Crucially,<strong> flumazenil</strong> <strong>does not</strong> counteract the effects of <strong>barbiturates</strong>, as these<strong> drugs do not act </strong>at the<strong> benzodiazepine binding site</strong> but rather have a <strong>distinct modulatory effect on the GABA-A receptor.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Options A, C, D:</span></strong><span style=\"font-size:12.0pt\"> These statements<strong> correctly </strong>describe<strong> flumazenil&rsquo;s</strong> <strong>pharmacological characteristics</strong> and <strong>mode of action.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Flumazenil </strong>is<strong> effective</strong> in<strong> reversing benzodiazepine effects</strong> but is<strong> not</strong> suitable for <strong>treating barbiturate poisoning</strong> due to <strong>different</strong> <strong>sites of action on the GABA-A receptor complex.</strong></span></span></p>",
    "correct_choice_id": 57858,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 14491,
    "choices": [
      {
        "id": 57925,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Sialorrhea </span></span></span></p>"
      },
      {
        "id": 57926,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Vivid dreams </span></span></span></p>"
      },
      {
        "id": 57927,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Nausea </span></span></span></p>"
      },
      {
        "id": 57928,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Anorgasmia</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A 38-year-old male with a history of depression and anxiety is started on escitalopram. After a week, he reports excessive drooling, vivid dreams, and mild nausea. He is concerned about these symptoms and asks you which of the following is not an adverse effect of escitalopram?</span></span></span></p>",
    "unique_key": "Q3487432",
    "question_audio": null,
    "question_video": null,
    "map_id": 36220,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Sialorrhea</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Escitalopram</strong> belongs to a group of<strong> anti-depressant drugs </strong>called <strong>Selective Serotonin Reuptake Inhibitors (SSRI). </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><strong><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">It is the active (S) enantiomer of citalopram. </span></span></span></strong></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Sialorrhea or excessive salivation</strong> is <strong>not</strong> a known <strong>adverse effect of escitalopram.</strong> It is important to remember from MCQ point that the only important drug used in CNS that causes<strong> sialorrhea is clozapine.</strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><strong>Vivid dreams and nausea </strong>are<strong> </strong><strong>common side effects of escitalopram,</strong> and <strong>anorgasmia</strong> is a <strong>potential sexual side effect </strong>like all <strong>SSRIs.</strong></span></span></span></li>\r\n</ul>",
    "correct_choice_id": 57925,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 14577,
    "choices": [
      {
        "id": 58269,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"DE\" style=\"font-size:12.0pt\">Mu </span></span></span></p>"
      },
      {
        "id": 58270,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"DE\" style=\"font-size:12.0pt\">Kappa</span></span></span></p>"
      },
      {
        "id": 58271,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"DE\" style=\"font-size:12.0pt\">Delta </span></span></span></p>"
      },
      {
        "id": 58272,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"DE\" style=\"font-size:12.0pt\">Sigma</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Dysphoria caused by opiates is mediated by which receptor? </span></span></span></p>",
    "unique_key": "Q4051240",
    "question_audio": null,
    "question_video": null,
    "map_id": 36226,
    "difficulty_level": "beginner",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"DE\" style=\"font-size:12.0pt\">Ans. B) Kappa</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The dysphoria caused by opiates is mediated by the kappa opioid receptor. The kappa receptor is one of the three major classes of opioid receptors (the other two being mu and delta) and is found throughout the central and peripheral nervous systems.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When activated, the kappa receptor produces a variety of effects, including analgesia, dysphoria, and sedation. The dysphoric effects of kappa receptor activation are thought to be due to its effects on the reward pathway in the brain, which can lead to feelings of discomfort, anxiety, and aversion.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In contrast, activation of the mu opioid receptor is associated with the pleasurable effects of opioids, including pain relief and euphoria. The delta receptor is less well understood but is thought to play a role in the modulation of pain perception and mood.</span></span></span></li>\r\n</ul>",
    "correct_choice_id": 58270,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  },
  {
    "id": 14609,
    "choices": [
      {
        "id": 58397,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Fluvoxamine</span></span></span></p>"
      },
      {
        "id": 58398,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Sertraline</span></span></span></p>"
      },
      {
        "id": 58399,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Citalopram</span></span></span></p>"
      },
      {
        "id": 58400,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Mirtazapine</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old teacher began to experience changes in mood. He was losing interest in his work and lacked the desire to play his daily tennis match. He was preoccupied with feelings of guilt, worthlessness, and hopelessness. In addition to the psychiatric symptoms, the patient complained of muscle aches throughout his body. Physical and laboratory tests were unremarkable. After 6 weeks of therapy with fluoxetine, his symptoms resolved. However, the patient complains of sexual dysfunction. Which of the following drugs might be useful in this patient? </span></span></p>",
    "unique_key": "Q6371340",
    "question_audio": null,
    "question_video": null,
    "map_id": 36213,
    "difficulty_level": "intermediate",
    "subjects_id": [
      4
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Mirtazapine</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In this case, the<strong> patient </strong>has <strong>experienced sexual dysfunction</strong> as a<strong> side effect of fluoxetine,</strong> a <strong>selective serotonin reuptake</strong> <strong>inhibitor (SSRI).</strong> <strong>Switching</strong> to <strong>another medication</strong> with a <strong>lower risk of sexual side effects</strong> may be<strong> helpful. </strong>Most <strong>typical antidepressants</strong> including<strong> SSRI, SNRI, MAO inhibitors and TCA </strong>can cause <strong>sexual adverse effects,</strong> so <strong>atypical</strong> <strong>antidepressant drugs</strong> are<strong> better </strong>option in this <strong>patient. </strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Other Options:</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Option A,Option B and Option C : Fluvoxamine, Sertraline and Citalopram are SSRI </strong>which may also<strong> cause sexual side effects</strong> whereas<strong> Mirtazapine</strong> is an <strong>atypical antidepressant</strong> that acts as an <strong>antagonist at alpha-2 adrenergic receptors</strong> and <strong>serotonin receptors (5-HT2 and 5-HT3).</strong> It has a<strong> lower risk </strong>of causing <strong>sexual side effects </strong>compared to <strong>SSRIs.</strong></span></span></span></p>",
    "correct_choice_id": 58400,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual"
    ]
  }
];
        let quizName = 'Central Nervous System';
        let hierarchy = ["Cerebellum", "qBank", "Pharmacology"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - QuizMaster Pro';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        const urlParams = new URLSearchParams(window.location.search);
        currentQuestionIndex = Math.min(parseInt(urlParams.get('startAt')) || 0, questionsData.length - 1);

        function goBack() {
            if (isQuizCompleted || confirm('Are you sure you want to leave the quiz? Your progress will be lost.')) {
                window.history.back();
            }
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                setTimeout(processAnswer, 300);
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            setTimeout(showSolution, 1500);
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }

            const audioContainer = document.getElementById('solutionAudio');
            audioContainer.innerHTML = '';
            if (question.explanation_audio_eng) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English Explanation:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
            }
            if (question.explanation_audio_hin) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish Explanation:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;
            }
            
            const imagesContainer = document.getElementById('solutionImages');
            imagesContainer.innerHTML = '';
            if (question.explanation_images) {
                 question.explanation_images.forEach(imgSrc => {
                    if(imgSrc) imagesContainer.innerHTML += `<div class="mt-4"><img src="${imgSrc}" alt="Explanation Image" class="w-full rounded-lg"></div>`;
                });
            }

            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';
                
                let audioHtml = '';
                if(question.explanation_audio_eng) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
                if(question.explanation_audio_hin) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;

                let imagesHtml = (question.explanation_images || []).map(src => src ? `<div class="mt-4"><img src="${src}" alt="Explanation Image" class="w-full rounded-lg"></div>` : '').join('');

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                        ${audioHtml}
                        ${imagesHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        function toggleSidebar() {
            document.getElementById('quizSidebar').classList.toggle('open');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (!window.location.pathname.endsWith('custom_quiz.html')) {
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>